

---

---

**LEGISLATIVE APPROPRIATIONS REQUEST**  
**FISCAL YEARS 2020 AND 2021**



Submitted to the Governor's Office  
and the Legislative Budget Board

**THE UNIVERSITY OF TEXAS**  
**SOUTHWESTERN MEDICAL CENTER**

**October 2018**

---

---



**TABLE OF CONTENTS**  
**THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER**  
**LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021**

---

Administrator’s Statement	1
Organizational Chart	9
Management Structure of Agency	10
Biennial Budget Overview Schedule	13
Summary of Base Request by Strategy	2.A. Page 1
Summary of Base Request by Method of Finance	2.B. Page 1
Summary of Base Request by Object of Expense	2.C. Page 1
Summary of Base Request Objective Outcomes	2.D. Page 1
Summary of Exceptional Items Request	2.E. Page 1
Summary of Total Request by Strategy	2.F. Page 1
Summary of Total Request Objective Outcomes	2.G. Page 1

**STRATEGY REQUEST**

Goal 1: Provide Instructional and Operations Support

Objective 01: Instructional Programs	
Strategy 01: Medical Education	3.A. Page 1
Strategy 02: Graduate Training in Biomedical Sciences	3.A. Page 5
Strategy 03: Allied Health Professions Training	3.A. Page 8
Strategy 04: Graduate Medical Education	3.A. Page 11
Objective 02: Operations – Staff Benefits	
Strategy 01: Staff Group Insurance Premiums	3.A. Page 13
Objective 03: Operations – Statutory Funds	
Strategy 01: Texas Public Education Grants	3.A. Page 15
Objective 05: Hold Harmless	
Strategy 01: Hold Harmless	3.A. Page 17

**TABLE OF CONTENTS**  
**THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER**  
**LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021**

---

Goal 2: Provide Research Support

Objective 01: Research Activities

Strategy 01: Research Enhancement

3.A. Page 19

Goal 3: Provide Infrastructure Support

Objective 01: Operations and Maintenance

Strategy 01: E&G Space Support

3.A. Page 21

Objective 02: Infrastructure Support

Strategy 01: Tuition Revenue Bond Retirement

3.A. Page 23

Goal 4: Provide Special Item Support

Objective 01: Residency Training Special Items

Strategy 01: Primary Care Residency Training

3.A. Page 25

Objective 02: Research Special Items

Strategy 01: Institute for Nobel/National-Academy Biomedical Research

3.A. Page 28

Strategy 02: Institute for Innovations in Medical Technology

3.A. Page 31

Strategy 03: Metroplex Comprehensive Medical Imaging Center

3.A. Page 34

Strategy 04: Center for Obesity, Diabetes and Metabolism Research

3.A. Page 37

Strategy 06: Center for Research of Sickle Cell Disease

3.A. Page 40

Strategy 07: Texas Institute for Brain Injury and Repair

3.A. Page 43

Strategy 08: Center for Regenerative Science and Medicine

3.A. Page 46

Strategy 09: Center for Advanced Radiation Therapy

3.A. Page 49

Objective 03: Health Care Special Items

Strategy 01: Regional Burn Care Center

3.A. Page 52

**TABLE OF CONTENTS**  
**THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER**  
**LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021**

---

Objective 04: Public Service Special Items  
    Strategy 01: Science Teacher Access to Resources (STARS) 3.A. Page 54

Objective 05: Institutional Support Special Items  
    Strategy 01: Institutional Enhancement 3.A. Page 57

Objective 06: Exceptional Item Request  
    Strategy 01: Exceptional Item Request 3.A. Page 60

Goal 6: Tobacco Funds

Objective 01: Tobacco Earnings for Eminent Scholars  
    Strategy 01: Tobacco Earnings for UT Southwestern Medical Center 3.A. Page 62  
    Strategy 02: Tobacco Earnings from the Permanent Health Fund for Higher Education 3.A. Page 64

Program Level Request Schedule 3.A.1 Page 1

**EXCEPTIONAL ITEMS:**

Center for Gene Therapy and Curative Medicine  
    Request Schedule 4.A. Page 1  
    Allocation Schedule 4.B. Page 1  
    Strategy Request 4.C. Page 3

Center for Advanced Radiation Therapy  
    Request Schedule 4.A. Page 3  
    Allocation Schedule 4.B. Page 2  
    Strategy Request 4.C. Page 2

**TABLE OF CONTENTS**  
**THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER**  
**LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021**

---

UTD/UTSW Translational Biomedical Engineering and Science Building	
Request Schedule	4.A. Page 5
Allocation Schedule	4.B. Page 3
Strategy Request	4.C. Page 1
Historically Underutilized Business Supporting Schedule	6.A. Page 1
Homeland Security Funding Schedule	6.G. Page 1
Estimated Total of All Funds Outside the General Appropriations Act Bill Pattern Schedule	6.H. Page 1
10 Percent Biennial Base Reduction Options Schedule	6.I. Page 1
Summary of Requests for Capital Project Financing	8. Page 1

**SUPPORTING SCHEDULES**

Schedule 1A: Other Educational and General Income	
Schedule 2: Selected Educational, General and Other Funds	
Schedule 3B: Group Health Insurance Data Elements (UT/A&M)	
Schedule 4: Computation of OASI	
Schedule 5: Calculation of Retirement Proportionality and ORP Differential	
Schedule 6: Capital Funding	
Schedule 7: Personnel	
Schedule 8A: Proposed Tuition Revenue Bond Projects	
Schedule 8B: Tuition Revenue Bond Issuance History	
Schedule 8C: Tuition Revenue Bonds Request by Project	
Schedule 9: Special Item Information	

## Schedules Not Included

<b>Agency Code:</b> 729	<b>Agency Name:</b> The University of Texas Southwestern Medical Center	<b>Prepared By:</b> Budget Office	<b>Date:</b> August 2018	<b>Request Level:</b> Base
----------------------------	--	--------------------------------------	-----------------------------	-------------------------------

For the schedules identified below, the University of Texas Southwestern Medical Center either has no information to report or the schedule is not applicable. Accordingly, these schedules have been excluded from the U.T. Southwestern Medical Center Legislative Appropriations Request for the 2020-21 biennium.

Number	Name
3.C	Rider Appropriations and Unexpended Balance Request
5.A	Capital Budget Project Schedule
5.B	Capital Budget Project Information
5.C	Capital Budget Allocation to Strategies
5.D	Capital Budget Operating and Maintenance Expenses Detail
5.E	Capital Budget Project: Object of Expense and Method of Finance by Strategy
6.B	Current Biennium One-time Expenditure Schedule
6.C	Federal Funds Supporting Schedule
6.D	Federal Funds Tracking Schedule
6.E	Estimated Revenue Collections Supporting Schedule
6.F	Advisory Committee Supporting Schedule
6.J	Summary of Behavioral Health Funding
7	Administrative and Support Costs
Schedule 1B	Health-Related Institutions Patient Income
Schedule 3A	Staff Group Insurance Data Elements (ERS)
Schedule 3C	Group Health Insurance Data Elements (Supplemental)
Schedule 3D	Staff Group Insurance Data Elements (Supplemental)
Schedule 10A	Formula Strategies by NACUBO Functions of Cost
Schedule 10B	Object of Expense Detail for Formula Strategies and NACUBO Functions of Cost





## Administrator's Statement

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

### 729 The University of Texas Southwestern Medical Center

---

#### OVERVIEW

This Legislative Appropriations Request for FY 2020-21 is predicated on a strategic assessment of the future of UT Southwestern Medical Center (UTSW) and careful consideration of the Legislature's historic priorities for higher education in Texas, including mechanisms for funding. In addition, this Request is based upon important priorities unique to UTSW and that impact other Health Related Institutions (HRIs) across Texas, such as providing the resources necessary to: educate a world-class healthcare and research workforce; invest in lifesaving biomedical research at Texas' established research schools, such as UTSW, that simultaneously serve to expand the Texas biotechnology sector; and improve the quality and availability of healthcare for all Texans.

#### BACKGROUND AND OPERATIONS

UTSW strives to achieve the public policy goals it was established to pursue, and leverages the State's investment in these goals to obtain additional federal and private support to advance its education, research and patient care missions. The State's investment in UTSW pays dividends much greater than the cost, both in terms of external dollars generated for the State and in results produced. Since its formation in makeshift quarters in 1943, UTSW has grown into a multifaceted academic medical center engaged in education with three schools, a robust research enterprise, healthcare for millions of patients and considerable community service. Celebrating its 75th Anniversary this year, UTSW began with an initial faculty of 20, housed in WWI barracks, and since expanded to a comprehensive academic medical center with a faculty of ~2,800 occupying ~13M sq ft of space. Administrative expense in FY15, at 2.5%, is the lowest among state HRIs.

#### Medical School and Graduate Medical Education

Now in its 75th year, UTSW's Medical School is consistently ranked in the Top 30 among 160 nationally for research and primary care, the only state medical school so rated. As of 2017, UTSW has educated 11,300+ undergraduate physicians. At student capacity since the early 2000s, with an average annual graduating class of 240, the medical school is the 9th largest in the U.S. In FY16, 52% of that year's graduates entered Primary Care residency and 56% of all UTSW medical school graduates were practicing in Texas. UTSW also provides Continuing Medical Education to ~53,200 practicing physicians per year.

The Graduate Medical Education program trains 1,370 residents in 104 accredited Primary and Specialty care programs across North Texas. With the largest public GME program in Texas, UTSW trains almost one in five doctors in the state, including a considerable number of primary care physicians. The OB/GYN program is the largest in the country, and the Internal Medicine and Pediatrics programs are the second largest in Texas. Almost 30% of UTSW residents are in Primary Care programs. Its 98 Specialty Care programs, such as Emergency Medicine, Psychiatry, Pediatric Cardiology and Neurosurgery, train residents in specialties with some of the greatest physician shortages in Texas, greater even than Primary Care. Six specialty training programs – including Forensic Psychiatry, Orthopaedic Trauma, and Toxicology – are the only programs in Texas training these physicians. In total, UTSW graduates ~500 practicing physicians per year from its GME programs and in FY18 >50% remained in practice in Texas.

#### Graduate School of Biomedical Sciences and School of Health Professions

UTSW's Graduate School of Biomedical Sciences and School of Health Professions are also highly regarded. The Graduate School trains ~1,000 students and post-doctoral fellows, helping to produce the next generation of scientists as the largest program encompassing 27% of all biomedical sciences students in Texas. The Graduate School includes two divisions, Basic and Clinical Science, offering Ph.D. degrees in 12 areas such as Biomedical Engineering, Neuroscience and Clinical Psychology

## Administrator's Statement

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

### 729 The University of Texas Southwestern Medical Center

---

A vibrant research enterprise is essential to the education of these students – most graduate training, by necessity for practice and accreditation standards, is done in the lab.

The School of Health Professions, although smaller with an enrollment of 340, educates students to address critical shortages in many healthcare professions that help to extend medical doctors' practice. Its Physician Assistant program is ranked among the Top 15 in the U.S. Other programs include Physical Therapy, Prosthetics/Orthotics, Clinical Nutrition, Rehabilitation Counseling and Radiation Therapy. Most of these are two-year programs and effectively blend classroom instruction with patient care experience, resulting in high licensure pass rates and job placement.

#### Patient Care – Linked to Education and Research

Though UTSW receives no State dollars to construct or operate clinical facilities, UTSW provides an enormous amount of primary and specialty care to patients from the area, and sought-after care to patients referred from across Texas and beyond who are in need of tertiary and quaternary care that only a top-ranked academic center can provide. Approximately 2.4M outpatients and 105,000 hospitalized patients are treated annually. Patients are cared for at two UTSW owned and operated State hospitals, Zale Lipshy and William P. Clements Jr. University Hospital, a state-of-the art teaching facility opened in December 2014 and already under expansion to meet patient demand, seven years ahead of schedule. Its original construction was accomplished – also ahead of schedule and under budget – with a large portion coming from faculty physician earnings, which they elected to invest in this transformative hospital, designed to integrate teaching and research missions while maximizing quality and efficiency in patient care. After just three years in operation, CUH has been ranked 2nd among all hospitals in Texas by US News & World Report, and patient satisfaction surveys put it in the top 1% of hospitals nationally. The goal for UTSW is to continue pioneering a patient-centric hospital offering broad clinical expertise so Texas residents need never again leave the state to access comprehensive care on par with world-renowned centers like the Mayo Clinic.

Significant care is also provided at our major teaching hospital partners, Parkland (one of the largest teaching hospitals in the U.S.) and Children's Medical Center (a Top 10 pediatric hospital), as well as the North Texas VA and many other locations across the region.

Through the quality of its providers and research, UTSW works to offer the most advanced and best caliber of care to all patients. Its Simmons Cancer Center secured the highest NCI Comprehensive Cancer Center designation in 2014, the second in Texas. In 2017, our nursing team secured Magnet designation, the highest honor awarded by the American Nurses Credentialing Center, which means our nurses are nationally recognized for providing excellent care and advancing their practice through research, while patients are assured they have chosen one of only 7% of hospital systems in the U.S. known for providing the “gold standard” of nursing excellence. UTSW is also certified as the only Advanced Comprehensive Stroke Center in North Texas, and access to some of the most innovative treatments is available only through clinical trials at UTSW and telehealth services offered to patients across the region.

UTSW physicians provide ~\$107M in uncompensated care, ~4% of our entire University expense. While no funding for patient care services or facilities is received from the State or UT System, the success of UTSW's university health system, in addition to promoting medical education and research, has generated funds ~\$120M per year that has been reinvested to support more GME training and resident positions.

#### Research – Essential to Excellence in Education and Patient Care

UTSW has earned a global reputation as a top research institution. Many of its programs and faculty members have achieved wide-ranging recognition for accomplishments in biomedical research, which is integral to excellence in patient care and education. Six UTSW faculty have been awarded the Nobel Prize. The first in 1987 for research that led to the development of cholesterol-controlling statin drugs – recognizing work performed in Texas, a first in Nobel history – and the most recent

**Administrator's Statement**

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

**729 The University of Texas Southwestern Medical Center**

---

in 2013 for seminal discoveries in cellular transport systems, with applications to all organ systems. UTSW also leads Texas in having 22 faculty elected to the National Academy of Sciences – the “hall of fame” for American scientists, 16 in the National Academy of Medicine, and 15 of 18 Howard Hughes Medical Institute investigators in Texas – three of the most objective national measures of faculty excellence.

In a significant achievement – and external validation of the strength of biomedical research in Texas – UTSW was ranked #1 within the healthcare category internationally for publishing high-quality scientific research, according to the most recent renowned Nature Index Annual Tables. This global listing evaluates institutions based on the number of peer-reviewed research articles published in the most prestigious scientific journals, and placed UTSW above peers such as Columbia University Medical Center, Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital.

In 2017, the Nature Index for innovation also ranked UTSW #5 in the world in the number of published research articles cited as significant sources in third-party patent applications. This new measurement evaluates an institution’s impact and influence on industrial innovation – how a scientific discovery leads to the commercialization of new therapies.

While we are proud of our faculty’s accomplishments, these recognitions represent far more than academic accolades. Each day, Texans directly benefit from our research as discoveries made in labs at UTSW are translated into treatments for rare diseases and chronic conditions.

For example, Dr. Marc Diamond at UTSW’s Peter O’Donnell Brain Institute, recently made a major breakthrough with exceptional promise to lead to actual treatment for Alzheimer’s, having discovered the "Big Bang" of the disease’s progression — the point at which the healthy tau protein believed to be responsible for the condition becomes toxic, but has not yet formed deadly tangles in the brain. Clinical trials based on his discovery are scheduled to begin in 2019. Last year, Dr. Eric Olson at the State-supported Hamon Center for Regenerative Science & Medicine developed a gene therapy treatment for Duchenne muscular dystrophy, bringing hope to thousands of boys stricken by this fatal disease. Advances in molecular genetics pioneered by Dr. Helen Hobbs have led to a new class of drugs to manage high cholesterol, and researchers at the State-supported Texas Institute for Brain Injury & Repair are leading the way to a better understanding of concussions and head trauma.

Research – State support and ROI

All of these major patient care breakthroughs are the culmination of years of scientific endeavor and could not happen without consistent core research funding.

As Research Formula support for Texas HRIs has declined from a high of 2.85% to a 1.16% match for every \$100M in research expenditures, the primary mechanism available to UTSW and used by the Legislature to invest in its core research operations has been Non-Formula Support (formerly termed “Special Items”). Beyond the lifesaving discoveries and impact on patients, this investment continues to pay significant economic dividends to the State.

In FY17, UTSW had \$455M in research expenditures, a majority from out of state competitive sources such as NIH. For every \$1 appropriated to UTSW to seed or invest in research infrastructure, UTSW secures \$7 in federal and other external funds brought to Texas. UTSW discoveries have led to the creation of 40 biotech companies, 8 in the last year, raising more than \$2B invested in Texas. With investment on par with more generous match support available to general academic universities, UTSW could exponentially capitalize on the State’s investment and augment its contributions to Texas’ economic development and stated desire to advance biotech, the only major industry in which our state appears to lag.

PRIORITIES – INSTITUTIONAL AND STATEWIDE

**Administrator's Statement**

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

**729 The University of Texas Southwestern Medical Center**

---

UTSW is grateful for the support the State has provided to develop this Texas institution into a world-class academic medical center. In the inextricably linked education, research and patient care missions of nationally-ranked medical centers, UTSW has grown remarkably over the past 20 years, in size and quality. Yet, work remains to accomplish UTSW's long-term goal of achieving national status for Texas as our state's first Top 10 institution.

To accomplish this, constant care and strategic State investment – equally important in times of economic recession and of prosperity – are essential to maintaining operations and advancing excellence at UTSW. The Legislature's decision to continue Non-Formula Support and Hold Harmless appropriations for UTSW and other impacted institutions of higher education in the FY20-21 base budget is deeply appreciated and essential to UTSW's trajectory.

**Institutional Priorities**

State support is the bedrock on which UTSW's education and research missions are built and is irreplaceable as there is no other source of funding to maintain infrastructure for these core functions. Yet, due to structural deficiencies in the State's higher education formulas to fund institutions like UTSW that are at student capacity and research intensive, UTSW has lost traditional access to formulaic increases in State support.

UTSW's State appropriation for FY18-19 totals \$282M (less debt service) and includes a critical \$21.8M hold harmless appropriation that prevented a significant ~8% reduction for this biennium. Despite long operating the largest public GME and biomedical sciences graduate student programs in Texas and the second largest medical school, and receiving vital Non-Formula core research support, for which the institution is very grateful, UTSW biennially weathers automatic formula reductions and more severe cuts to both formula and non-formula support in constrained budget sessions.

For almost two decades, the only option available to UTSW to maintain funding and core research operations has been to request unpredictable Non-Formula Support. UTSW has benefited from the Legislature's appropriating such support, yet this mechanism is understandably not favored by many and even with such vital funding, other biennial reductions have maintained UTSW below its appropriations from ten years ago. Importantly, the unpredictability of Non-Formula funding has impeded UTSW's trajectory and ability to plan and capitalize its deployment of the State's investment to provide even greater ROI to patients and Texas.

UTSW respectfully submits that an institution-specific performance-driven biomedical research formula mechanism is needed to enable predictable funding to one of Texas' most established research institutions. Such a mechanism can be overlaid by Intent Rider onto the Hold Harmless appropriation already included in UTSW's base budget, with appropriate performance metrics to be authorized by the Legislature and, importantly, serving to inject accountability into UTSW's core research funding. This approach has precedent in appropriations to HRIs with institution-specific formula support, while requiring enhanced benchmark attainment.

In the absence of a formula-driven mechanism necessary to maintain and foster operations, UTSW is compelled to continue to request Exceptional Items for the purposes of strategic research investment and hope that they are funded as one of the only available mechanisms to increase its funding from the last biennium for targeted purposes that also deliver ROI to the State. (Other avenues to address at-capacity institutions through the Formulas and/or through full funding of enrollment growth in the I&O Formula remain at the Legislature's discretion.)

**Exceptional Item Requests**

UTSW respectfully submits three Exceptional Item requests. All are in areas of existing research and clinical expertise that would capitalize on State support, promising

**Administrator's Statement**

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

**729 The University of Texas Southwestern Medical Center**

---

tremendous ROI in future medical discoveries and external funds brought to Texas.

**1. Center for Gene Therapy & Curative Medicine**

In recent years, biomedical researchers have made important discoveries to help us understand the enormous potential of gene therapy in the treatment of disease, which holds the promise of a one-time "forever fix" for patients. UTSW's Center for Gene Therapy & Curative Medicine - with recent recruitment of a leader in gene replacement therapy and significant investment in a drug development facility - is poised to lead the U.S. in this next frontier of medicine, starting with the most rare conditions, ~7,000 that typically present in children, and eventually more complex diseases such as Alzheimer's. UTSW requests \$18M in State core research support to realize this goal.

Rather than just managing the symptoms of chronic and untreatable diseases, gene therapy can fix a genetic problem at its source and stop the disease permanently. Many diseases have genetic causes, so the potential is boundless to move towards a care model of early diagnosis, followed by transformative treatment to prevent incurable conditions from ever developing. Several years ago, UTSW recognized the need to invest in this new frontier as a means of bringing hope to patients with rare or previously untreatable diseases.

Early steps towards establishment of the Center included recruitment of a national leader in the successful development of an innocuous human virus as a vehicle for the delivery of gene therapy, and establishment of a rare Viral Vector Production Facility, on which the success of moving more gene therapy discovery into clinical testing is dependent. The planned facility and its scale is the only one of its kind at an HRI in Texas and the U.S., meeting FDA regulations to produce gene-based investigational drugs that may be injected into humans, and helping UTSW move researchers' discoveries into Phase I clinical trials. UTSW also concurrently invested in offering a seamless bench-to-bedside pipeline with regulatory support to its researchers, emphasized a model of partnerships with nonprofits and disease stakeholders to help fund treatments, and begun building relationships with industry partners to ensure that early-phase trial drugs don't get stuck forever in research phase. The facility will be a driver for greater commercialization of gene therapies, with all of the benefits to patients and impact on the state economy that come with this.

Yet, in addition to this groundwork by UTSW, much technical and proof-of-concept research remains to be conducted. UTSW requests State investment to capitalize on efforts to date to make Texas the leader in this new frontier of medicine - starting with genes responsible for devastating neurodevelopmental disorders in infants and children that are individually rare but collectively common - to achieve gene therapy as a standard, curative therapy for all patients suffering from one of these more than 7,000 rare diseases.

**2. Texas Center for Advanced Radiation Therapy (TCART) – Heavy Ion Research & Treatment Facility**

Heavy Ion therapy is the most potent and effective form of radiation for cancer patients, but is not available in the U.S. In 2015, TCART – with the research consortium led by UTSW and including MD Anderson, UT Austin, UTHSC San Antonio, Texas A&M, Prairie View A&M, Baylor Medical Center, NASA and others – secured one of two National Cancer Institute planning grants, which the 84th Legislature matched to help bring a center to Texas. A California team received the second grant, leaving Texas vying with California to secure sufficient support to establish the first U.S. Heavy Ion facility and an NCI Research Center of Excellence grant. UTSW requests \$9M more in State core research support to build on progress to date.

UTSW has made significant progress, including completing the technical design of the sizable and highly specialized equipment needed, architectural design plans, securing FY18 federal omnibus budget intent to establish a center, and enabling competitive pilot projects by Texas research consortium members to advance the technology. We are perfectly positioned to capitalize on this opportunity for Texas, to establish the most comprehensive advanced radiation center in the world for cancer therapy, capable of carrying out basic, pre-clinical, clinical and physics-related research, as well as large scale clinical trials. Efficacy of Heavy Ions has been established by foreign centers, but still critically needed to uncover its full potential are improved accelerator/beam delivery technology, an understanding of the underlying biology,

**729 The University of Texas Southwestern Medical Center**

---

and more clinical trials, including a rare international trial using foreign centers that UTSW has coordinated.

The establishment of all centers worldwide has been made possible with government support given the prohibitive expense, ~\$230M at UTSW. UTSW is working to secure stakeholder commitment with vendor discussions and federal requests in work, as well as philanthropic donations, contingent on State and federal support. Now needed is additional State support to produce correlating data and advance the technology to the extent needed to competitively secure the inaugural NCI-designated U.S. center for Texas.

**3. Tuition Revenue Bond Request – Joint UT Dallas/UTSW Translational Biomedical Engineering & Science Building**

Recent advances have begun to show the promise of application of previously unimaginable bioengineering approaches – such as tissue engineering, organ fabrication, and neuroprosthesis – to restore function to damaged tissues and organs. Yet, there is a pressing need to translate biomedical technologies from the idea stage to improved treatment for millions of patients in Texas and beyond. UTD and UTSW – leveraging research strengths in basic and applied biomedical and engineering sciences – are poised to expand their collaborations into a center for biomedical innovation and translation. A critical missing ingredient is the proposed properly designed facility on UTSW’s campus to optimally connect engineers and scientists with physicians and patients, accelerating the advancement of medical technologies, and training and education for students. The project will provide up to 180,000 GSF of research and support space to dozens of faculty and students from UTD and UTSW. The estimated cost is \$120M, fully funded with TRB support, as there is no other source of construction funding from either campus.

**Statewide Priorities**

UTSW is also supportive of the priorities of the University of Texas System that are consistent with longstanding statewide priorities that benefit UTSW and all HRIs in Texas. To the extent that additional funds in the 86th Session are available for HRIs, we hope that the following will be considered.

**GME Formula.** UTSW applauds the 85th Legislature’s continued efforts to ensure that all Texas medical school graduates have a GME residency position available in state for their continued training. UTSW hopes that if additional funds are available, continued and increased funding for current residency programs through the GME Formula be considered, since that formula rate (\$5,824) remains ~30% of the Texas Higher Education Coordinating Board’s 2004 inflation-adjusted determination of actual cost (~\$20,000). This is essential for Texas to maintain its efforts to keep the recipients of the state’s investment in medical education in state.

**Governor’s University Research Initiative.** In the 84th Session, Governor Abbott obtained ~\$40M for GURI, a new effort to attract leading national researchers to Texas, an essential component in elevating Texas to top tier research status. While UTSW was unable to participate this biennium, the continuation and expansion of the program categories of eligible researchers to “rising stars” is vital, and could prove an even better investment of State support.

**IMPACT OF FY20-21 10% REDUCTION PLAN**

UTSW has submitted the required plan to decrease its non-formula funding by 10%. At UTSW, this would result in a reduction to important Non-Formula Support items that are primarily state targeted research investments – a necessary complement to education and advancing patient care, and essential given the depreciation in overall Research Formula support. UTSW has already identified, realized and maximized cost-saving opportunities and implemented personnel reductions to absorb separate 15%, 25% and 4% reductions received within the last nine years. An additional 10% non-formula reduction would necessitate significant further reductions in personnel and further affect the services, activities and outcomes from these programs.

**Administrator's Statement**

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

**729 The University of Texas Southwestern Medical Center**

---

UTSW research Non-Formula Support items provide high value to Texas. These programs are leveraged to bring outstanding researchers from top institutions around the U.S. to Texas, as well as millions of dollars in new external research funding on an ongoing basis, fueling economic development. State funding is essential to seed the research infrastructure needed for faculty to be competitive for grants. The additional 10% reduction would restrict UTSW's ability to retain the current level of external dollars brought to Texas and to make life-changing and cost-saving discoveries for Texans. Current Non-Formula research support totals \$43M per year. A 10% reduction would result in an annual loss of \$4.3M in critical research support, which pays dividends many times over to the State. Based on UTSW's historical 7:1 ROI, an annual loss of \$30M can eventually be expected as a result of this reduction and undoubtedly would also lead to loss of top faculty to peer institutions in other states.

Additional information on the specific impact to date on research and advances in patient care enabled by UTSW's Non-Formula support can be found in each item's description in Schedule 9.

**CONCLUSION**

UTSW greatly appreciates the State's support and respectfully requests consideration of the outlined funding priorities and implementation by legislative intent rider of performance drivers to be associated with a Core Research Operations formula using UTSW's Hold Harmless appropriation included in its base appropriation. With sufficient funding, UTSW can continue to deliver tremendous ROI on the State's investment – training a remarkable number of medical and other practicing healthcare professions for Texas, more successfully retaining its star faculty, and recruiting and developing more recognized investigators to further increase Texas' fitting claim as a research leader and destination for the best and brightest from around the world.

UTSW also supports statewide funding policies for HRIs that provide the resources necessary to develop a world-class healthcare and research workforce; enhance research capacity; expand the Texas economy through technology and improve the quality and availability of healthcare for all Texans. Objective measures demonstrate UTSW provides exceptional value to Texas per State dollar received, and UTSW pledges to continue to return the State's investment many times over, while assuring quality education and health services for future generations of Texans.

The University of Texas System is governed by a Board of Regents.

**AGENCY STATUTORY AUTHORITY TO CONDUCT BACKGROUND CHECKS**

The statutory authority for conducting background checks is Government Code Section 411.094 and Education Code section 51.215. UTSW Human Resources Policy Memorandum 1.020 states:

"Positions shall be designated as security-sensitive if they are senior level administrator positions, or positions with authority for committing the financial resources of the university, or if duties of the position include handling currency, access to a computer, access to a master key, patient care, child-care in a child-care facility, access to or responsibility for pharmaceuticals, other controlled substances or hazardous substances, or the shipping, transporting, possession, receipt or access to any select agent (as defined in 18 U.S.C. Section 175b) or provide access to an area in which such agents are stored, used, disposed of, or present, or access to an area of the institution which has been designated as a security sensitive area. A criminal background check will be performed on the finalist for a security sensitive position, and if circumstances require that an offer of employment be made before the completion of an investigation, the offer will be in writing and include the following: This offer is contingent on the completion of a satisfactory criminal background investigation. An individual will not begin work until completion of a background check and determination by the Office of Human Resources that the individual's background is suitable for employment."

**Administrator's Statement**

10/19/2018 3:28:00PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---


**729 The University of Texas Southwestern Medical Center**

---

Background checks for UTSW are run through a third party vendor, GroupOne Services, Inc., a division of the DFW Hospital Council. Information provided to UTSW by GroupOne Services include criminal history (Dallas Co., Tarrant Co. and TX DPS), educational history, employment history, address verification, address locator, verification of licensure, motor vehicle record (if required for job), terrorist suspect/OFAC list, social security verification, state Medicaid sanctions, OIG Medicare sanctions and individually selected federal searches if the candidate has lived outside Texas.



# UT Southwestern Medical Center Organizational Chart



THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER  
LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021  
MANAGEMENT STRUCTURE OF AGENCY

---

President – leads the medical center which includes three degree-granting institutions: UT Southwestern Medical School, UT Southwestern Graduate School of Biomedical Sciences, and UT Southwestern Allied Health Sciences School as well as the University Hospitals and physician practice plan. The President leads one of the country's leading academic medical centers, patient-care providers and research institutions.

Vice President and Chief of Staff – key adviser to the president, working with faculty and staff on a wide range of issues as his personal representative and will collaborate on a regular basis with other members of the senior leadership team, in a number of areas, most notably the implementation of plans emerging from the several task forces focused on the strategic priorities.

Vice President for Technology Development – serves as the principal administrative officer for technology development for UT Southwestern and is responsible for participating in administrative consideration of all policies, plans, and programs relating to technology development of intellectual property at UT Southwestern, representing UT Southwestern on matters pertaining to technology development, and coordinating and facilitating the development of technology at UT Southwestern.

Vice President for Legal Affairs – serves as the administrative officer for legal affairs of UT Southwestern, including the representation of UT Southwestern in legal matters, on and off campus. The Vice President of Legal Affairs is also responsible for coordinating and facilitating legal and technology transfer matters with UT System administration, including the Office of General Counsel, and coordinating with the Office of the Attorney General and outside counsel as needed.

Vice President for Strategic Initiatives - identifies, develops and oversees the implementation of key strategic initiatives such as new service line development, organizational partnerships, and other efforts which support the mission of UT Southwestern.

Executive Vice President for Institutional Advancement – responsible for developing and overseeing a comprehensive and coordinated strategic agenda to promote and advance UT Southwestern's mission and goals, including oversight of communications, marketing and public affairs, community and corporate relations, development, and government affairs and policy.

Vice President for Development and Alumni Relations - responsible for the oversight of the Office of Development, which receives gift donations and keeps records of all gifts donated to UT Southwestern and works to enlist new donors. Also leads alumni affairs, which is responsible for providing students with support long after graduation.

Vice President for Communications, Marketing and Public Affairs – serves as the administrative officer for communications, marketing and public affairs for UT Southwestern.

Vice President for Government Affairs & Policy – serves as the administrative officer for government affairs and policy for UT Southwestern.

Vice President for Community and Corporate Relations – serves as the principal administrative officer for community and corporate relations for UT Southwestern and represents UT Southwestern in community and corporate relations support activities as well as coordinating and facilitating community and corporate relations activities which affect UT Southwestern.

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER  
LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021  
MANAGEMENT STRUCTURE OF AGENCY

---

Vice President Global Advancement - responsible for planning and implementation of a comprehensive international philanthropy program, establishing a global brand presence for UT Southwestern and Dallas healthcare institutions in order to develop new market channels for international patient populations.

Provost and Executive Vice President for Academic Affairs – serves as the principal executive and administrative officer for all academically related operations of UT Southwestern, including oversight for UT Southwestern’s three schools.

Vice Provost and Dean of Basic Research – responsible for oversight of the graduate school, maintaining leadership of the highest quality for our basic science efforts, fostering a scientific environment of excellence by promoting our strategic initiatives, and assuring that UT Southwestern stays at the forefront of research technologies.

Vice Provost & Senior Associate Dean for Education: Provides support to the Dean and Provost in all matters related to the effective and efficient running of UT Southwestern Medical School, School of Health Professions and Graduate School of Biomedical Sciences. Position also serves as Title IX Coordinator.

Vice President and Chief Operating Officer for Academic Affairs – responsible for aligning administrative and fiscal resources to allow achievement of operational objectives. Position serves as a liaison between leadership for Academic Affairs, Business Affairs, and Health System Affairs for fiscal and administrative functions.

Vice Provost and Senior Associate Dean for Faculty Affairs and Initiatives: advises and implements policies of the Provost and Dean of UT Southwestern Medical School in all matters of faculty affairs and clinical department initiatives.

Executive Vice President for Health System Affairs – responsible for the overall management of university outpatient clinics, University Hospitals, and the integrated health system, as well as faculty practice operations.

Vice President for Clinical Operations – has responsibility for the development, review and recommendation of “best practices” for primary care and specialty services through the clinical services initiative which was established to lead UT Southwestern’s plan for transforming patient care.

Vice President and CEO for University Hospitals – serves as the principal executive and administrative officer for the University Hospitals.

Vice President Chief Quality Officer - provides leadership in the development and measurement of UT Southwestern’s approach to quality/performance improvement, patient outcomes and medical safety while ensuring compliance with laws, government regulations, JCAHO requirements, and UT Southwestern policies.

Vice President Medical Affairs - provide medical leadership and oversight in the development, planning, and operations for the UT Southwestern Health System University-Based Physician Practice and Affiliate Physician Networks.

Vice President and Chief Operations Officer of Health System Affairs - leads the administrative and operational functions of the UT Southwestern physician practice and Health System and Population Health Services Company.

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER  
LEGISLATIVE APPROPRIATIONS FOR FY 2020 – 2021  
MANAGEMENT STRUCTURE OF AGENCY

---

Executive Vice President for Business Affairs – serves as the principal executive and administrative officer for all business related operations of UT Southwestern, including oversight of such departments as financial affairs, human resources, facilities management and university police.

Vice President for Facilities Management – responsible for the support of UT Southwestern Medical Center, including its Hospitals and Clinics, by providing general services, building maintenance, utilities services, planning, design and construction, site wide services, and landscaping services to the medical center.

Vice President for Financial Affairs – responsible for oversight of fiscally related operations such as accounting, budget, financial planning, and purchasing.

Vice President, CIO Information Resources – responsible for the support of UT Southwestern Medical Center, including its Hospitals and Clinics, by providing computing, networking, audiovisual, voice and data telecommunication, and television services to all client organizations.

Vice President for Human Resources – responsible for the oversight of the Office of Human Resources, which is responsible for employee relations, compensation and performance management, organization development and training, and recruitment and retention of employees.

**Budget Overview - Biennial Amounts**  
**86th Regular Session, Agency Submission, Version 1**  
Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center  
Appropriation Years: 2020-21

	GENERAL REVENUE FUNDS		GR DEDICATED		FEDERAL FUNDS		OTHER FUNDS		ALL FUNDS		EXCEPTIONAL ITEM FUNDS	
	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2020-21	
<b>Goal: 1. Provide Instructional and Operations Support</b>												
1.1.1. Medical Education	118,195,042		5,630,920						123,825,962			
1.1.2. Biomedical Sciences Training	13,915,727		47,400						13,963,127			
1.1.3. Allied Health Professions Training	8,224,698		1,168,950						9,393,648			
1.1.4. Graduate Medical Education	15,118,653								15,118,653			
1.2.1. Staff Group Insurance Premiums			4,278,337	6,609,672					4,278,337	6,609,672		
1.3.1. Texas Public Education Grants			2,502,084	2,435,272					2,502,084	2,435,272		
1.5.1. Hold Harmless		21,817,302								21,817,302		
<b>Total, Goal</b>	<b>155,454,120</b>	<b>21,817,302</b>	<b>13,627,691</b>	<b>9,044,944</b>					<b>169,081,811</b>	<b>30,862,246</b>		
<b>Goal: 2. Provide Research Support</b>												
2.1.1. Research Enhancement	9,475,096		285,828						9,760,924			
<b>Total, Goal</b>	<b>9,475,096</b>		<b>285,828</b>						<b>9,760,924</b>			
<b>Goal: 3. Provide Infrastructure Support</b>												
3.1.1. E&G Space Support	24,855,701		726,025						25,581,726			
3.2.1. Tuition Revenue Bond Retirement	37,040,230	37,032,100							37,040,230	37,032,100	10,460,000	
<b>Total, Goal</b>	<b>61,895,931</b>	<b>37,032,100</b>	<b>726,025</b>						<b>62,621,956</b>	<b>37,032,100</b>	<b>10,460,000</b>	

**Budget Overview - Biennial Amounts**  
**86th Regular Session, Agency Submission, Version 1**  
Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center  
Appropriation Years: 2020-21

	GENERAL REVENUE FUNDS		GR DEDICATED		FEDERAL FUNDS		OTHER FUNDS		ALL FUNDS		EXCEPTIONAL ITEM FUNDS
	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2018-19	2020-21	2020-21
<b>Goal: 4. Provide Non-formula Support</b>											
4.1.1. Primary Care Residency Training	2,367,388	1,943,152							2,367,388	1,943,152	
4.2.1. Institute For Nobel/Na Bio Research	12,533,732	11,430,764	77,450						12,611,182	11,430,764	
4.2.2. Innovations In Med Technology	13,679,416	12,475,628	111,508						13,790,924	12,475,628	
4.2.3. Metroplex Comp Med Imaging Center	11,399,984	10,396,784	74,110						11,474,094	10,396,784	
4.2.4. Cntr Obesity, Diabetes & Metab Rsch	13,679,984	12,476,150	85,428						13,765,412	12,476,150	
4.2.6. Center For Research Of Sickle Cell	2,255,507	2,079,342	7,120						2,262,627	2,079,342	
4.2.7. Tx Inst For Brain Injury And Repair	15,026,430	13,680,000	56,958						15,083,388	13,680,000	
4.2.8. Center For Reg. Science & Medicine	16,000,000	14,592,000	93,484						16,093,484	14,592,000	
4.2.9. Center For Adv Radiation Therapy	2,000,982	1,824,000	982						2,001,964	1,824,000	9,000,000
4.3.1. Regional Burn Care Center	190,219	173,264	235						190,454	173,264	
4.4.1. Science Teacher Access To Resources	1,152,472	1,039,664	8,946						1,161,418	1,039,664	
4.5.1. Institutional Enhancement	1,487,340	1,459,184	44,580						1,531,920	1,459,184	
4.6.1. Exceptional Item Request											18,000,000
<b>Total, Goal</b>	<b>91,773,454</b>	<b>83,569,932</b>	<b>560,801</b>						<b>92,334,255</b>	<b>83,569,932</b>	<b>27,000,000</b>
<b>Goal: 6. Tobacco Funds</b>											
6.1.1. Tobacco Earnings - Ut Swmc							9,538,787	6,280,000	9,538,787	6,280,000	
6.1.2. Tobacco - Permanent Health Fund							6,921,009	5,772,728	6,921,009	5,772,728	
<b>Total, Goal</b>							<b>16,459,796</b>	<b>12,052,728</b>	<b>16,459,796</b>	<b>12,052,728</b>	
<b>Total, Agency</b>	<b>318,598,601</b>	<b>142,419,334</b>	<b>15,200,345</b>	<b>9,044,944</b>			<b>16,459,796</b>	<b>12,052,728</b>	<b>350,258,742</b>	<b>163,517,006</b>	<b>37,460,000</b>
<b>Total FTEs</b>									<b>1,956.8</b>	<b>1,956.8</b>	<b>140.0</b>

2.A. Summary of Base Request by Strategy

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal / Objective / STRATEGY	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b>1</b> Provide Instructional and Operations Support					
<b>1</b> <i>Instructional Programs</i>					
<b>1</b> MEDICAL EDUCATION (1)	63,143,174	63,396,635	60,429,327	0	0
<b>2</b> BIOMEDICAL SCIENCES TRAINING (1)	6,837,371	6,968,666	6,994,461	0	0
<b>3</b> ALLIED HEALTH PROFESSIONS TRAINING (1)	3,951,152	4,685,149	4,708,499	0	0
<b>4</b> GRADUATE MEDICAL EDUCATION (1)	9,909,415	7,805,083	7,313,570	0	0
<b>2</b> <i>Operations - Staff Benefits</i>					
<b>1</b> STAFF GROUP INSURANCE PREMIUMS	1,614,075	2,234,249	2,044,088	3,304,836	3,304,836
<b>3</b> <i>Operations - Statutory Funds</i>					
<b>1</b> TEXAS PUBLIC EDUCATION GRANTS	1,045,658	1,284,448	1,217,636	1,217,636	1,217,636
<b>5</b> <i>Hold Harmless</i>					
<b>1</b> HOLD HARMLESS	0	0	0	10,908,652	10,908,650
<b>TOTAL, GOAL</b> <b>1</b>	<b>\$86,500,845</b>	<b>\$86,374,230</b>	<b>\$82,707,581</b>	<b>\$15,431,124</b>	<b>\$15,431,122</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

2.A. Summary of Base Request by Strategy

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal / Objective / STRATEGY	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b>2</b> Provide Research Support					
<b>1</b> <i>Research Activities</i>					
<b>1 RESEARCH ENHANCEMENT</b> (1)	3,868,718	3,972,830	5,788,094	0	0
<b>TOTAL, GOAL</b> <b>2</b>	<b>\$3,868,718</b>	<b>\$3,972,830</b>	<b>\$5,788,094</b>	<b>\$0</b>	<b>\$0</b>
<b>3</b> Provide Infrastructure Support					
<b>1</b> <i>Operations and Maintenance</i>					
<b>1 E&amp;G SPACE SUPPORT</b> (1)	11,690,605	12,072,988	13,508,738	0	0
<b>2</b> <i>Infrastructure Support</i>					
<b>1 TUITION REVENUE BOND RETIREMENT</b>	18,520,163	18,520,099	18,520,131	18,515,700	18,516,400
<b>TOTAL, GOAL</b> <b>3</b>	<b>\$30,210,768</b>	<b>\$30,593,087</b>	<b>\$32,028,869</b>	<b>\$18,515,700</b>	<b>\$18,516,400</b>
<b>4</b> Provide Non-formula Support					
<b>1</b> <i>Residency Training</i>					
<b>1 PRIMARY CARE RESIDENCY TRAINING</b>	1,183,694	1,183,694	1,183,694	971,576	971,576

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.



2.A. Summary of Base Request by Strategy

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal / Objective / STRATEGY	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b>2 Research</b>					
1 INSTITUTE FOR NOBEL/NA BIO RESEARCH	6,178,546	6,291,670	6,319,512	5,715,382	5,715,382
2 INNOVATIONS IN MED TECHNOLOGY	6,715,284	6,871,378	6,919,546	6,237,814	6,237,814
3 METROPLEX COMP MED IMAGING CENTER	5,614,054	5,724,485	5,749,609	5,198,392	5,198,392
4 CNTR OBESITY, DIABETES & METAB RSCH	6,569,863	6,864,883	6,900,529	6,238,075	6,238,075
6 CENTER FOR RESEARCH OF SICKLE CELL	1,148,166	1,147,112	1,115,515	1,039,671	1,039,671
7 TX INST FOR BRAIN INJURY AND REPAIR	6,713,769	7,528,384	7,555,004	6,840,000	6,840,000
8 CENTER FOR REG. SCIENCE & MEDICINE	4,638,766	8,044,308	8,049,176	7,296,000	7,296,000
9 CENTER FOR ADV RADIATION THERAPY	952,713	1,000,982	1,000,982	912,000	912,000
<b>3 Health Care</b>					
1 REGIONAL BURN CARE CENTER	95,228	95,227	95,227	86,632	86,632
<b>4 Public Service</b>					
1 SCIENCE TEACHER ACCESS TO RESOURCES	542,252	578,938	582,480	519,832	519,832

2.A. Summary of Base Request by Strategy

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal / Objective / STRATEGY	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<u>5</u> Institutional					
1 INSTITUTIONAL ENHANCEMENT	708,858	763,804	768,116	729,592	729,592
<u>6</u> Exceptional Item Request					
1 EXCEPTIONAL ITEM REQUEST	0	0	0	0	0
TOTAL, GOAL 4	<b>\$41,061,193</b>	<b>\$46,094,865</b>	<b>\$46,239,390</b>	<b>\$41,784,966</b>	<b>\$41,784,966</b>
<u>6</u> Tobacco Funds					
<u>1</u> Tobacco Earnings for Eminent Scholars					
1 TOBACCO EARNINGS - UT SWMC	2,371,544	4,755,442	4,783,345	3,140,000	3,140,000
2 TOBACCO - PERMANENT HEALTH FUND	2,738,389	3,442,496	3,478,513	2,886,364	2,886,364
TOTAL, GOAL 6	<b>\$5,109,933</b>	<b>\$8,197,938</b>	<b>\$8,261,858</b>	<b>\$6,026,364</b>	<b>\$6,026,364</b>
TOTAL, AGENCY STRATEGY REQUEST	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>
TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST*				\$0	\$0
GRAND TOTAL, AGENCY REQUEST	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>

2.A. Summary of Base Request by Strategy

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal / Objective / STRATEGY	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b>METHOD OF FINANCING:</b>					
<b>General Revenue Funds:</b>					
1 General Revenue Fund	155,707,280	159,283,242	159,315,359	71,209,318	71,210,016
<b>SUBTOTAL</b>	<b>\$155,707,280</b>	<b>\$159,283,242</b>	<b>\$159,315,359</b>	<b>\$71,209,318</b>	<b>\$71,210,016</b>
<b>General Revenue Dedicated Funds:</b>					
704 Est Bd Authorized Tuition Inc	554,230	606,350	610,000	0	0
770 Est. Other Educational & General	5,380,014	7,145,420	6,838,575	4,522,472	4,522,472
<b>SUBTOTAL</b>	<b>\$5,934,244</b>	<b>\$7,751,770</b>	<b>\$7,448,575</b>	<b>\$4,522,472</b>	<b>\$4,522,472</b>
<b>Other Funds:</b>					
810 Perm Health Fund Higher Ed, est	2,738,389	3,442,496	3,478,513	2,886,364	2,886,364
813 Perm Endow FD UT SW MED, estimated	2,371,544	4,755,442	4,783,345	3,140,000	3,140,000
<b>SUBTOTAL</b>	<b>\$5,109,933</b>	<b>\$8,197,938</b>	<b>\$8,261,858</b>	<b>\$6,026,364</b>	<b>\$6,026,364</b>
<b>TOTAL, METHOD OF FINANCING</b>	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>

\*Rider appropriations for the historical years are included in the strategy amounts.

2.B. Summary of Base Request by Method of Finance  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

10/19/2018 3:28:06PM

Agency code: 729		Agency name: The University of Texas Southwestern Medical Center				
METHOD OF FINANCING		Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b><u>GENERAL REVENUE</u></b>						
<b>1</b>	General Revenue Fund					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2016-17 GAA)	\$153,139,690	\$0	\$0	\$0	\$0
	Regular Appropriations from MOF Table (2018-19 GAA)	\$0	\$159,283,274	\$159,315,359	\$71,209,318	\$71,210,016
	<i>TRANSFERS</i>					
	THECB Rider 71/HB100 Tuition Revenue Bond	\$6,187,656	\$0	\$0	\$0	\$0
	<i>LAPSED APPROPRIATIONS</i>					
	Lapsed appropriations attributable to Governor's Hiring Freeze in fiscal year 2017	\$(3,620,066)	\$0	\$0	\$0	\$0
	Lapsed Appropriations	\$0	\$(32)	\$0	\$0	\$0
<b>TOTAL,</b>	<b>General Revenue Fund</b>	<b>\$155,707,280</b>	<b>\$159,283,242</b>	<b>\$159,315,359</b>	<b>\$71,209,318</b>	<b>\$71,210,016</b>

2.B. Summary of Base Request by Method of Finance

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 729		Agency name: The University of Texas Southwestern Medical Center				
METHOD OF FINANCING		Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b>TOTAL, ALL</b>	<b>GENERAL REVENUE</b>	<b>\$155,707,280</b>	<b>\$159,283,242</b>	<b>\$159,315,359</b>	<b>\$71,209,318</b>	<b>\$71,210,016</b>
<b><u>GENERAL REVENUE FUND - DEDICATED</u></b>						
<b>704</b>	GR Dedicated - Estimated Board Authorized Tuition Increases Account No. 704					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2016-17 GAA)	\$349,425	\$0	\$0	\$0	\$0
	Regular Appropriations from MOF Table (2018-19 GAA)	\$0	\$498,306	\$498,306	\$0	\$0
	<i>BASE ADJUSTMENT</i>					
	Revised Receipts	\$204,805	\$108,044	\$111,694	\$0	\$0
<b>TOTAL,</b>	<b>GR Dedicated - Estimated Board Authorized Tuition Increases Account No. 704</b>	<b>\$554,230</b>	<b>\$606,350</b>	<b>\$610,000</b>	<b>\$0</b>	<b>\$0</b>
<b>770</b>	GR Dedicated - Estimated Other Educational and General Income Account No. 770					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2016-17 GAA)	\$7,103,654	\$0	\$0	\$0	\$0

2.B. Summary of Base Request by Method of Finance  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

10/19/2018 3:28:06PM

Agency code: 729		Agency name: The University of Texas Southwestern Medical Center				
METHOD OF FINANCING		Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
<b><u>GENERAL REVENUE FUND - DEDICATED</u></b>						
	Regular Appropriations from MOF Table (2018-19 GAA)	\$0	\$6,746,270	\$6,746,271	\$4,522,472	\$4,522,472
<i>BASE ADJUSTMENT</i>						
	Revised Receipts	\$(666,237)	\$399,150	\$92,304	\$0	\$0
	Adjust to Expended	\$(1,057,403)	\$0	\$0	\$0	\$0
<b>TOTAL,</b>	<b>GR Dedicated - Estimated Other Educational and General Income Account No. 770</b>	<b>\$5,380,014</b>	<b>\$7,145,420</b>	<b>\$6,838,575</b>	<b>\$4,522,472</b>	<b>\$4,522,472</b>
<b>TOTAL GENERAL REVENUE FUND - DEDICATED - 704, 708 &amp; 770</b>						
		<b>\$5,934,244</b>	<b>\$7,751,770</b>	<b>\$7,448,575</b>	<b>\$4,522,472</b>	<b>\$4,522,472</b>
<b>TOTAL, ALL</b>	<b>GENERAL REVENUE FUND - DEDICATED</b>	<b>\$5,934,244</b>	<b>\$7,751,770</b>	<b>\$7,448,575</b>	<b>\$4,522,472</b>	<b>\$4,522,472</b>
<b>TOTAL,</b>	<b>GR &amp; GR-DEDICATED FUNDS</b>	<b>\$161,641,524</b>	<b>\$167,035,012</b>	<b>\$166,763,934</b>	<b>\$75,731,790</b>	<b>\$75,732,488</b>

**OTHER FUNDS**

2.B. Summary of Base Request by Method of Finance

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 729

Agency name: The University of Texas Southwestern Medical Center

METHOD OF FINANCING	Exp 2017	Est 2018	Bud 2019	Req 2020	Req 2021
---------------------	----------	----------	----------	----------	----------

**OTHER FUNDS**

**810** Permanent Health Fund for Higher Education

*REGULAR APPROPRIATIONS*

Regular Appropriations from MOF Table (2016-17 GAA)

\$2,676,419	\$0	\$0	\$0	\$0
-------------	-----	-----	-----	-----

Regular Appropriations from MOF Table (2018-19 GAA)

\$0	\$2,684,972	\$2,684,972	\$2,886,364	\$2,886,364
-----	-------------	-------------	-------------	-------------

*RIDER APPROPRIATION*

Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2016

\$1,222,443	\$0	\$0	\$0	\$0
-------------	-----	-----	-----	-----

Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2018

\$(1,178,947)	\$1,178,947	\$0	\$0	\$0
---------------	-------------	-----	-----	-----

Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2018

\$0	\$(589,474)	\$589,474	\$0	\$0
-----	-------------	-----------	-----	-----

*BASE ADJUSTMENT*

Revised Receipts - Distribution

2.B. Summary of Base Request by Method of Finance

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: <b>729</b>		Agency name: <b>The University of Texas Southwestern Medical Center</b>				
<b>METHOD OF FINANCING</b>		<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>Req 2020</b>	<b>Req 2021</b>
<b><u>OTHER FUNDS</u></b>						
		\$8,553	\$160,027	\$201,392	\$0	\$0
	Revised Receipts - Interest					
		\$9,921	\$8,024	\$2,675	\$0	\$0
<b>TOTAL,</b>	<b>Permanent Health Fund for Higher Education</b>					
		<b>\$2,738,389</b>	<b>\$3,442,496</b>	<b>\$3,478,513</b>	<b>\$2,886,364</b>	<b>\$2,886,364</b>
<b><u>813</u></b>	Permanent Endowment Fund, UT Southwestern Medical Center at Dallas					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2016-17 GAA)					
		\$2,985,000	\$0	\$0	\$0	\$0
	Regular Appropriations from MOF Table (2018-19 GAA)					
		\$0	\$3,060,000	\$3,060,000	\$3,140,000	\$3,140,000
	<i>RIDER APPROPRIATION</i>					
	Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2016)					
		\$2,549,021	\$0	\$0	\$0	\$0
	Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2018)					



2.B. Summary of Base Request by Method of Finance

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: <b>729</b>		Agency name: <b>The University of Texas Southwestern Medical Center</b>				
<b>METHOD OF FINANCING</b>		<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>Req 2020</b>	<b>Req 2021</b>
<b><u>OTHER FUNDS</u></b>						
		\$ (3,269,591)	\$ 3,269,591	\$ 0	\$ 0	\$ 0
	Estimated Unexpended Balances, Appropriation Rider 3 for UT Southwestern Medical Center (2018)	\$ 0	\$ (1,634,796)	\$ 1,634,796	\$ 0	\$ 0
<i>BASE ADJUSTMENT</i>						
	Revised Receipts - Distribution	\$ 75,000	\$ 35,000	\$ 80,000	\$ 0	\$ 0
	Revised Receipts - Interest	\$ 32,114	\$ 25,647	\$ 8,549	\$ 0	\$ 0
<b>TOTAL,</b>	<b>Permanent Endowment Fund, UT Southwestern Medical Center at Dallas</b>	<b>\$ 2,371,544</b>	<b>\$ 4,755,442</b>	<b>\$ 4,783,345</b>	<b>\$ 3,140,000</b>	<b>\$ 3,140,000</b>
<b>TOTAL, ALL</b>	<b>OTHER FUNDS</b>	<b>\$ 5,109,933</b>	<b>\$ 8,197,938</b>	<b>\$ 8,261,858</b>	<b>\$ 6,026,364</b>	<b>\$ 6,026,364</b>
<b>GRAND TOTAL</b>		<b>\$ 166,751,457</b>	<b>\$ 175,232,950</b>	<b>\$ 175,025,792</b>	<b>\$ 81,758,154</b>	<b>\$ 81,758,852</b>

**2.B. Summary of Base Request by Method of Finance**

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: <b>729</b>	Agency name: <b>The University of Texas Southwestern Medical Center</b>				
<b>METHOD OF FINANCING</b>	<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>Req 2020</b>	<b>Req 2021</b>
<b>FULL-TIME-EQUIVALENT POSITIONS</b>					
REGULAR APPROPRIATIONS					
Regular Appropriations from MOF Table (2016-17 GAA)	1,956.8	0.0	0.0	0.0	0.0
Regular Appropriations from MOF Table (2018-19 GAA)	0.0	1,910.6	1,910.3	1,922.9	1,922.9
Other Appropriated FTEs	0.0	46.2	46.5	33.9	33.9
<b>Comments:</b> FTEs related to Other Funds (810 & 813)					
LAPSED APPROPRIATIONS					
Unfilled FTE position due to Governor's Hiring Freeze	(56.3)	0.0	0.0	0.0	0.0
UNAUTHORIZED NUMBER OVER (BELOW) CAP					
Unauthorized Number Over (Below) Cap	(100.5)	0.0	0.0	0.0	0.0
<b>TOTAL, ADJUSTED FTES</b>	<b>1,800.0</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>
<b>NUMBER OF 100% FEDERALLY FUNDED FTEs</b>					

2.C. Summary of Base Request by Object of Expense

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

OBJECT OF EXPENSE	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
1001 SALARIES AND WAGES	\$77,023,676	\$79,342,130	\$79,493,095	\$21,124,107	\$21,124,107
1002 OTHER PERSONNEL COSTS	\$3,256,618	\$4,157,362	\$3,986,211	\$4,087,159	\$4,087,159
1005 FACULTY SALARIES	\$58,465,555	\$65,512,921	\$65,335,026	\$31,585,636	\$31,585,636
2001 PROFESSIONAL FEES AND SERVICES	\$63,664	\$92,357	\$93,153	\$71,580	\$71,580
2003 CONSUMABLE SUPPLIES	\$42,575	\$64,881	\$65,419	\$48,975	\$48,975
2004 UTILITIES	\$42,558	\$77,266	\$77,781	\$53,435	\$53,435
2006 RENT - BUILDING	\$1,457	\$2,922	\$2,939	\$1,929	\$1,929
2008 DEBT SERVICE	\$18,520,163	\$18,520,099	\$18,520,131	\$18,515,700	\$18,516,400
2009 OTHER OPERATING EXPENSE	\$9,252,707	\$7,337,909	\$7,325,889	\$6,174,964	\$6,174,962
5000 CAPITAL EXPENDITURES	\$82,484	\$125,103	\$126,148	\$94,669	\$94,669
<b>OOE Total (Excluding Riders)</b>	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>
<b>OOE Total (Riders)</b>					
<b>Grand Total</b>	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>

2.D. Summary of Base Request Objective Outcomes

10/19/2018 3:28:06PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation system of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Goal/ Objective / Outcome	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
1 Provide Instructional and Operations Support 1 Instructional Programs					
<b>KEY 1 % Medical School Students Passing NLE Part 1 or Part 2 on First Try</b>	96.73%	97.50%	97.50%	97.50%	97.50%
<b>KEY 2 % Medical School Graduates Practicing Primary Care in Texas</b>	23.30%	17.46%	17.98%	18.52%	19.08%
<b>3 % Med School Grads Practicing Primary Care in Texas Underserved Area</b>	1.77%	1.67%	1.72%	1.77%	1.82%
<b>KEY 4 Percent of Medical Residency Completers Practicing in Texas</b>	54.13%	54.27%	55.90%	57.58%	59.30%
<b>5 Total Uncompensated Care Provided by Faculty</b>	106,841,662.00	136,330,236.00	137,693,538.00	139,070,473.00	140,461,178.00
<b>6 Total Net Patient Revenue by Faculty</b>	636,955,950.00	662,852,474.00	705,996,737.00	757,393,283.00	825,770,621.00
<b>KEY 7 Percent Allied Health Grads Passing Certif/Licensure Exam First Try</b>	98.44%	98.50%	98.50%	98.50%	98.50%
<b>KEY 8 Percent Allied Health Graduates Licensed or Certified in Texas</b>	76.30%	77.00%	77.00%	77.00%	77.00%
<b>KEY 9 Administrative (Instit Support) Cost As % of Total Expenditures</b>	2.99%	3.00%	3.00%	3.00%	3.00%
<b>KEY 12 % Medical School Graduates Practicing in Texas</b>	53.30%	59.77%	59.77%	59.77%	59.77%

**2.D. Summary of Base Request Objective Outcomes**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation system of Texas (ABEST)

10/19/2018 3:28:06PM

---

**729 The University of Texas Southwestern Medical Center**

---

Goal/ Objective / Outcome	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
2 Provide Research Support					
1 Research Activities					
<b>KEY</b> 1 Total External Research Expenditures	346,547,046.00	353,368,060.00	360,417,886.00	367,652,473.00	374,906,297.00
2 External Research Expends As % of State Appropriations for Research	685.02%	711.29%	725.48%	740.05%	754.65%
3 Research Expenditures Supported by the Hughes Institute and VA Center	22,837,740.00	22,000,000.00	22,000,000.00	22,000,000.00	22,000,000.00

**2.E. Summary of Exceptional Items Request**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME : 3:28:06PM

Agency code: 729

Agency name: **The University of Texas Southwestern Medical Center**

Priority	Item	2020			2021			Biennium	
		GR and GR/GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds
1	Gene Therapy & Curative Medicine	\$9,000,000	\$9,000,000	50.0	\$9,000,000	\$9,000,000	90.0	\$18,000,000	\$18,000,000
2	Advanced Radiation Therapy	\$4,500,000	\$4,500,000	50.0	\$4,500,000	\$4,500,000	50.0	\$9,000,000	\$9,000,000
3	UTD/UTSW Joint Project	\$5,230,000	\$5,230,000		\$5,230,000	\$5,230,000		\$10,460,000	\$10,460,000
<b>Total, Exceptional Items Request</b>		<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>100.0</b>	<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>140.0</b>	<b>\$37,460,000</b>	<b>\$37,460,000</b>

**Method of Financing**

General Revenue	\$18,730,000	\$18,730,000		\$18,730,000	\$18,730,000		\$37,460,000	\$37,460,000
General Revenue - Dedicated								
Federal Funds								
Other Funds								
	<b>\$18,730,000</b>	<b>\$18,730,000</b>		<b>\$18,730,000</b>	<b>\$18,730,000</b>		<b>\$37,460,000</b>	<b>\$37,460,000</b>

**Full Time Equivalent Positions**

**100.0**

**140.0**

**Number of 100% Federally Funded FTEs**

**2.F. Summary of Total Request by Strategy**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE : 10/19/2018  
 TIME : 3:28:06PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Goal/Objective/STRATEGY	Base 2020	Base 2021	Exceptional 2020	Exceptional 2021	Total Request 2020	Total Request 2021
<b>1 Provide Instructional and Operations Support</b>						
<i>1 Instructional Programs</i>						
1 MEDICAL EDUCATION	\$0	\$0	\$0	\$0	\$0	\$0
2 BIOMEDICAL SCIENCES TRAINING	0	0	0	0	0	0
3 ALLIED HEALTH PROFESSIONS TRAINING	0	0	0	0	0	0
4 GRADUATE MEDICAL EDUCATION	0	0	0	0	0	0
<i>2 Operations - Staff Benefits</i>						
1 STAFF GROUP INSURANCE PREMIUMS	3,304,836	3,304,836	0	0	3,304,836	3,304,836
<i>3 Operations - Statutory Funds</i>						
1 TEXAS PUBLIC EDUCATION GRANTS	1,217,636	1,217,636	0	0	1,217,636	1,217,636
<i>5 Hold Harmless</i>						
1 HOLD HARMLESS	10,908,652	10,908,650	0	0	10,908,652	10,908,650
<b>TOTAL, GOAL 1</b>	<b>\$15,431,124</b>	<b>\$15,431,122</b>	<b>\$0</b>	<b>\$0</b>	<b>\$15,431,124</b>	<b>\$15,431,122</b>
<b>2 Provide Research Support</b>						
<i>1 Research Activities</i>						
1 RESEARCH ENHANCEMENT	0	0	0	0	0	0
<b>TOTAL, GOAL 2</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>
<b>3 Provide Infrastructure Support</b>						
<i>1 Operations and Maintenance</i>						
1 E&G SPACE SUPPORT	0	0	0	0	0	0
<i>2 Infrastructure Support</i>						
1 TUITION REVENUE BOND RETIREMENT	18,515,700	18,516,400	5,230,000	5,230,000	23,745,700	23,746,400
<b>TOTAL, GOAL 3</b>	<b>\$18,515,700</b>	<b>\$18,516,400</b>	<b>\$5,230,000</b>	<b>\$5,230,000</b>	<b>\$23,745,700</b>	<b>\$23,746,400</b>

**2.F. Summary of Total Request by Strategy**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE : 10/19/2018

TIME : 3:28:06PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

<b>Goal/Objective/STRATEGY</b>	<b>Base 2020</b>	<b>Base 2021</b>	<b>Exceptional 2020</b>	<b>Exceptional 2021</b>	<b>Total Request 2020</b>	<b>Total Request 2021</b>
<b>4 Provide Non-formula Support</b>						
<i>1 Residency Training</i>						
1 PRIMARY CARE RESIDENCY TRAINING	\$971,576	\$971,576	\$0	\$0	\$971,576	\$971,576
<i>2 Research</i>						
1 INSTITUTE FOR NOBEL/NA BIO RESEARCH	5,715,382	5,715,382	0	0	5,715,382	5,715,382
2 INNOVATIONS IN MED TECHNOLOGY	6,237,814	6,237,814	0	0	6,237,814	6,237,814
3 METROPLEX COMP MED IMAGING CENTER	5,198,392	5,198,392	0	0	5,198,392	5,198,392
4 CNTR OBESITY, DIABETES & METAB RSCH	6,238,075	6,238,075	0	0	6,238,075	6,238,075
6 CENTER FOR RESEARCH OF SICKLE CELL	1,039,671	1,039,671	0	0	1,039,671	1,039,671
7 TX INST FOR BRAIN INJURY AND REPAIR	6,840,000	6,840,000	0	0	6,840,000	6,840,000
8 CENTER FOR REG. SCIENCE & MEDICINE	7,296,000	7,296,000	0	0	7,296,000	7,296,000
9 CENTER FOR ADV RADIATION THERAPY	912,000	912,000	4,500,000	4,500,000	5,412,000	5,412,000
<i>3 Health Care</i>						
1 REGIONAL BURN CARE CENTER	86,632	86,632	0	0	86,632	86,632
<i>4 Public Service</i>						
1 SCIENCE TEACHER ACCESS TO RESOURCES	519,832	519,832	0	0	519,832	519,832
<i>5 Institutional</i>						
1 INSTITUTIONAL ENHANCEMENT	729,592	729,592	0	0	729,592	729,592
<i>6 Exceptional Item Request</i>						
1 EXCEPTIONAL ITEM REQUEST	0	0	9,000,000	9,000,000	9,000,000	9,000,000
<b>TOTAL, GOAL 4</b>	<b>\$41,784,966</b>	<b>\$41,784,966</b>	<b>\$13,500,000</b>	<b>\$13,500,000</b>	<b>\$55,284,966</b>	<b>\$55,284,966</b>



**2.F. Summary of Total Request by Strategy**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE : 10/19/2018  
 TIME : 3:28:06PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

<b>Goal/Objective/STRATEGY</b>	<b>Base 2020</b>	<b>Base 2021</b>	<b>Exceptional 2020</b>	<b>Exceptional 2021</b>	<b>Total Request 2020</b>	<b>Total Request 2021</b>
<b>6 Tobacco Funds</b>						
<i>1 Tobacco Earnings for Eminent Scholars</i>						
1 TOBACCO EARNINGS - UT SWMC	\$3,140,000	\$3,140,000	\$0	\$0	\$3,140,000	\$3,140,000
2 TOBACCO - PERMANENT HEALTH FUND	2,886,364	2,886,364	0	0	2,886,364	2,886,364
<b>TOTAL, GOAL 6</b>	<b>\$6,026,364</b>	<b>\$6,026,364</b>	<b>\$0</b>	<b>\$0</b>	<b>\$6,026,364</b>	<b>\$6,026,364</b>
<b>TOTAL, AGENCY STRATEGY REQUEST</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>	<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>\$100,488,154</b>	<b>\$100,488,852</b>
<b>TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST</b>						
<b>GRAND TOTAL, AGENCY REQUEST</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>	<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>\$100,488,154</b>	<b>\$100,488,852</b>

**2.F. Summary of Total Request by Strategy**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE : 10/19/2018  
 TIME : 3:28:06PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

<b>Goal/Objective/STRATEGY</b>	<b>Base 2020</b>	<b>Base 2021</b>	<b>Exceptional 2020</b>	<b>Exceptional 2021</b>	<b>Total Request 2020</b>	<b>Total Request 2021</b>
<b>General Revenue Funds:</b>						
1 General Revenue Fund	\$71,209,318	\$71,210,016	\$18,730,000	\$18,730,000	\$89,939,318	\$89,940,016
	<b>\$71,209,318</b>	<b>\$71,210,016</b>	<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>\$89,939,318</b>	<b>\$89,940,016</b>
<b>General Revenue Dedicated Funds:</b>						
704 Est Bd Authorized Tuition Inc	0	0	0	0	0	0
770 Est. Other Educational & General	4,522,472	4,522,472	0	0	4,522,472	4,522,472
	<b>\$4,522,472</b>	<b>\$4,522,472</b>	<b>\$0</b>	<b>\$0</b>	<b>\$4,522,472</b>	<b>\$4,522,472</b>
<b>Other Funds:</b>						
810 Perm Health Fund Higher Ed, est	2,886,364	2,886,364	0	0	2,886,364	2,886,364
813 Perm Endow FD UT SW MED, estimated	3,140,000	3,140,000	0	0	3,140,000	3,140,000
	<b>\$6,026,364</b>	<b>\$6,026,364</b>	<b>\$0</b>	<b>\$0</b>	<b>\$6,026,364</b>	<b>\$6,026,364</b>
<b>TOTAL, METHOD OF FINANCING</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>	<b>\$18,730,000</b>	<b>\$18,730,000</b>	<b>\$100,488,154</b>	<b>\$100,488,852</b>
<b>FULL TIME EQUIVALENT POSITIONS</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>100.0</b>	<b>140.0</b>	<b>2,056.8</b>	<b>2,096.8</b>



**2.G. Summary of Total Request Objective Outcomes**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation system of Texas (ABEST)

Date : 10/19/2018

Time: 3:28:07PM

Agency code: 729

Agency name: The University of Texas Southwestern Medical Center

Goal/ Objective / Outcome

	BL 2020	BL 2021	Excp 2020	Excp 2021	Total Request 2020	Total Request 2021
<b>KEY</b> <b>9 Administrative (Instit Support) Cost As % of Total Expenditures</b>	3.00%	3.00%			3.00%	3.00%
<b>KEY</b> <b>12 % Medical School Graduates Practicing in Texas</b>	59.77%	59.77%			59.77%	59.77%
2      Provide Research Support						
1 <i>Research Activities</i>						
<b>KEY</b> <b>1 Total External Research Expenditures</b>	367,652,473.00	374,906,297.00			367,652,473.00	374,906,297.00
<b>2 External Research Expends As % of State Appropriations for Research</b>	740.05%	754.65%			740.05%	754.65%
<b>3 Research Expenditures Supported by the Hughes Institute and VA Center</b>	22,000,000.00	22,000,000.00			22,000,000.00	22,000,000.00

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 1 Medical Education

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Output Measures:</b>						
1	Minority Graduates as a Percent of Total Graduates (All Schools)	11.46 %	12.69 %	13.07 %	13.46 %	13.87 %
2	Minority Graduates As a Percent of Total MD/DO Graduates	13.22 %	16.80 %	17.30 %	17.82 %	18.36 %
3	Total Number of Outpatient Visits	2,717,434.00	2,939,443.00	3,083,936.00	3,237,661.00	3,412,678.00
4	Total Number of Inpatient Days	582,909.00	594,396.00	608,430.00	623,403.00	642,291.00
5	Total Number of Postdoctoral Research Trainees (All Schools)	405.00	430.00	425.00	425.00	425.00
KEY 7	Number of Combined MD/PhD Graduates	13.00	11.00	11.00	11.00	11.00
<b>Efficiency Measures:</b>						
1	Avg Cost of Resident Undergraduate Tuition and Fees for 15 Sch	0.00	0.00	0.00	0.00	0.00
<b>Explanatory/Input Measures:</b>						
KEY 1	Minority Admissions As % of Total First-year Admissions (All Schools)	13.61 %	10.84 %	11.17 %	11.50 %	11.85 %
KEY 2	Minority MD Admissions As % of Total MD Admissions	22.27 %	15.61 %	16.08 %	16.56 %	17.06 %
KEY 3	% Medical School Graduates Entering a Primary Care Residency	42.29 %	47.63 %	49.06 %	50.53 %	52.05 %

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 1 Medical Education

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
KEY 4	Average Student Loan Debt for Medical School Graduates	77,760.00	85,000.00	87,550.00	90,175.00	92,900.00
KEY 5	Percent of Medical School Graduates with Student Loan Debt	60.35 %	70.00 %	70.00 %	70.00 %	70.00 %
6	Average Financial Aid Award Per Full-time Student	0.00	0.00	0.00	0.00	0.00
7	Percent of Full-time Students Receiving Financial Aid	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$43,094,845	\$43,267,830	\$41,242,660	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$684,484	\$687,233	\$655,065	\$0	\$0
1005	FACULTY SALARIES	\$19,363,845	\$19,441,572	\$18,531,602	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$63,143,174</b>	<b>\$63,396,635</b>	<b>\$60,429,327</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$61,668,242	\$60,405,160	\$57,789,882	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$61,668,242</b>	<b>\$60,405,160</b>	<b>\$57,789,882</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$1,474,932	\$2,991,475	\$2,639,445	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$1,474,932</b>	<b>\$2,991,475</b>	<b>\$2,639,445</b>	<b>\$0</b>	<b>\$0</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 1 Medical Education

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$63,143,174</b>	<b>\$63,396,635</b>	<b>\$60,429,327</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>763.0</b>	<b>816.5</b>	<b>766.7</b>	<b>687.5</b>	<b>687.5</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Instruction and Operations Formula provides funding for faculty salaries, departmental operating expense, library, instructional administration, student services and institutional support. The formula for this strategy is based on weighted medical student headcounts. The rate per weighted student headcount or full time equivalent is established by the Legislature each biennium.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 1 Medical Education

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
------	-------------	----------	----------	----------	------------------------	------------------------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$123,825,962	\$0	\$(123,825,962)	\$(123,825,962)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<b>\$(123,825,962)</b>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.



**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 2 Graduate Training in Biomedical Sciences

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$2,577,181	\$2,626,670	\$2,636,392	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$22,237	\$22,664	\$22,748	\$0	\$0
1005	FACULTY SALARIES	\$4,181,069	\$4,261,357	\$4,277,130	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$56,884	\$57,975	\$58,191	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$6,837,371</b>	<b>\$6,968,666</b>	<b>\$6,994,461</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$6,818,446	\$6,949,416	\$6,966,311	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$6,818,446</b>	<b>\$6,949,416</b>	<b>\$6,966,311</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
704	Est Bd Authorized Tuition Inc	\$18,925	\$19,250	\$28,150	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$18,925</b>	<b>\$19,250</b>	<b>\$28,150</b>	<b>\$0</b>	<b>\$0</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 2 Graduate Training in Biomedical Sciences

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$6,837,371</b>	<b>\$6,968,666</b>	<b>\$6,994,461</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>102.5</b>	<b>104.5</b>	<b>104.9</b>	<b>104.9</b>	<b>104.9</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Instruction and Operations Formula provides funding for faculty salaries, departmental operating expense, library, instructional administration, student services and institutional support. The formula for this strategy is based on weighted biomedical student full time equivalent. The rate per weighted student headcount or full time equivalent is established by the Legislature each biennium.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 2 Graduate Training in Biomedical Sciences

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
------	-------------	----------	----------	----------	------------------------	------------------------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$13,963,127	\$0	\$(13,963,127)	\$(13,963,127)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<b>\$(13,963,127)</b>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 3 Allied Health Professions Training

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,159,646	\$1,375,071	\$1,381,924	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$24,032	\$28,497	\$28,639	\$0	\$0
1005	FACULTY SALARIES	\$2,728,579	\$3,235,462	\$3,251,587	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$38,895	\$46,119	\$46,349	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$3,951,152</b>	<b>\$4,685,149</b>	<b>\$4,708,499</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$3,415,847	\$4,098,049	\$4,126,649	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$3,415,847</b>	<b>\$4,098,049</b>	<b>\$4,126,649</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
704	Est Bd Authorized Tuition Inc	\$535,305	\$587,100	\$581,850	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$535,305</b>	<b>\$587,100</b>	<b>\$581,850</b>	<b>\$0</b>	<b>\$0</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 3 Allied Health Professions Training

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$3,951,152</b>	<b>\$4,685,149</b>	<b>\$4,708,499</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>68.2</b>	<b>80.9</b>	<b>81.3</b>	<b>81.3</b>	<b>81.3</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Instruction and Operations Formula provides funding for faculty salaries, departmental operating expense, library, instructional administration, student services and institutional support. The formula for this strategy is based on weighted allied health student full time equivalent. The rate per weighted student headcount or full time equivalent is established by the Legislature each biennium.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 3 Allied Health Professions Training

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
------	-------------	----------	----------	----------	------------------------	------------------------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$9,393,648	\$0	\$(9,393,648)	\$(9,393,648)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<u>\$(9,393,648)</u>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 4 Graduate Medical Education

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Output Measures:</b>						
KEY 1	Total Number of MD or DO Residents	1,348.00	1,388.00	1,430.00	1,459.00	1,488.00
<b>Explanatory/Input Measures:</b>						
KEY 1	Minority MD or DO Residents as a Percent of Total MD or DO Residents	12.17 %	12.56 %	12.94 %	13.32 %	13.72 %
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,146,226	\$1,242,095	\$1,150,673	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$16,389	\$15,610	\$14,627	\$0	\$0
1005	FACULTY SALARIES	\$6,254,737	\$6,337,727	\$5,938,619	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$2,492,063	\$209,651	\$209,651	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$9,909,415</b>	<b>\$7,805,083</b>	<b>\$7,313,570</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$9,909,415	\$7,805,083	\$7,313,570	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$9,909,415</b>	<b>\$7,805,083</b>	<b>\$7,313,570</b>	<b>\$0</b>	<b>\$0</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 1 Instructional Programs  
 STRATEGY: 4 Graduate Medical Education

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>					<b>\$9,909,415</b>	<b>\$7,805,083</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>					<b>38.9</b>	<b>30.6</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>					<b>28.7</b>	<b>28.7</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Graduate Medical Education formula allocates funding based on the number of medical residents. These funds shall be used to support the number of resident slots in the State of Texas as well as faculty costs related to GME.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$15,118,653	\$0	\$(15,118,653)	\$(15,118,653)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<b>\$(15,118,653)</b>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.



**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 2 Operations - Staff Benefits  
 STRATEGY: 1 Staff Group Insurance Premiums

Service Categories:

Service: 06      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1002	OTHER PERSONNEL COSTS	\$1,614,075	\$2,234,249	\$2,044,088	\$3,304,836	\$3,304,836
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$1,614,075</b>	<b>\$2,234,249</b>	<b>\$2,044,088</b>	<b>\$3,304,836</b>	<b>\$3,304,836</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$1,614,075	\$2,234,249	\$2,044,088	\$3,304,836	\$3,304,836
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$1,614,075</b>	<b>\$2,234,249</b>	<b>\$2,044,088</b>	<b>\$3,304,836</b>	<b>\$3,304,836</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$3,304,836</b>	<b>\$3,304,836</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$1,614,075</b>	<b>\$2,234,249</b>	<b>\$2,044,088</b>	<b>\$3,304,836</b>	<b>\$3,304,836</b>

**FULL TIME EQUIVALENT POSITIONS:**

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

This strategy is to provide proportional share of staff group insurance premiums paid from Other Educational and General funds.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 2 Operations - Staff Benefits  
 STRATEGY: 1 Staff Group Insurance Premiums

Service Categories:

Service: 06      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>		
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)	
\$4,278,337	\$6,609,672	\$2,331,335	\$2,331,335	Increase in number of participants and use of other non-appropriated funds in FY18 and FY19 to cover costs.	
			<b>\$2,331,335</b>	<b>Total of Explanation of Biennial Change</b>	

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 3 Operations - Statutory Funds  
 STRATEGY: 1 Texas Public Education Grants

Service Categories:

Service: 20      Income: A.1      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
2009	OTHER OPERATING EXPENSE	\$1,045,658	\$1,284,448	\$1,217,636	\$1,217,636	\$1,217,636
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$1,045,658</b>	<b>\$1,284,448</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$1,045,658	\$1,284,448	\$1,217,636	\$1,217,636	\$1,217,636
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$1,045,658</b>	<b>\$1,284,448</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$1,217,636</b>	<b>\$1,217,636</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$1,045,658</b>	<b>\$1,284,448</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>	<b>\$1,217,636</b>

**FULL TIME EQUIVALENT POSITIONS:**

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

This strategy represents tuition set aside for the Texas Public Education Grants program as required by Section 56.033 of the Texas Education Code.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 3 Operations - Statutory Funds Service Categories:  
 STRATEGY: 1 Texas Public Education Grants Service: 20 Income: A.1 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$2,502,084	\$2,435,272	\$(66,812)	\$(66,812)	Amounts requested are in line with set aside requirements.
			<u>\$(66,812)</u>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 5 Hold Harmless  
 STRATEGY: 1 Hold Harmless

Service Categories:  
 Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$0	\$0	\$0	\$5,607,766	\$5,607,766
1002	OTHER PERSONNEL COSTS	\$0	\$0	\$0	\$97,597	\$97,597
1005	FACULTY SALARIES	\$0	\$0	\$0	\$4,736,876	\$4,736,876
2009	OTHER OPERATING EXPENSE	\$0	\$0	\$0	\$466,413	\$466,411
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$10,908,652</b>	<b>\$10,908,650</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$0	\$0	\$0	\$10,908,652	\$10,908,650
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$10,908,652</b>	<b>\$10,908,650</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$10,908,652</b>	<b>\$10,908,650</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$10,908,652</b>	<b>\$10,908,650</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>135.6</b>	<b>135.6</b>
<b>STRATEGY DESCRIPTION AND JUSTIFICATION:</b>						

**729 The University of Texas Southwestern Medical Center**

GOAL: 1 Provide Instructional and Operations Support  
 OBJECTIVE: 5 Hold Harmless  
 STRATEGY: 1 Hold Harmless

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>	<u>CHANGE</u>	<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$0	\$21,817,302	\$21,817,302	\$21,817,302	Hold Harmless funds were reported in the strategies in which they were expended.
			<u>\$21,817,302</u>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 2 Provide Research Support  
 OBJECTIVE: 1 Research Activities  
 STRATEGY: 1 Research Enhancement

Service Categories:

Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,657,545	\$1,702,152	\$2,479,898	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$32,937	\$33,823	\$49,278	\$0	\$0
1005	FACULTY SALARIES	\$2,140,259	\$2,197,856	\$3,202,100	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$37,977	\$38,999	\$56,818	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$3,868,718</b>	<b>\$3,972,830</b>	<b>\$5,788,094</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$3,868,718	\$3,861,180	\$5,613,916	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$3,868,718</b>	<b>\$3,861,180</b>	<b>\$5,613,916</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$111,650	\$174,178	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$111,650</b>	<b>\$174,178</b>	<b>\$0</b>	<b>\$0</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 2 Provide Research Support  
 OBJECTIVE: 1 Research Activities  
 STRATEGY: 1 Research Enhancement

Service Categories:

Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$3,868,718</b>	<b>\$3,972,830</b>	<b>\$5,788,094</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>61.9</b>	<b>63.6</b>	<b>92.7</b>	<b>92.7</b>	<b>92.7</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Research Enhancement formula allocates a base amount to each institution in addition to a percent of the research expenditures as reported to the Texas Higher Education Coordinating Board. These funds are used to support the research activities of the institution.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$9,760,924	\$0	\$(9,760,924)	\$(9,760,924)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<b>\$(9,760,924)</b>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.



**729 The University of Texas Southwestern Medical Center**

GOAL: 3 Provide Infrastructure Support  
 OBJECTIVE: 1 Operations and Maintenance  
 STRATEGY: 1 E&G Space Support

Service Categories:

Service: 10      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$11,316,591	\$11,686,740	\$13,076,556	\$0	\$0
1002	OTHER PERSONNEL COSTS	\$250,034	\$258,212	\$288,920	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$123,980	\$128,036	\$143,262	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$11,690,605</b>	<b>\$12,072,988</b>	<b>\$13,508,738</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$11,690,605	\$11,753,473	\$13,102,228	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$11,690,605</b>	<b>\$11,753,473</b>	<b>\$13,102,228</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$319,515	\$406,510	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$319,515</b>	<b>\$406,510</b>	<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$11,690,605</b>	<b>\$12,072,988</b>	<b>\$13,508,738</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>324.3</b>	<b>354.9</b>	<b>374.7</b>	<b>374.7</b>	<b>374.7</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 3 Provide Infrastructure Support  
 OBJECTIVE: 1 Operations and Maintenance  
 STRATEGY: 1 E&G Space Support

Service Categories:  
 Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020 <sup>(1)</sup>	BL 2021 <sup>(1)</sup>
------	-------------	----------	----------	----------	------------------------	------------------------

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Infrastructure Support formula distributes funding associated with plant support and utilities. This formula is driven by the predicted square feet for health related institutions produced by the Coordinating Board Space Projection Model.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$25,581,726	\$0	\$(25,581,726)	\$(25,581,726)	Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.
			<u>\$(25,581,726)</u>	<b>Total of Explanation of Biennial Change</b>

(1) - Formula funded strategies are not requested in 2020-21 because amounts are not determined by institutions.

**729 The University of Texas Southwestern Medical Center**

GOAL: 3 Provide Infrastructure Support  
 OBJECTIVE: 2 Infrastructure Support  
 STRATEGY: 1 Tuition Revenue Bond Retirement

Service Categories:  
 Service: 10      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
2008	DEBT SERVICE	\$18,520,163	\$18,520,099	\$18,520,131	\$18,515,700	\$18,516,400
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$18,520,163</b>	<b>\$18,520,099</b>	<b>\$18,520,131</b>	<b>\$18,515,700</b>	<b>\$18,516,400</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$18,520,163	\$18,520,099	\$18,520,131	\$18,515,700	\$18,516,400
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$18,520,163</b>	<b>\$18,520,099</b>	<b>\$18,520,131</b>	<b>\$18,515,700</b>	<b>\$18,516,400</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$18,515,700</b>	<b>\$18,516,400</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$18,520,163</b>	<b>\$18,520,099</b>	<b>\$18,520,131</b>	<b>\$18,515,700</b>	<b>\$18,516,400</b>

**FULL TIME EQUIVALENT POSITIONS:**

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Tuition Revenue Bond strategy provides for bond indebtedness payments of General Tuition Revenue Bonds. Bond indebtedness payments of General Tuition Revenue Bonds is authorized under Texas Education Code Section 55.17.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**729 The University of Texas Southwestern Medical Center**

GOAL: 3 Provide Infrastructure Support  
 OBJECTIVE: 2 Infrastructure Support Service Categories:  
 STRATEGY: 1 Tuition Revenue Bond Retirement Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$37,040,230	\$37,032,100	\$(8,130)	\$(8,130)	Change in debt service requirement for bond authorizations.
			<b>\$(8,130)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 1 Residency Training

STRATEGY: 1 Primary Care Residency Training Program

Service Categories:

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
2099	OTHER OPERATING EXPENSE	\$1,183,694	\$1,183,694	\$1,183,694	\$971,576	\$971,576
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$971,576</b>	<b>\$971,576</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$1,183,694	\$1,183,694	\$1,183,694	\$971,576	\$971,576
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$971,576</b>	<b>\$971,576</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$971,576</b>	<b>\$971,576</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$1,183,694</b>	<b>\$971,576</b>	<b>\$971,576</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>						
<b>STRATEGY DESCRIPTION AND JUSTIFICATION:</b>						

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 1 Residency Training Service Categories:  
 STRATEGY: 1 Primary Care Residency Training Program Service: 19    Income: A.2    Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

Medical education is only partially complete when the M.D. degree is awarded. Further education in accredited residency programs is essential for the development of the full range of knowledge and skills to perform medical diagnosis and treatment and the certification required for a doctor to practice. This residency education is a major part of the primary mission of all Texas medical schools. UTSW shoulders the burden of training the vast majority of residents, in primary and specialty care, in all of N Texas. Consequently, it has more residents than every other State institution, and thus bears the greatest share of the State’s resident costs. Serving the mission of training residents has significant costs, and the primary cost borne by medical schools is that of providing education by faculty. A portion of the costs associated with faculty supervising the care residents provide is paid with Medicare GME funds. Other than the State GME formula, which pays only ~1/3rd of the ~\$18,000 annual per resident faculty supervision cost, there are no dedicated funds for residents’ education.

This strategy helps fund the disproportionate cost UTSW bears in educating one of the State’s largest number of primary care residents, including direct resident support through payment of 15 stipends. It is essential to continue the number and quality of primary care residency programs at UTSW since such programs are the most important source of primary care doctors in N Texas and statewide.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 1 Residency Training Service Categories:  
 STRATEGY: 1 Primary Care Residency Training Program Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$2,367,388	\$1,943,152	\$(424,236)	\$(424,236)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(424,236)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 1 Institute for Nobel/National-Academy Biomedical Research

Service Categories:

Service: 21

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,204,961	\$1,227,023	\$1,232,453	\$1,114,633	\$1,114,633
1002	OTHER PERSONNEL COSTS	\$32,946	\$33,549	\$33,697	\$30,476	\$30,476
1005	FACULTY SALARIES	\$4,879,792	\$4,969,136	\$4,991,126	\$4,513,986	\$4,513,986
2009	OTHER OPERATING EXPENSE	\$60,847	\$61,962	\$62,236	\$56,287	\$56,287
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$6,178,546</b>	<b>\$6,291,670</b>	<b>\$6,319,512</b>	<b>\$5,715,382</b>	<b>\$5,715,382</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$6,178,546	\$6,266,866	\$6,266,866	\$5,715,382	\$5,715,382
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$6,178,546</b>	<b>\$6,266,866</b>	<b>\$6,266,866</b>	<b>\$5,715,382</b>	<b>\$5,715,382</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$24,804	\$52,646	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$24,804</b>	<b>\$52,646</b>	<b>\$0</b>	<b>\$0</b>



**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research Service Categories:  
 STRATEGY: 1 Institute for Nobel/National-Academy Biomedical Research Service: 21    Income: A.2    Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$5,715,382</b>	<b>\$5,715,382</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$6,178,546</b>	<b>\$6,291,670</b>	<b>\$6,319,512</b>	<b>\$5,715,382</b>	<b>\$5,715,382</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>52.8</b>	<b>53.8</b>	<b>54.0</b>	<b>48.8</b>	<b>48.8</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The Institute for Nobel/National-Academy Biomedical Research began in 2004, predicated on the fact that Texas' long-term success in biomedical science and biotechnology industry depends on having research leaders at our health institutions who rank among the best in the world. This Institute is extremely effective in facilitating this for Texas future. The National Academy of Sciences is the scientific hall of fame and election as a member is the highest honor in the U.S. for a scientist. With 70% of all National Academy members at Texas health institutions at UTSW, and with four of its five Nobel laureates as active faculty members, UTSW is exclusively positioned in Texas for the Institute for Nobel/National-Academy Biomedical Research. Investigators of Nobel Prize-and National Academy-caliber conduct cutting-edge research, bring to Texas millions of dollars in grant funds, and attract the best and brightest co-workers.

UTSW is working to further leverage the success of our globally-recognized research leaders in order to expand research opportunities, recruit more world-class scientists and secure more funds from sources outside Texas. Special Item funding has been appropriated specifically to:

- Provide incentives for highly sought-after scientists to remain in Texas
- Bring millions in outside grants to Texas
- Cultivate state-of-the-art research and commercializable technologies,
- Recruit rising-star scientists mentored by our accomplished faculty members

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 1 Institute for Nobel/National-Academy Biomedical Research

Service Categories:  
 Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$12,611,182	\$11,430,764	\$(1,180,418)	\$(1,180,418)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(1,180,418)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 2 Institute for Innovations in Medical Technology

Service Categories:

Service: 21

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$4,641,975	\$4,749,876	\$4,783,172	\$4,311,921	\$4,311,921
1002	OTHER PERSONNEL COSTS	\$51,534	\$52,732	\$53,102	\$47,870	\$47,870
1005	FACULTY SALARIES	\$1,954,563	\$1,999,996	\$2,014,016	\$1,815,590	\$1,815,590
2009	OTHER OPERATING EXPENSE	\$67,212	\$68,774	\$69,256	\$62,433	\$62,433
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$6,715,284</b>	<b>\$6,871,378</b>	<b>\$6,919,546</b>	<b>\$6,237,814</b>	<b>\$6,237,814</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$6,715,284	\$6,839,708	\$6,839,708	\$6,237,814	\$6,237,814
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$6,715,284</b>	<b>\$6,839,708</b>	<b>\$6,839,708</b>	<b>\$6,237,814</b>	<b>\$6,237,814</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$31,670	\$79,838	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$31,670</b>	<b>\$79,838</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research Service Categories:  
 STRATEGY: 2 Institute for Innovations in Medical Technology Service: 21    Income: A.2    Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$6,237,814</b>	<b>\$6,237,814</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$6,715,284</b>	<b>\$6,871,378</b>	<b>\$6,919,546</b>	<b>\$6,237,814</b>	<b>\$6,237,814</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>82.8</b>	<b>84.7</b>	<b>85.3</b>	<b>76.9</b>	<b>76.9</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The mission of the Institute for Innovations in Medical Technology (IIMT) is to cultivate cutting-edge research with potential to develop into commercializable technologies, and to help transition them from discovery to patient care. This goal is being accomplished by developing and maintaining a unique group of specialized "Core" Laboratory facilities that support such research affordably and efficiently, retaining an extraordinary concentration of innovative biomedical scientists on our faculty and facilitating the recruitment of rising star faculty to Texas, bringing millions in federal and private grants to the state, and maintaining enhanced infrastructure and expert staff to facilitate commercialization, which in turn attracts vital biotechnology partners to North Texas.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research Service Categories:  
 STRATEGY: 2 Institute for Innovations in Medical Technology Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>		
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)	
\$13,790,924	\$12,475,628	\$(1,315,296)	\$(1,315,296)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.	
			<b>\$(1,315,296)</b>	<b>Total of Explanation of Biennial Change</b>	

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 3 Metroplex Comprehensive Medical Imaging Center

Service Categories:

Service: 21

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$2,052,882	\$2,093,263	\$2,102,450	\$1,900,887	\$1,900,887
1002	OTHER PERSONNEL COSTS	\$32,210	\$32,843	\$32,987	\$29,825	\$29,825
1005	FACULTY SALARIES	\$3,471,766	\$3,540,057	\$3,555,594	\$3,214,718	\$3,214,718
2009	OTHER OPERATING EXPENSE	\$57,196	\$58,322	\$58,578	\$52,962	\$52,962
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$5,614,054</b>	<b>\$5,724,485</b>	<b>\$5,749,609</b>	<b>\$5,198,392</b>	<b>\$5,198,392</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$5,614,054	\$5,699,992	\$5,699,992	\$5,198,392	\$5,198,392
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$5,614,054</b>	<b>\$5,699,992</b>	<b>\$5,699,992</b>	<b>\$5,198,392</b>	<b>\$5,198,392</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$24,493	\$49,617	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$24,493</b>	<b>\$49,617</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 3 Metroplex Comprehensive Medical Imaging Center

Service Categories:  
 Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$5,198,392</b>	<b>\$5,198,392</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$5,614,054</b>	<b>\$5,724,485</b>	<b>\$5,749,609</b>	<b>\$5,198,392</b>	<b>\$5,198,392</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>68.0</b>	<b>69.3</b>	<b>69.6</b>	<b>62.9</b>	<b>62.9</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Modern imaging techniques permit exquisite views of both structure and function from views of every atom in a protein molecule to functional magnetic resonance images of the neural activities that underlie complex behaviors in humans. With such amazing opportunities, the Imaging Center’s scientists and doctors are engaged in both the development of imaging technologies and their exploitation to understand and treat disease. The goals of the Center are to:

- Provide the only imaging center of its kind in the Southwest, allowing UT Southwestern researchers and collaborators at local universities to investigate molecular and cellular mechanisms of disease.
- Advance the diagnosis, treatment, and prevention of numerous debilitating diseases through the development and use of advanced medical imaging.
- Retain highly sought-after basic and clinical researchers and recruit rising star faculty to Texas.
- Bring millions in federal and private grants to Texas.

To achieve these goals, the Center at UT Southwestern encompasses a broad spectrum of imaging activities. The Advanced Imaging Research Center established in collaboration with UT Dallas and UT Arlington houses necessary state-of-the-art instruments and a variety of other imaging capabilities are encompassed in Core Labs. Ultimately, the unprecedented images and measurements of healthy and diseased tissue that modern imaging provides are crucial to developing more effective treatments for the sick and, eventually, preventive care to the well.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 3 Metroplex Comprehensive Medical Imaging Center

Service Categories:  
 Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>	<u>CHANGE</u>	<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$11,474,094	\$10,396,784	\$(1,077,310)	\$(1,077,310)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(1,077,310)</b>	<b>Total of Explanation of Biennial Change</b>



**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 4 Center for Obesity, Diabetes and Metabolism Research

Service Categories:  
 Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,976,509	\$2,065,264	\$2,075,988	\$1,876,692	\$1,876,692
1002	OTHER PERSONNEL COSTS	\$38,460	\$40,187	\$40,396	\$36,518	\$36,518
1005	FACULTY SALARIES	\$4,488,804	\$4,690,374	\$4,714,729	\$4,262,113	\$4,262,113
2009	OTHER OPERATING EXPENSE	\$66,090	\$69,058	\$69,416	\$62,752	\$62,752
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$6,569,863</b>	<b>\$6,864,883</b>	<b>\$6,900,529</b>	<b>\$6,238,075</b>	<b>\$6,238,075</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$6,569,863	\$6,839,992	\$6,839,992	\$6,238,075	\$6,238,075
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$6,569,863</b>	<b>\$6,839,992</b>	<b>\$6,839,992</b>	<b>\$6,238,075</b>	<b>\$6,238,075</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$24,891	\$60,537	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$24,891</b>	<b>\$60,537</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research Service Categories:  
 STRATEGY: 4 Center for Obesity, Diabetes and Metabolism Research Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$6,238,075</b>	<b>\$6,238,075</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$6,569,863</b>	<b>\$6,864,883</b>	<b>\$6,900,529</b>	<b>\$6,238,075</b>	<b>\$6,238,075</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>67.7</b>	<b>70.7</b>	<b>71.1</b>	<b>64.3</b>	<b>64.3</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Since it was founded in 2007, the interdisciplinary Center for Obesity, Diabetes and Metabolism Research has become widely recognized as the top obesity center in the world and uniquely positioned to tackle a medical crisis that costs Texas \$10 billion annually and continues to spiral out of control. The trends in obesity and related diseases are frightening, with the percent of overweight Texans increasing from 43% to 63% in just 15 years. What was once unheard of Type II diabetes occurring in children is now common and obesity dramatically increases not only the risk of diabetes but also heart disease, kidney failure, stroke, high blood pressure, respiratory problems and other chronic conditions. UT Southwestern's Obesity Center is committed to developing novel treatments for the prevention and treatment of obesity, to continued outreach to thousands of Dallas ISD elementary students to provide early intervention and an effective model for Texas, and to ensuring significant benefit to Texas from millions in external grant funding secured and eventual cost savings and revenue possible from breakthrough treatments.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 4 Center for Obesity, Diabetes and Metabolism Research

Service Categories:  
 Service: 21      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$13,765,412	\$12,476,150	\$(1,289,262)	\$(1,289,262)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(1,289,262)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 6 Center for Research of Sickle Cell Disease

Service Categories:

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$88,343	\$88,262	\$85,831	\$79,995	\$79,995
1002	OTHER PERSONNEL COSTS	\$4,321	\$4,317	\$4,198	\$3,912	\$3,912
1005	FACULTY SALARIES	\$1,044,178	\$1,043,219	\$1,014,483	\$955,764	\$955,764
2009	OTHER OPERATING EXPENSE	\$11,324	\$11,314	\$11,003	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$1,148,166</b>	<b>\$1,147,112</b>	<b>\$1,115,515</b>	<b>\$1,039,671</b>	<b>\$1,039,671</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$1,148,166	\$1,139,992	\$1,115,515	\$1,039,671	\$1,039,671
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$1,148,166</b>	<b>\$1,139,992</b>	<b>\$1,115,515</b>	<b>\$1,039,671</b>	<b>\$1,039,671</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$7,120	\$0	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$7,120</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 6 Center for Research of Sickle Cell Disease

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$1,039,671</b>	<b>\$1,039,671</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$1,148,166</b>	<b>\$1,147,112</b>	<b>\$1,115,515</b>	<b>\$1,039,671</b>	<b>\$1,039,671</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>8.3</b>	<b>8.3</b>	<b>8.1</b>	<b>7.5</b>	<b>7.5</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Sickle cell disease, the most serious disorder in the United States resulting from a single gene mutation, is most prevalent in persons of African descent. The condition causes excruciating pain, organ damage, and premature death in children and adults. There is a pressing need to better understand the biology of the disease and to translate scientific discovery into better treatments and eventually a cure. UT Southwestern's Comprehensive Sickle Cell Center has made dramatic progress in clinical research which has brought improved treatments and set the stage for future scientific discoveries. With continuing added support from this State Special Item, UT Southwestern's mission is to maintain and build upon its world class Comprehensive Sickle Cell Center focused on the following: research leading to curative treatments, development and refinement of new and improved therapies to control disease complications, and marked expansion of its outpatient clinics and inpatient services for children and adults with sickle cell disease in order to improve the length and quality of life. The Center has been and plans to continue to be recognized as one of the world's best.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 6 Center for Research of Sickle Cell Disease

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$2,262,627	\$2,079,342	\$(183,285)	\$(183,285)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(183,285)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 7 Texas Institute for Brain Injury and Repair

Service Categories:

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$2,904,503	\$2,956,920	\$2,968,437	\$2,659,112	\$2,659,112
1002	OTHER PERSONNEL COSTS	\$42,516	\$47,674	\$47,843	\$43,315	\$43,315
1005	FACULTY SALARIES	\$2,586,502	\$3,200,335	\$3,210,590	\$2,935,133	\$2,935,133
2001	PROFESSIONAL FEES AND SERVICES	\$2,000	\$2,243	\$2,251	\$2,038	\$2,038
2009	OTHER OPERATING EXPENSE	\$1,178,248	\$1,321,212	\$1,325,883	\$1,200,402	\$1,200,402
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$6,713,769</b>	<b>\$7,528,384</b>	<b>\$7,555,004</b>	<b>\$6,840,000</b>	<b>\$6,840,000</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$5,468,420	\$7,513,215	\$7,513,215	\$6,840,000	\$6,840,000
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$5,468,420</b>	<b>\$7,513,215</b>	<b>\$7,513,215</b>	<b>\$6,840,000</b>	<b>\$6,840,000</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$1,245,349	\$15,169	\$41,789	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$1,245,349</b>	<b>\$15,169</b>	<b>\$41,789</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

STRATEGY: 7 Texas Institute for Brain Injury and Repair

Service Categories:

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$6,840,000</b>	<b>\$6,840,000</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>					<b>\$6,713,769</b>	<b>\$7,528,384</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>					<b>72.2</b>	<b>81.0</b>
					<b>81.3</b>	<b>73.6</b>
					<b>73.6</b>	<b>73.6</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Translational research efforts by UTSW faculty who apply their basic discoveries to specific diseases have led to its successful history in the bench -to-bedside development of new treatments. UTSW is at a pivotal point for advancing our faculty’s discoveries, with their efforts uniquely supported by a new University Hospital opened in December 2014 designed to support clinical research, and a licensing revenue-funded BioCenter, a state-of-the-art commercial campus facility strategically positioned for the biomedical industry to interact with academic medicine to accelerate bench-to-bedside progress. Recent examples of translational research success at UTSW include:

- A way to direct heart cells to regenerate and heal injury caused by heart attack and other diseases, with drugs already in development by a newly formed biotech company
- A new biochemical pathway and inhibitor molecule with promise to stop the growth of kidney cancers
- A novel protein target for the development of drugs to treat and prevent Alzheimer’s.

Despite these successes, development of basic discoveries into transformative therapies at UTSW suffers from lack of funding for the early steps in translational research. State funding supports the extension of basic discoveries from the lab for which there are no other sources of funding, yet are essential for producing novel patient therapies to treat brain injury, with great promise for better patient care, lower costs, and ROI to the State.



**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 7 Texas Institute for Brain Injury and Repair

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$15,083,388	\$13,680,000	\$(1,403,388)	\$(1,403,388)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(1,403,388)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 8 Center for Regenerative Science and Medicine

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$1,425,616	\$1,872,230	\$1,873,726	\$1,642,255	\$1,642,255
1002	OTHER PERSONNEL COSTS	\$17,700	\$30,695	\$30,713	\$27,839	\$27,839
1005	FACULTY SALARIES	\$1,482,574	\$5,071,004	\$5,072,560	\$4,831,840	\$4,831,840
2009	OTHER OPERATING EXPENSE	\$1,712,876	\$1,070,379	\$1,072,177	\$794,066	\$794,066
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$4,638,766</b>	<b>\$8,044,308</b>	<b>\$8,049,176</b>	<b>\$7,296,000</b>	<b>\$7,296,000</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$4,638,766	\$8,000,000	\$8,000,000	\$7,296,000	\$7,296,000
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$4,638,766</b>	<b>\$8,000,000</b>	<b>\$8,000,000</b>	<b>\$7,296,000</b>	<b>\$7,296,000</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$44,308	\$49,176	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$44,308</b>	<b>\$49,176</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research Service Categories:  
 STRATEGY: 8 Center for Regenerative Science and Medicine Service: 19    Income: A.2    Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$7,296,000</b>	<b>\$7,296,000</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$4,638,766</b>	<b>\$8,044,308</b>	<b>\$8,049,176</b>	<b>\$7,296,000</b>	<b>\$7,296,000</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>40.9</b>	<b>70.9</b>	<b>70.9</b>	<b>64.3</b>	<b>64.3</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Regenerative medicine is a new frontier of science that seeks to understand the mechanisms of tissue aging, injury, and repair. This is the most important and transformative mission in medicine today, extending from molecular biology to tissue engineering and organ fabrication to deliver novel solutions to damage affecting diverse organs including heart, liver, lung, and others, and improve human health.

UTSW has launched CRSM, a transformational large-scale initiative in this rapidly developing field, underrepresented in Texas. The goals are to: 1) discover fundamental mechanisms of tissue formation and repair; 2) develop transformative strategies and medicines for tissue regeneration; 3) train future generations of scientists and clinicians to translate this new scientific knowledge into novel human therapies; and 4) offer education and community outreach programs.

Degenerative diseases of the heart, brain and other tissues represent the largest causes of death/disability in the world, affecting virtually everyone over 40 and accounting for the lion's share of healthcare costs in Texas and the U.S. With State investment, CRSM can capitalize on competitive and private seed funding to strengthen our program, with profound implications for millions of Texans incapacitated by organ injury and disease. By bringing the vision, scientific excellence, and resources of UTSW to bear, we can make transformative contributions and novel regenerative therapies to improve care.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 8 Center for Regenerative Science and Medicine

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$16,093,484	\$14,592,000	\$(1,501,484)	\$(1,501,484)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(1,501,484)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 9 Center for Advanced Radiation Therapy

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$294,361	\$309,275	\$309,275	\$281,782	\$281,782
1002	OTHER PERSONNEL COSTS	\$1,974	\$2,074	\$2,074	\$1,889	\$1,889
1005	FACULTY SALARIES	\$635,953	\$668,173	\$668,173	\$608,776	\$608,776
2009	OTHER OPERATING EXPENSE	\$20,425	\$21,460	\$21,460	\$19,553	\$19,553
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$952,713</b>	<b>\$1,000,982</b>	<b>\$1,000,982</b>	<b>\$912,000</b>	<b>\$912,000</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$952,713	\$1,000,000	\$1,000,982	\$912,000	\$912,000
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$952,713</b>	<b>\$1,000,000</b>	<b>\$1,000,982</b>	<b>\$912,000</b>	<b>\$912,000</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$982	\$0	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$982</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 9 Center for Advanced Radiation Therapy

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$912,000</b>	<b>\$912,000</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$952,713</b>	<b>\$1,000,982</b>	<b>\$1,000,982</b>	<b>\$912,000</b>	<b>\$912,000</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>6.3</b>	<b>6.6</b>	<b>6.6</b>	<b>6.0</b>	<b>6.0</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Heavy Ion therapy was developed in the U.S. in the 70s, but despite progress using clinical trials, the program closed due to federal budget cuts and the U.S. ceded the field. The National Cancer Institute recognizes this void for cancer patients in the U.S., and in 2013 issued an RFP to plan a Heavy Ion research center. In 2015, a Texas team led by UTSW secured one of two NCI 2-year planning grants. The 84th Legislature - recognizing the opportunity for Texas to lead the country - matched the NCI grant with a \$2M appropriation. A California team received a 2nd planning grant, with TX and CA now vying for an NCI Center of Excellence grant expected after the planning period.

UTSW, with the research consortium including MD Anderson, UT Austin, UTHSC SA, Texas A&M, Prairie View A&M, Baylor MC, NASA, and others, is perfectly positioned to capitalize on this opportunity for Texas. Efficacy of Heavy Ions has been established by foreign centers, but still needed are improved accelerator/beam technology, an understanding of the underlying biology, and clinical trials. A U.S. facility must be a comprehensive center capable of carrying out basic, pre-clinical, physics-related and clinical research. UTSW is poised to do this. The establishment of all centers worldwide has been possible only with government support given the expense, ~\$200M at UTSW. UTSW is working to secure vendor and federal commitments, as well as philanthropic donations, contingent on State and federal support.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 2 Research  
 STRATEGY: 9 Center for Advanced Radiation Therapy

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$2,001,964	\$1,824,000	\$(177,964)	\$(177,964)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<u>\$(177,964)</u>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 3 Health Care  
 STRATEGY: 1 Regional Burn Care Center

Service Categories:  
 Service: 22      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1005	FACULTY SALARIES	\$95,228	\$95,227	\$95,227	\$86,632	\$86,632
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$95,228</b>	<b>\$95,227</b>	<b>\$95,227</b>	<b>\$86,632</b>	<b>\$86,632</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$95,228	\$94,992	\$95,227	\$86,632	\$86,632
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$95,228</b>	<b>\$94,992</b>	<b>\$95,227</b>	<b>\$86,632</b>	<b>\$86,632</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$235	\$0	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$235</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$86,632</b>	<b>\$86,632</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$95,228</b>	<b>\$95,227</b>	<b>\$95,227</b>	<b>\$86,632</b>	<b>\$86,632</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>



**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 3 Health Care  
 STRATEGY: 1 Regional Burn Care Center

Service Categories:

Service: 22      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

To provide state-of-the-art comprehensive acute burn care, burn rehabilitation, education, supplies, and banked skin allograft tissues for clinical transplant for adult and pediatric patients and healthcare professionals. The Center is also the only American Burn Association and American College of Surgeons-verified burn center in North Texas, providing a regional resource for disaster management for those with burns.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$190,454	\$173,264	\$(17,190)	\$(17,190)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(17,190)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 4 Public Service  
 STRATEGY: 1 Program for Science Teacher Access to Resources (STARS)

Service Categories:  
 Service: 18      Income: A.2      Age: B.1

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$276,654	\$295,371	\$297,178	\$265,216	\$265,216
1002	OTHER PERSONNEL COSTS	\$3,023	\$3,227	\$3,247	\$2,898	\$2,898
1005	FACULTY SALARIES	\$257,237	\$274,640	\$276,320	\$251,718	\$251,718
2009	OTHER OPERATING EXPENSE	\$5,338	\$5,700	\$5,735	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$542,252</b>	<b>\$578,938</b>	<b>\$582,480</b>	<b>\$519,832</b>	<b>\$519,832</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$542,252	\$569,992	\$582,480	\$519,832	\$519,832
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$542,252</b>	<b>\$569,992</b>	<b>\$582,480</b>	<b>\$519,832</b>	<b>\$519,832</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$8,946	\$0	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$8,946</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 4 Public Service  
 STRATEGY: 1 Program for Science Teacher Access to Resources (STARS)

Service Categories:  
 Service: 18      Income: A.2      Age: B.1

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$519,832</b>	<b>\$519,832</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$542,252</b>	<b>\$578,938</b>	<b>\$582,480</b>	<b>\$519,832</b>	<b>\$519,832</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>7.9</b>	<b>8.4</b>	<b>8.5</b>	<b>7.6</b>	<b>7.6</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

The STARS program is dedicated to maintaining a robust educational partnership between UTSW and secondary teachers, and providing programs for bright secondary school students. STARS has two goals: to improve science education in the North Texas area and beyond, and to increase the interest and enthusiasm among bright secondary school students to pursue careers in STEM fields, especially as they impact the future of biomedicine.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 4 Public Service  
 STRATEGY: 1 Program for Science Teacher Access to Resources (STARS)

Service Categories:  
 Service: 18      Income: A.2      Age: B.1

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$1,161,418	\$1,039,664	\$(121,754)	\$(121,754)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(121,754)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 5 Institutional  
 STRATEGY: 1 Institutional Enhancement

Service Categories:  
 Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$400,965	\$432,045	\$434,484	\$412,693	\$412,693
1002	OTHER PERSONNEL COSTS	\$2,895	\$3,120	\$3,137	\$2,980	\$2,980
1005	FACULTY SALARIES	\$297,887	\$320,977	\$322,789	\$306,600	\$306,600
2009	OTHER OPERATING EXPENSE	\$7,111	\$7,662	\$7,706	\$7,319	\$7,319
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$708,858</b>	<b>\$763,804</b>	<b>\$768,116</b>	<b>\$729,592</b>	<b>\$729,592</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$708,858	\$742,339	\$745,001	\$729,592	\$729,592
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$708,858</b>	<b>\$742,339</b>	<b>\$745,001</b>	<b>\$729,592</b>	<b>\$729,592</b>
<b>Method of Financing:</b>						
770	Est. Other Educational & General	\$0	\$21,465	\$23,115	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)</b>		<b>\$0</b>	<b>\$21,465</b>	<b>\$23,115</b>	<b>\$0</b>	<b>\$0</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 5 Institutional  
 STRATEGY: 1 Institutional Enhancement

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$729,592</b>	<b>\$729,592</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$708,858</b>	<b>\$763,804</b>	<b>\$768,116</b>	<b>\$729,592</b>	<b>\$729,592</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>5.3</b>	<b>5.7</b>	<b>5.7</b>	<b>5.4</b>	<b>5.4</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Institutional Enhancement funding plays a significant role in financing the core missions of all Health Related Institutions by providing a base level of funding for services and programs. Institutional Enhancement funding helps support leading-edge and innovative programs in graduate research education not otherwise supported by formula funding. The purpose of Institutional Enhancement at UT Southwestern is to help provide the highest quality education in the prevention, diagnosis, and treatment of disease to our medical students.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

Additional information for this strategy is available in Schedule 9, Special Item Information.

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 5 Institutional  
 STRATEGY: 1 Institutional Enhancement

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$1,531,920	\$1,459,184	\$(72,736)	\$(72,736)	Change primarily reflects the shift to the Hold Harmless strategy. UT Southwestern is requesting a shift from special item funding to a research based funding formula.
			<b>\$(72,736)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 6 Exceptional Item Request  
 STRATEGY: 1 Exceptional Item Request

Service Categories:

Service: 19      Income: A.2      Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$0	\$0	\$0	\$0	\$0
1005	FACULTY SALARIES	\$0	\$0	\$0	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$0	\$0	\$0	\$0	\$0
5000	CAPITAL EXPENDITURES	\$0	\$0	\$0	\$0	\$0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>
<b>Method of Financing:</b>						
1	General Revenue Fund	\$0	\$0	\$0	\$0	\$0
<b>SUBTOTAL, MOF (GENERAL REVENUE FUNDS)</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$0</b>	<b>\$0</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

This strategy is used to request exceptional items. Additional information for this strategy is available in Schedules 4.A through 4.C, Exceptional Item Request.



**729 The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support  
 OBJECTIVE: 6 Exceptional Item Request Service Categories:  
 STRATEGY: 1 Exceptional Item Request Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
------	-------------	----------	----------	----------	---------	---------

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$0	\$0	\$0	\$0	New exceptional item request for FY20-21.
			<b>\$0</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 6 Tobacco Funds  
 OBJECTIVE: 1 Tobacco Earnings for Eminent Scholars Service Categories:  
 STRATEGY: 1 Tobacco Earnings for UT Southwestern Medical Center Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$454,785	\$911,939	\$917,289	\$602,149	\$602,149
1002	OTHER PERSONNEL COSTS	\$190,954	\$382,903	\$385,149	\$252,829	\$252,829
1005	FACULTY SALARIES	\$1,195,103	\$2,396,431	\$2,410,492	\$1,582,354	\$1,582,354
2001	PROFESSIONAL FEES AND SERVICES	\$16,835	\$33,758	\$33,956	\$22,290	\$22,290
2003	CONSUMABLE SUPPLIES	\$15,184	\$30,447	\$30,625	\$20,104	\$20,104
2004	UTILITIES	\$31,769	\$63,703	\$64,077	\$42,063	\$42,063
2009	OTHER OPERATING EXPENSE	\$438,295	\$878,873	\$884,032	\$580,318	\$580,318
5000	CAPITAL EXPENDITURES	\$28,619	\$57,388	\$57,725	\$37,893	\$37,893
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$2,371,544</b>	<b>\$4,755,442</b>	<b>\$4,783,345</b>	<b>\$3,140,000</b>	<b>\$3,140,000</b>
<b>Method of Financing:</b>						
813	Perm Endow FD UT SW MED, estimated	\$2,371,544	\$4,755,442	\$4,783,345	\$3,140,000	\$3,140,000
<b>SUBTOTAL, MOF (OTHER FUNDS)</b>		<b>\$2,371,544</b>	<b>\$4,755,442</b>	<b>\$4,783,345</b>	<b>\$3,140,000</b>	<b>\$3,140,000</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 6 Tobacco Funds  
 OBJECTIVE: 1 Tobacco Earnings for Eminent Scholars Service Categories:  
 STRATEGY: 1 Tobacco Earnings for UT Southwestern Medical Center Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					<b>\$3,140,000</b>	<b>\$3,140,000</b>
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>		<b>\$2,371,544</b>	<b>\$4,755,442</b>	<b>\$4,783,345</b>	<b>\$3,140,000</b>	<b>\$3,140,000</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>		<b>13.5</b>	<b>27.0</b>	<b>27.1</b>	<b>17.8</b>	<b>17.8</b>

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

Funding for this strategy is derived from annual distributions of Permanent Health Funds established Section 63.101 of the Texas Education Code. These are appropriated for research and other programs that are conducted by the institution and that benefit the public health.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2018 + Bud 2019)	Baseline Request (BL 2020 + BL 2021)	CHANGE	\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$9,538,787	\$6,280,000	\$(3,258,787)	\$(3,258,787)	Base spending (Est 2018 + Bud 2019) includes the use of prior year balances.
			<b>\$(3,258,787)</b>	<b>Total of Explanation of Biennial Change</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 6 Tobacco Funds  
 OBJECTIVE: 1 Tobacco Earnings for Eminent Scholars Service Categories:  
 STRATEGY: 2 Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810 Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>Objects of Expense:</b>						
1001	SALARIES AND WAGES	\$350,088	\$440,104	\$444,709	\$369,006	\$369,006
1002	OTHER PERSONNEL COSTS	\$193,897	\$243,753	\$246,303	\$204,375	\$204,375
1005	FACULTY SALARIES	\$1,407,479	\$1,769,378	\$1,787,889	\$1,483,536	\$1,483,536
2001	PROFESSIONAL FEES AND SERVICES	\$44,829	\$56,356	\$56,946	\$47,252	\$47,252
2003	CONSUMABLE SUPPLIES	\$27,391	\$34,434	\$34,794	\$28,871	\$28,871
2004	UTILITIES	\$10,789	\$13,563	\$13,704	\$11,372	\$11,372
2006	RENT - BUILDING	\$1,457	\$2,922	\$2,939	\$1,929	\$1,929
2009	OTHER OPERATING EXPENSE	\$648,594	\$814,271	\$822,806	\$683,247	\$683,247
5000	CAPITAL EXPENDITURES	\$53,865	\$67,715	\$68,423	\$56,776	\$56,776
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$2,738,389</b>	<b>\$3,442,496</b>	<b>\$3,478,513</b>	<b>\$2,886,364</b>	<b>\$2,886,364</b>
<b>Method of Financing:</b>						
810	Perm Health Fund Higher Ed, est	\$2,738,389	\$3,442,496	\$3,478,513	\$2,886,364	\$2,886,364
<b>SUBTOTAL, MOF (OTHER FUNDS)</b>		<b>\$2,738,389</b>	<b>\$3,442,496</b>	<b>\$3,478,513</b>	<b>\$2,886,364</b>	<b>\$2,886,364</b>

**729 The University of Texas Southwestern Medical Center**

GOAL: 6 Tobacco Funds  
 OBJECTIVE: 1 Tobacco Earnings for Eminent Scholars Service Categories:  
 STRATEGY: 2 Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810 Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)</b>					\$2,886,364	\$2,886,364
<b>TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)</b>					\$2,738,389	\$3,442,496
<b>FULL TIME EQUIVALENT POSITIONS:</b>					15.3	19.2
					19.4	16.1
					16.1	16.1

**STRATEGY DESCRIPTION AND JUSTIFICATION:**

This strategy includes the institution's allocation of the Permanent Health Fund for Higher Education. The purpose of these funds includes medical research, health education or treatment programs.

**EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:**

**EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):**

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2018 + Bud 2019)</u>	<u>Baseline Request (BL 2020 + BL 2021)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$6,921,009	\$5,772,728	\$(1,148,281)	\$(1,148,281)	Base spending (Est 2018 + Bud 2019) includes the use of prior year balances.
			<b>\$(1,148,281)</b>	<b>Total of Explanation of Biennial Change</b>

---

**SUMMARY TOTALS:**

<b>OBJECTS OF EXPENSE:</b>	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>
<b>METHODS OF FINANCE (INCLUDING RIDERS):</b>				<b>\$81,758,154</b>	<b>\$81,758,852</b>
<b>METHODS OF FINANCE (EXCLUDING RIDERS):</b>	<b>\$166,751,457</b>	<b>\$175,232,950</b>	<b>\$175,025,792</b>	<b>\$81,758,154</b>	<b>\$81,758,852</b>
<b>FULL TIME EQUIVALENT POSITIONS:</b>	<b>1,800.0</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>

**3.A.1. PROGRAM-LEVEL REQUEST SCHEDULE**  
85th Regular Session, Agency Submission, Version 1

729		UT Southwestern Medical Center				Prepared By: Budget office					
Date:						18 - 19	Requested	Requested	Biennial Total	Biennial Difference	
Goal	Goal Name	Strategy	Strategy Name	Program	Program Name	Base GAA	2020	2021	20 - 21	\$	%
A	Provide Instruction and Operations Support	A.3.1	Texas Public Education Grants	A.3.1.1	Texas Public Education Grants	\$2,459,440	\$1,217,636	\$1,217,636	\$2,435,272	(\$24,168)	-1.0%
A	Provide Instruction and Operations Support	A.3.2	Medical Loans	A.3.2.1	Medical Loans	\$0	\$0	\$0	\$0	\$0	
A	Provide Instruction and Operations Support	A.2.1	Staff Group Insurance Premiums	A.2.1.1	Staff Group Insurance Premiums	\$1,438,550	\$3,304,836	\$3,304,836	\$6,609,672	\$5,171,122	359.5%
A	Provide Instruction and Operations Support	A.1.4	Graduate Medical Training	A.1.4.1	Graduate Medical Training	\$15,153,110	\$0	\$0	\$0	(\$15,153,110)	-100.0%
A	Provide Instruction and Operations Support	A.1.1	Medical Education	A.1.1.1	Medical Education	\$85,625,340	\$0	\$0	\$0	(\$85,625,340)	-100.0%
A	Provide Instruction and Operations Support	A.1.2	Graduate Training in Biomedical Sciences	A.1.2.1	Graduate Training in Biomedical Sciences	\$14,133,342	\$0	\$0	\$0	(\$14,133,342)	-100.0%
A	Provide Instruction and Operations Support	A.1.3	Allied Health Professions Training	A.1.3.1	Allied Health Professions Training	\$8,956,042	\$0	\$0	\$0	(\$8,956,042)	-100.0%
A	Provide Instruction and Operations Support	A.4.1	Hold Harmless		Hold Harmless	\$21,817,302	\$10,908,652	\$10,908,650	\$21,817,302	\$0	0.0%
B	Provide Research Support	B.1.1	Research Enhancement	B.1.1.1	Research Enhancement	\$12,858,218	\$0	\$0	\$0	(\$12,858,218)	-100.0%
C	Provide Infrastructure Support	C.1.1	E & G Space Support	C.1.1.1	E & G Space Support	\$50,036,248	\$0	\$0	\$0	(\$50,036,248)	-100.0%
C	Provide Infrastructure Support	C.2.1	Tuition Revenue Bond Retirement	C.2.1.1	Tuition Revenue Bond Retirement	\$37,040,262	\$23,745,700	\$23,746,400	\$47,492,100	\$10,451,838	28.2%
D	Provide Non-formula Support	D.5.1	Institutional Enhancement	D.5.1.1	Institutional Enhancement - Research	\$1,459,184	\$729,592	\$729,592	\$1,459,184	\$0	0.0%
D	Provide Non-formula Support	D.2.1	Institute for Nobel/National-Academy Biomedical Research	D.2.1.1	Institute for Nobel/National-Academy Biomedical Research	\$11,430,764	\$5,715,382	\$5,715,382	\$11,430,764	\$0	0.0%
D	Provide Non-formula Support	D.4.1	Program for Science Teacher Access to Resources (STAR)	D.4.1.1	Program for Science Teacher Access to Resources (STAR)	\$1,039,664	\$519,832	\$519,832	\$1,039,664	\$0	0.0%
D	Provide Non-formula Support	D.1.1	Primary Care Residency Training Program	D.1.1.1	Primary Care Residency Training Program	\$1,943,152	\$971,576	\$971,576	\$1,943,152	\$0	0.0%
D	Provide Non-formula Support	D.3.1	Regional Burn Care Center	D.3.1.1	Regional Burn Care Center	\$173,264	\$86,632	\$86,632	\$173,264	\$0	0.0%
D	Provide Non-formula Support	D.2.6	Center for Research of Sickle Cell Disease	D.2.6.1	Center for Research of Sickle Cell Disease	\$2,079,342	\$1,039,671	\$1,039,671	\$2,079,342	\$0	0.0%
D	Provide Non-formula Support	D.2.2	Institute for Innovations in Medical Technology	D.2.2.1	Institute for Innovations in Medical Technology	\$12,475,628	\$6,237,814	\$6,237,814	\$12,475,628	\$0	0.0%
D	Provide Non-formula Support	D.2.3	Metroplex Comprehensive Medical Imaging Center	D.2.3.1	Metroplex Comprehensive Medical Imaging Center	\$10,396,784	\$5,198,392	\$5,198,392	\$10,396,784	\$0	0.0%
D	Provide Non-formula Support	D.2.4	Center for Obesity, Diabetes and Metabolism Research	D.2.4.1	Center for Obesity, Diabetes and Metabolism Research	\$12,476,150	\$6,238,075	\$6,238,075	\$12,476,150	\$0	0.0%
D	Provide Non-formula Support	D.2.7	Texas Institute for Brain Injury and Repair	D.2.7.1	Texas Institute for Brain Injury and Repair	\$13,680,000	\$6,840,000	\$6,840,000	\$13,680,000	\$0	0.0%
D	Provide Non-formula Support	D.2.8	Regenerative Science and Medicine	D.2.8.1	Regenerative Science and Medicine	\$14,592,000	\$7,296,000	\$7,296,000	\$14,592,000	\$0	0.0%
D	Provide Non-formula Support	D.2.9	Center for Advanced Radiation Therapy	D.2.9.1	Center for Advanced Radiation Therapy	\$1,824,000	\$912,000	\$912,000	\$1,824,000	\$0	0.0%
D	Exceptional Item		Center for Gene Therapy & Curative Medicine		Center for Gene Therapy & Curative Medicine	\$0	\$9,000,000	\$9,000,000	\$18,000,000	\$18,000,000	
D	Exceptional Item		Center for Advanced Radiation Therapy		Center for Advanced Radiation Therapy	\$0	\$4,500,000	\$4,500,000	\$9,000,000	\$9,000,000	
E	Tobacco Funds	E.6.1	Tobacco Earnings for UT Southwestern Medical Center	E.6.1.1	Tobacco Earnings for UT Southwestern Medical Center	\$6,120,000	\$3,140,000	\$3,140,000	\$6,280,000	\$160,000	2.6%
E	Tobacco Funds	E.6.2	Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810	E.6.2.1	Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810	\$5,369,944	\$2,886,364	\$2,886,364	\$5,772,729	\$402,785	7.5%

**4.A. Exceptional Item Request Schedule**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729

Agency name: **The University of Texas Southwestern Medical Center**

CODE	DESCRIPTION	Excp 2020	Excp 2021
	<b>Item Name:</b> Center for Gene Therapy & Curative Medicine <b>Item Priority:</b> 1 <b>IT Component:</b> No <b>Anticipated Out-year Costs:</b> Yes <b>Involve Contracts &gt; \$50,000:</b> No <b>Includes Funding for the Following Strategy or Strategies:</b> 04-06-01 Exceptional Item Request		
<b>OBJECTS OF EXPENSE:</b>			
1001	SALARIES AND WAGES	1,288,924	3,003,647
1005	FACULTY SALARIES	4,211,076	5,296,353
2009	OTHER OPERATING EXPENSE	2,000,000	700,000
5000	CAPITAL EXPENDITURES	1,500,000	0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$9,000,000</b>	<b>\$9,000,000</b>
<b>METHOD OF FINANCING:</b>			
1	General Revenue Fund	9,000,000	9,000,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$9,000,000</b>	<b>\$9,000,000</b>
<b>FULL-TIME EQUIVALENT POSITIONS (FTE):</b>		50.00	90.00

**DESCRIPTION / JUSTIFICATION:**

In recent years, biomedical researchers have made groundbreaking discoveries to help us understand the enormous potential of gene therapy in the treatment of disease, which holds the promise of a one-time "forever fix" or treatment for patients. UTSW's Center for Gene Therapy & Curative Medicine - with recent recruitment of a leader in gene replacement therapy and significant investment in a drug development facility - is poised to lead the U.S. in this next frontier of medicine, starting with the most rare conditions, ~7,000 that typically present in children, and eventually more complex diseases such as Alzheimer's. The Center's goal is to offer one-time curative treatment to children suffering from one of these 7,000 rare diseases caused by a single genetic mutation and eventually all patients suffering from diseases caused by more complex genetic mutations, forever changing the lives of impacted children, adults and their families. UTSW requests \$9M per year in State core research support to realize this goal.

**EXTERNAL/INTERNAL FACTORS:**

**Major Accomplishments to Date:**

UTSW has recognized the need to invest in gene therapy to bring hope to patients with previously untreatable diseases. Early steps towards establishing a Center included recruitment of a leader in development of an innocuous human virus as a vehicle for delivering gene therapy, and establishment of a rare Viral Vector Production Facility, on which the success of moving more discoveries into clinical testing is dependent. The facility will be unique among HRIs in the U.S., meeting FDA regulations to produce gene-based investigational drugs.

UTSW concurrently invested in offering bench-to-bedside regulatory support to its researchers, emphasized partnerships with stakeholders to help fund treatments, and



Agency code: **729**

Agency name:  
**The University of Texas Southwestern Medical Center**

<b>CODE</b>	<b>DESCRIPTION</b>	<b>Excp 2020</b>	<b>Excp 2021</b>
-------------	--------------------	------------------	------------------

begun building relationships with industry to ensure that early-phase trial drugs do not stall in research phase. The facility will drive greater commercialization of gene therapies, with all of the resulting benefits to patients and impact on the state economy.

**Accomplishments Expected Over Next Two Years:**

Gene therapy can fix the source problem and stop the disease permanently. Many diseases have genetic causes, so the potential is boundless to move towards a care model of early diagnosis, followed by transformative treatment to prevent incurable conditions from developing.

Yet, in addition to Center groundwork by UTSW, much proof-of-concept research remains to be conducted. UTSW requests core research investment to capitalize on efforts to date to make Texas the leader in this new frontier of medicine - starting with genes responsible for the more than 7,000 rare devastating neurodevelopmental disorders in children that are individually rare but collectively common - to achieve gene therapy as a standard, curative therapy for all patients.

**Consequences of Not Funding:**

Without core research support, the Center cannot realize the promise of gene therapy. More detail can be found in Schedule 9 for this item.

**PCLS TRACKING KEY:**

**DESCRIPTION OF ANTICIPATED OUT-YEAR COSTS :**

Ongoing core research support necessary to realize the promise of gene therapy for children suffering from one of the 7,000 rare neurodevelopmental disorders caused by a single genetic mutation and eventually for children and adults suffering from diseases such as autism and Alzheimer's caused by more complex mutations.

**ESTIMATED ANTICIPATED OUT-YEAR COSTS FOR ITEM:**

	<b>2022</b>	<b>2023</b>	<b>2024</b>
	\$9,000,000	\$9,000,000	\$9,000,000

**4.A. Exceptional Item Request Schedule**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729

Agency name:  
**The University of Texas Southwestern Medical Center**

CODE	DESCRIPTION	Excp 2020	Excp 2021
	<b>Item Name:</b> Center for Advanced Radiation Therapy <b>Item Priority:</b> 2 <b>IT Component:</b> No <b>Anticipated Out-year Costs:</b> Yes <b>Involve Contracts &gt; \$50,000:</b> No <b>Includes Funding for the Following Strategy or Strategies:</b> 04-02-09 Center for Advanced Radiation Therapy		
<b>OBJECTS OF EXPENSE:</b>			
1001	SALARIES AND WAGES	1,642,000	1,642,000
1005	FACULTY SALARIES	2,733,000	2,733,000
2009	OTHER OPERATING EXPENSE	125,000	125,000
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$4,500,000</b>	<b>\$4,500,000</b>
<b>METHOD OF FINANCING:</b>			
1	General Revenue Fund	4,500,000	4,500,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$4,500,000</b>	<b>\$4,500,000</b>
<b>FULL-TIME EQUIVALENT POSITIONS (FTE):</b>		50.00	50.00

**DESCRIPTION / JUSTIFICATION:**

Heavy Ion therapy is the exponentially more potent and precise next generation of proton therapy for cancer patients, with application in the hardest to treat cancers, including brain and pancreatic, and potential applications to many other disease areas requiring the most precise laser therapy. The technology was developed in the U.S. in the 1970s, but despite successful progress utilizing clinical trials, the program was closed due to federal budget cuts and the U.S. ceded the field.

The National Cancer Institute recognizes this void for cancer patients in the U.S., and issued an RFP to plan a research center using the heavy ion modality. In 2015, a Texas research team led by UTSW secured one of two NCI planning grants. The 84th Legislature – recognizing the opportunity for Texas to lead the country – matched the NCI grant, enabling UTSW to compete with a California research consortium who secured a second NCI planning grant. Texas and California are now in pursuit of an expected NCI Center of Excellence research grant.

TCART – with the research consortium led by UTSW and including MD Anderson, UT Austin, UTHSC SA, Texas A&M, Prairie View A&M, Baylor Medical School, NASA and others – is perfectly positioned to capitalize on this opportunity for Texas and the U.S., to establish the most advanced radiation center in the world for cancer therapy and research. Efficacy of Heavy Ions has been established by foreign centers, but still critically needed to uncover its full potential are improved accelerator/beam delivery technology, an understanding of the underlying biology, and clinical trials. A U.S. facility must be a comprehensive center capable of carrying out basic, pre-clinical and physics-related research, as well as large scale clinical trials. With sufficient State support, UTSW will accomplish the necessary scientific and planning proof work, and secure the first Heavy Ion facility in the U.S. for Texas.

Agency code: 729

Agency name:  
**The University of Texas Southwestern Medical Center**

CODE	DESCRIPTION	Excp 2020	Excp 2021
------	-------------	-----------	-----------

**EXTERNAL/INTERNAL FACTORS:**

Major Accomplishments to Date:

Heavy Ion therapy is the most potent and effective form of radiation for cancer patients, but is not available in the U.S. In 2015, the Texas research consortium led by UTSW and including MD Anderson, UT Austin, NASA and others – secured one of two National Cancer Institute planning grants, which the 84th Legislature matched to help bring a center to Texas. A California team received the second grant, leaving Texas vying with California to secure the first U.S. Heavy Ion facility and an NCI Research Center of Excellence grant.

UTSW has made significant progress to date, including completing the technical design of the large-scale, specialized equipment needed, architectural design plans, securing FY18 federal omnibus budget intent language, and enabling competitive pilot projects by Texas research partners to advance the technology.

Accomplishments Expected Over Next Two Years:

UTSW is perfectly positioned to capitalize on this opportunity for Texas, to establish the most comprehensive advanced radiation center in the world for cancer therapy. Efficacy of Heavy Ions has been established by foreign centers, but still critically needed to uncover its full potential are improved accelerator/beam delivery technology, an understanding of the underlying biology, and more clinical trials, including a rare international trial using foreign centers that UTSW has coordinated. With sufficient funding, UTSW researchers will continue to plan and conduct the scientific proof and technical planning work needed to equip and construct the facility.

Consequences of Not Funding:

Without State support, TCART cannot secure the first Heavy Ion Research & Treatment Facility in the U.S. for Texas. More detail can be found in Schedule 9 for this item.

**PCLS TRACKING KEY:**

**DESCRIPTION OF ANTICIPATED OUT-YEAR COSTS :**

Ongoing core research support of Heavy Ion therapy including improved accelerator/beam delivery technology, an understanding of the underlying biology, and more clinical trials, including a rare international trial using foreign centers that UTSW has coordinated. This research support is needed to competitively secure the first U.S. center for Texas.

**ESTIMATED ANTICIPATED OUT-YEAR COSTS FOR ITEM:**

	2022	2023	2024
	\$4,500,000	\$4,500,000	\$4,500,000

**4.A. Exceptional Item Request Schedule**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729

Agency name:  
**The University of Texas Southwestern Medical Center**

CODE	DESCRIPTION	Excp 2020	Excp 2021
	<b>Item Name:</b> UTD/UTSW Translational Biomedical Engineering and Science Building <b>Item Priority:</b> 3 <b>IT Component:</b> No <b>Anticipated Out-year Costs:</b> Yes <b>Involve Contracts &gt; \$50,000:</b> Yes <b>Includes Funding for the Following Strategy or Strategies:</b> 03-02-01 Tuition Revenue Bond Retirement		

**OBJECTS OF EXPENSE:**

2008	DEBT SERVICE	5,230,000	5,230,000
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$5,230,000</b>	<b>\$5,230,000</b>

**METHOD OF FINANCING:**

1	General Revenue Fund	5,230,000	5,230,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$5,230,000</b>	<b>\$5,230,000</b>

**DESCRIPTION / JUSTIFICATION:**

Recent advances have begun to show the promise of application of previously unimaginable bioengineering approaches – such as tissue engineering, organ fabrication, and neuroprosthesis to restore function to damaged tissues and organs. Yet, there is a pressing need to translate biomedical technologies from the idea stage to improved treatment for millions of patients in Texas and beyond. UT Dallas (UTD) and UT Southwestern Medical Center (UTSW) – leveraging research strengths in basic and applied biomedical and engineering sciences – are poised to expand their collaborations into a center for biomedical innovation and translation. A critical missing ingredient is the proposed properly designed facility on UTSW’s campus to optimally connect engineers and scientists with physicians and patients, accelerating the advancement of medical technologies, and training and education for students. This facility is essential to accelerating deeper collaboration between UTD and UTSW, which will result in improved technologies to advance patient care. The collaboration will also raise the national profile of the biomedical engineering program and departmental activities across both institutions and support UTSW’s goal of accelerating the bench-to-bedside translation of its groundbreaking basic science.

The project will provide 150,000 to 180,000 GSF (90,000-110,000 ASF) of research and support space to dozens of faculty, graduate and undergraduate students from UTD and UTSW. The estimated cost is \$120 million, fully funded with tuition revenue bond support, as there is no other source of construction support from either campus.

Debt Assumptions: 20 year bond term @6% interest; Issue Date 09/01/2020

**EXTERNAL/INTERNAL FACTORS:**

Both UTD and UTSW are well positioned to partner on biomedical innovation and translation. UTD's Department of Bioengineering, established in 2014 and already ranked 78th nationally by US News & World Report, has over 23 research faculty focused on areas spanning from biomechanics and systems biology to biomaterials, imaging and neural engineering. A UTD barrier is the limited exposure that faculty and students have to clinical problems, environments, and physicians. UTSW Medical School is ranked in the Top 30 among 160 nationally for research and primary care and operates a graduate program in biomedical engineering (BME) that draws together over 60 faculty from

**4.A. Exceptional Item Request Schedule**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729

Agency name:  
**The University of Texas Southwestern Medical Center**

<b>CODE</b>	<b>DESCRIPTION</b>	<b>Excp 2020</b>	<b>Excp 2021</b>
-------------	--------------------	------------------	------------------

basic science and clinical departments who perform fundamental and applied bioengineering research and serve as mentors for BME PhD students. Limiting UTSW's success in translating findings to clinical solutions is the lack of access on UTSW's campus to engineers as well as to mathematicians, physicists and computer scientists who are not typically housed at a health related institution, but are indispensable to successful collaboration and translation.

A joint building would solve the lack of needed proximity and provide essential access to a patient population. Current collaborations between the two institutions include unique work on a therapeutic neurostimulation and data processing to improve imaging not only of patient organ structure but function to aid in more precise diagnoses. Progress is impeded by the distance between researchers and patients.

This specialized facility would provide space for more effective collaboration including: properly designed labs for equipment development and testing; research bench space; interactive office space for informatics experts and software developers; patient space for assessment of research participants and pilot clinical studies and trials; shared support space; and potential co-location of imaging equipment and services.

**PCLS TRACKING KEY:**

**DESCRIPTION OF ANTICIPATED OUT-YEAR COSTS :**

Annual debt service.

**ESTIMATED ANTICIPATED OUT-YEAR COSTS FOR ITEM:**

	<b>2022</b>	<b>2023</b>	<b>2024</b>
	\$5,230,000	\$5,230,000	\$5,230,000

**APPROXIMATE PERCENTAGE OF EXCEPTIONAL ITEM :** 95.00%

**CONTRACT DESCRIPTION :**

Construction and other construction related contracts will be selected through RFP process after competitive bidding. Expected duration of anticipated contracts is from Fall 2020 to Fall 2023.

4.B. Exceptional Items Strategy Allocation Schedule  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Code	Description	Excp 2020	Excp 2021
<b>Item Name:</b> Center for Gene Therapy & Curative Medicine			
<b>Allocation to Strategy:</b> 4-6-1 Exceptional Item Request			
<b>OBJECTS OF EXPENSE:</b>			
1001	SALARIES AND WAGES	1,288,924	3,003,647
1005	FACULTY SALARIES	4,211,076	5,296,353
2009	OTHER OPERATING EXPENSE	2,000,000	700,000
5000	CAPITAL EXPENDITURES	1,500,000	0
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$9,000,000</b>	<b>\$9,000,000</b>
<b>METHOD OF FINANCING:</b>			
1 General Revenue Fund		9,000,000	9,000,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$9,000,000</b>	<b>\$9,000,000</b>
<b>FULL-TIME EQUIVALENT POSITIONS (FTE):</b>		50.0	90.0

4.B. Exceptional Items Strategy Allocation Schedule  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

DATE: 10/19/2018  
 TIME: 3:29:11PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Code	Description	Excp 2020	Excp 2021
<b>Item Name:</b> Center for Advanced Radiation Therapy			
<b>Allocation to Strategy:</b> 4-2-9 Center for Advanced Radiation Therapy			
<b>OBJECTS OF EXPENSE:</b>			
1001	SALARIES AND WAGES	1,642,000	1,642,000
1005	FACULTY SALARIES	2,733,000	2,733,000
2009	OTHER OPERATING EXPENSE	125,000	125,000
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$4,500,000</b>	<b>\$4,500,000</b>
<b>METHOD OF FINANCING:</b>			
1	General Revenue Fund	4,500,000	4,500,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$4,500,000</b>	<b>\$4,500,000</b>
<b>FULL-TIME EQUIVALENT POSITIONS (FTE):</b>		50.0	50.0

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Code	Description	Excp 2020	Excp 2021
<b>Item Name:</b> UTD/UTSW Translational Biomedical Engineering and Science Building			
<b>Allocation to Strategy:</b> 3-2-1 Tuition Revenue Bond Retirement			
<b>OBJECTS OF EXPENSE:</b>			
2008	DEBT SERVICE	5,230,000	5,230,000
<b>TOTAL, OBJECT OF EXPENSE</b>		<b>\$5,230,000</b>	<b>\$5,230,000</b>
<b>METHOD OF FINANCING:</b>			
1	General Revenue Fund	5,230,000	5,230,000
<b>TOTAL, METHOD OF FINANCING</b>		<b>\$5,230,000</b>	<b>\$5,230,000</b>



**4.C. Exceptional Items Strategy Request**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

**DATE: 10/19/2018**  
**TIME: 3:29:11PM**

Agency Code: **729** Agency name: **The University of Texas Southwestern Medical Center**

GOAL: 3 Provide Infrastructure Support

OBJECTIVE: 2 Infrastructure Support

STRATEGY: 1 Tuition Revenue Bond Retirement

Service Categories:

Service: 10 Income: A.2 Age: B.3

<b>CODE DESCRIPTION</b>	<b>Exp 2020</b>	<b>Exp 2021</b>
-------------------------	-----------------	-----------------

**OBJECTS OF EXPENSE:**

2008 DEBT SERVICE	5,230,000	5,230,000
-------------------	-----------	-----------

<b>Total, Objects of Expense</b>	<b>\$5,230,000</b>	<b>\$5,230,000</b>
----------------------------------	--------------------	--------------------

**METHOD OF FINANCING:**

1 General Revenue Fund	5,230,000	5,230,000
------------------------	-----------	-----------

<b>Total, Method of Finance</b>	<b>\$5,230,000</b>	<b>\$5,230,000</b>
---------------------------------	--------------------	--------------------

**EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:**

UTD/UTSW Translational Biomedical Engineering and Science Building

**4.C. Exceptional Items Strategy Request**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

**DATE: 10/19/2018**  
**TIME: 3:29:11PM**

Agency Code: **729** Agency name: **The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 2 Research

Service Categories:

STRATEGY: 9 Center for Advanced Radiation Therapy

Service: 19 Income: A.2 Age: B.3

<b>CODE DESCRIPTION</b>	<b>Excp 2020</b>	<b>Excp 2021</b>
-------------------------	------------------	------------------

**OBJECTS OF EXPENSE:**

1001 SALARIES AND WAGES	1,642,000	1,642,000
1005 FACULTY SALARIES	2,733,000	2,733,000
2009 OTHER OPERATING EXPENSE	125,000	125,000
<b>Total, Objects of Expense</b>	<b>\$4,500,000</b>	<b>\$4,500,000</b>

**METHOD OF FINANCING:**

1 General Revenue Fund	4,500,000	4,500,000
<b>Total, Method of Finance</b>	<b>\$4,500,000</b>	<b>\$4,500,000</b>

**FULL-TIME EQUIVALENT POSITIONS (FTE):**

50.0	50.0
------	------

**EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:**

Center for Advanced Radiation Therapy

**4.C. Exceptional Items Strategy Request**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

**DATE: 10/19/2018**  
**TIME: 3:29:11PM**

Agency Code: **729** Agency name: **The University of Texas Southwestern Medical Center**

GOAL: 4 Provide Non-formula Support

OBJECTIVE: 6 Exceptional Item Request

STRATEGY: 1 Exceptional Item Request

Service Categories:

Service: 19 Income: A.2 Age: B.3

<b>CODE DESCRIPTION</b>	<b>Excp 2020</b>	<b>Excp 2021</b>
-------------------------	------------------	------------------

**OBJECTS OF EXPENSE:**

1001 SALARIES AND WAGES	1,288,924	3,003,647
1005 FACULTY SALARIES	4,211,076	5,296,353
2009 OTHER OPERATING EXPENSE	2,000,000	700,000
5000 CAPITAL EXPENDITURES	1,500,000	0
<b>Total, Objects of Expense</b>	<b>\$9,000,000</b>	<b>\$9,000,000</b>

**METHOD OF FINANCING:**

1 General Revenue Fund	9,000,000	9,000,000
<b>Total, Method of Finance</b>	<b>\$9,000,000</b>	<b>\$9,000,000</b>

**FULL-TIME EQUIVALENT POSITIONS (FTE):**

50.0	90.0
------	------

**EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:**

Center for Gene Therapy & Curative Medicine

**6.A. Historically Underutilized Business Supporting Schedule**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

Date: **10/19/2018**  
 Time: **3:29:11PM**

Agency Code: **729** Agency: **The University of Texas Southwestern Medical Center**

COMPARISON TO STATEWIDE HUB PROCUREMENT GOALS

**A. Fiscal Year 2016 - 2017 HUB Expenditure Information**

Statewide HUB Goals	Procurement Category	% Goal	HUB Expenditures FY 2016			Total Expenditures FY 2016		HUB Expenditures FY 2017			Total Expenditures FY 2017	
			% Actual	Diff	Actual \$	% Goal	% Actual	Diff	Actual \$	FY 2017		
11.2%	Heavy Construction	11.2 %	0.0%	-11.2%	\$0	\$2,505	11.2 %	0.0%	-11.2%	\$0	\$529,842	
21.1%	Building Construction	21.1 %	17.0%	-4.1%	\$9,167,204	\$53,828,838	21.1 %	0.5%	-20.6%	\$838,260	\$160,398,268	
32.9%	Special Trade	32.9 %	28.5%	-4.4%	\$2,366,511	\$8,293,577	32.9 %	19.4%	-13.5%	\$2,574,289	\$13,251,935	
23.7%	Professional Services	23.7 %	15.1%	-8.6%	\$1,893,707	\$12,578,870	23.7 %	0.0%	-23.7%	\$0	\$3,736,047	
26.0%	Other Services	26.0 %	6.1%	-19.9%	\$11,514,914	\$190,135,821	26.0 %	7.5%	-18.5%	\$13,047,254	\$174,365,218	
21.1%	Commodities	21.1 %	10.1%	-11.0%	\$42,600,194	\$423,165,585	21.1 %	11.2%	-9.9%	\$55,293,533	\$492,693,629	
	<b>Total Expenditures</b>		<b>9.8%</b>		<b>\$67,542,530</b>	<b>\$688,005,196</b>		<b>8.5%</b>		<b>\$71,753,336</b>	<b>\$844,974,939</b>	

**B. Assessment of Fiscal Year 2016 - 2017 Efforts to Meet HUB Procurement Goals**

**Attainment:**

FY16: The agency did not meet the category goals. FY17: The agency did not meet the category goals.

**Applicability:**

The "Heavy Construction" category was not applicable to agency operations in either FY2016 or FY2017.

**Factors Affecting Attainment:**

UTSW faces many challenges to increasing HUB participation and HUB diversity in today's contracting and procurement marketplace. In both FY16 and FY17, UTSW lacked the comprehensive reporting structure required to accurately depict HUB spend categories thereby negatively impacting the percentage of actual HUB spend reported. Additionally, the agency's business as a dedicated research and patient care center poses challenges to achieving HUB objectives. Specialized pharmaceutical expenditures, major medical and research equipment and blood products limit HUB availability and result in an adverse impact on the agency's ability to meet HUB objectives.

**"Good-Faith" Efforts:**

The agency made the following good faith efforts to comply with statewide HUB procurement goals per 1TAC Sec 34 TAC Sec. 20.284. Throughout FY16 and FY17, UT Southwestern facilitated 4 mentor protégé meetings, pursued 2 mentor protégé sponsorships, reviewed over 980 HUB Plans for compliance and monitored an average of 240 subcontract plans monthly. In addition, UT Southwestern attended 120 pre-proposal meetings, distributed bid request information on a monthly basis to 4 community advocacy groups and hosted annual HUB Market Expo and Hard Hats and Coffee for 40 firms. The Strategic Sourcing and HUB staff participated in over 32 various networking events. All of these efforts were recognized with UT Southwestern receiving the "Top 10 Agency Awarding the Most HUB Procurement Dollars" award and the "Top 10 Agency Awarding the Most Procurement Dollars" award. In an effort to improve HUB expansion, all HSPs were audited for

**6.A. Historically Underutilized Business Supporting Schedule**  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: **10/19/2018**  
Time: **3:29:11PM**

---

Agency Code: **729** Agency: **The University of Texas Southwestern Medical Center**

identification back to PO's. Improved processes to ensure accurate data capture and comprehensive reporting, including subcontractor data, have been implemented and are expected to have a material impact on the HUB spend categories reported.

**6.G HOMELAND SECURITY FUNDING SCHEDULE - PART A TERRORISM**

DATE: 10/19/2018  
TIME: 3:29:11PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Agency code: **729**      Agency name: **UT SW Med Center**

CODE	DESCRIPTION	Exp 2017	Est 2018	Bud 2019	BL 2020	BL 2021
<b>OBJECTS OF EXPENSE</b>						
1001	SALARIES AND WAGES	\$126,381	\$114,264	\$115,978	\$117,718	\$119,483
1002	OTHER PERSONNEL COSTS	\$23,829	\$21,727	\$22,053	\$22,384	\$22,719
1005	FACULTY SALARIES	\$120,513	\$108,636	\$110,266	\$111,920	\$113,598
2001	PROFESSIONAL FEES AND SERVICES	\$5,398	\$9,435	\$0	\$0	\$0
2003	CONSUMABLE SUPPLIES	\$95	\$107	\$107	\$107	\$107
2005	TRAVEL	\$2,692	\$4,042	\$4,042	\$4,042	\$4,042
2009	OTHER OPERATING EXPENSE	\$300,266	\$274,527	\$274,526	\$274,526	\$274,528
<b>TOTAL, OBJECTS OF EXPENSE</b>		<b>\$579,174</b>	<b>\$532,738</b>	<b>\$526,972</b>	<b>\$530,697</b>	<b>\$534,477</b>
<b>METHOD OF FINANCING</b>						
555	Federal Funds					
	CFDA 12.420.000, Military Medical Researc	\$28,198	\$19,296	\$28,746	\$28,746	\$28,746
	CFDA 93.847.000, Diabetes, Endocrinology a	\$383,681	\$394,181	\$388,930	\$392,655	\$396,435
	CFDA 93.853.000, Clinical Research Related	\$172,394	\$86,197	\$85,844	\$85,844	\$85,844
	CFDA 93.855.000, Allergy, Immunology and T	\$(5,099)	\$33,064	\$23,452	\$23,452	\$23,452
	Subtotal, MOF (Federal Funds)	\$579,174	\$532,738	\$526,972	\$530,697	\$534,477
<b>TOTAL, METHOD OF FINANCE</b>		<b>\$579,174</b>	<b>\$532,738</b>	<b>\$526,972</b>	<b>\$530,697</b>	<b>\$534,477</b>
<b>FULL-TIME-EQUIVALENT POSITIONS</b>		<b>3.2</b>	<b>2.9</b>	<b>2.9</b>	<b>2.9</b>	<b>2.9</b>

**NO FUNDS WERE PASSED THROUGH TO LOCAL ENTITIES**

**NO FUNDS WERE PASSED THROUGH TO OTHER STATE AGENCIES OR INSTITUTIONS OF HIGHER EDUCATION**

**6.G HOMELAND SECURITY FUNDING SCHEDULE - PART A TERRORISM**

DATE: 10/19/2018

TIME: 3:29:11PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

Agency code: **729**      Agency name: **UT SW Med Center**

---

<b>CODE</b>	<b>DESCRIPTION</b>	<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>BL 2020</b>	<b>BL 2021</b>
-------------	--------------------	-----------------	-----------------	-----------------	----------------	----------------

---

**USE OF HOMELAND SECURITY FUNDS**

Funds are used for salaries and operating expenses related to the projects

**6.G HOMELAND SECURITY FUNDING SCHEDULE - PART A TERRORISM**

DATE: 10/19/2018

**Funds Passed through to Local Entities**

TIME: 3:29:11PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

Agency code: **729**      Agency name: **UT SW Med Center**

---

<b>CODE</b>	<b>DESCRIPTION</b>	<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>BL 2020</b>	<b>BL 2021</b>
-------------	--------------------	-----------------	-----------------	-----------------	----------------	----------------

---



**6.G HOMELAND SECURITY FUNDING SCHEDULE - PART A TERRORISM**

DATE: 10/19/2018

**Funds Passed through to State Agencies**

TIME: 3:29:11PM

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

---

Agency code: **729**      Agency name: **UT SW Med Center**

---

<b>CODE</b>	<b>DESCRIPTION</b>	<b>Exp 2017</b>	<b>Est 2018</b>	<b>Bud 2019</b>	<b>BL 2020</b>	<b>BL 2021</b>
-------------	--------------------	-----------------	-----------------	-----------------	----------------	----------------

---

**UT Southwestern Medical Center (729)**  
**Estimated Funds Outside the Institution's Bill Pattern**  
**2018-19 and 2020-21 Biennia**

	2018-19 Biennium				2020-21 Biennium			
	FY 2018 Revenue	FY 2019 Revenue	Biennium Total	Percent of Total	FY 2020 Revenue	FY 2021 Revenue	Biennium Total	Percent of Total
<b>APPROPRIATED SOURCES INSIDE THE BILL PATTERN</b>								
State Appropriations (excluding HEGI & State Paid Fringes)	\$ 156,445,948	\$ 159,315,359	\$ 315,761,307		\$ 159,334,851	\$ 159,334,851	\$ 318,669,702	
Tuition and Fees (net of Discounts and Allowances)	8,010,255	7,288,658	15,298,913		7,288,658	7,288,658	14,577,316	
Endowment and Interest Income	1,279,406	1,277,636	2,557,042		1,277,636	1,277,636	2,555,272	
Sales and Services of Educational Activities (net)	-	-	-		-	-	-	
Sales and Services of Hospitals (net)	-	-	-		-	-	-	
Other Income	37,580	11,792	49,372		11,792	11,792	23,584	
<b>Total</b>	<b>165,773,189</b>	<b>167,893,445</b>	<b>333,666,634</b>	<b>5.5%</b>	<b>167,912,937</b>	<b>167,912,937</b>	<b>335,825,874</b>	<b>4.9%</b>
<b>APPROPRIATED SOURCES OUTSIDE THE BILL PATTERN</b>								
State Appropriations (HEGI & State Paid Fringes)	\$ 34,025,052	\$ 34,630,134	\$ 68,655,186		\$ 34,630,134	\$ 34,630,134	69,260,268	
Higher Education Assistance Funds	-	-	-		-	-	-	
Available University Fund	-	-	-		-	-	-	
State Grants and Contracts	24,955	30,465	55,420		30,465	30,465	60,930	
<b>Total</b>	<b>34,050,007</b>	<b>34,660,599</b>	<b>68,710,606</b>	<b>1.1%</b>	<b>34,660,599</b>	<b>34,660,599</b>	<b>69,321,198</b>	<b>1.0%</b>
<b>NON-APPROPRIATED SOURCES</b>								
Tuition and Fees (net of Discounts and Allowances)	17,217,090	18,972,136	\$ 36,189,226		19,557,543	20,384,946	39,942,489	
Federal Grants and Contracts	190,834,524	209,092,940	399,927,464		215,267,131	221,626,218	436,893,349	
State Grants and Contracts	47,740,491	41,562,529	89,303,020		42,852,756	44,171,800	87,024,556	
Local Government Grants and Contracts	198,242	198,242	396,484		198,242	198,242	396,484	
Private Gifts and Grants	369,012,010	371,527,793	740,539,803		383,177,255	388,530,937	771,708,192	
Endowment and Interest Income	105,262,308	117,849,309	223,111,617		121,129,110	125,441,330	246,570,440	
Sales and Services of Educational Activities (net)	9,391,077	11,095,714	20,486,791		15,009,171	15,234,575	30,243,746	
Sales and Services of Hospitals (net)	1,118,516,359	1,385,085,088	2,503,601,447		1,462,804,140	1,567,505,052	3,030,309,192	
Professional Fees (net)	598,954,895	714,349,889	1,313,304,784		688,145,084	757,567,183	1,445,712,267	
Auxiliary Enterprises (net)	25,200,698	25,784,377	50,985,075		26,557,908	27,354,645	53,912,553	
Other Income	130,533,394	122,013,241	252,546,635		127,711,550	128,981,738	256,693,288	
<b>Total</b>	<b>2,612,861,088</b>	<b>3,017,531,258</b>	<b>5,630,392,346</b>	<b>93.3%</b>	<b>3,102,409,890</b>	<b>3,296,996,666</b>	<b>6,399,406,556</b>	<b>94.0%</b>
<b>TOTAL SOURCES</b>	<b>\$ 2,812,684,284</b>	<b>\$ 3,220,085,302</b>	<b>\$ 6,032,769,586</b>	<b>100.0%</b>	<b>\$ 3,304,983,426</b>	<b>\$ 3,499,570,202</b>	<b>\$ 6,804,553,628</b>	<b>100.0%</b>

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018  
Time: 3:29:11PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

**1 Initial 2.5% of the Base Reduction Option**

**Category:** Programs - Service Reductions (FTEs-Layoffs)

**Item Comment:** A 2.5% incremental reduction planned by UTSW would cause the elimination of 14.7 FTE's each year. This reduction would be applied across-the-board to all our Special Item programs and would directly impact the services, activities and outcomes from these Special Item programs, disproportionately impacting research and education in the basic sciences.

Strategy: 1-5-1 Hold Harmless

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$272,716	\$272,716	\$545,432
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$272,716</b>	<b>\$272,716</b>	<b>\$545,432</b>

Strategy: 4-1-1 Primary Care Residency Training Program

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$24,289	\$24,289	\$48,578
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$24,289</b>	<b>\$24,289</b>	<b>\$48,578</b>

Strategy: 4-2-1 Institute for Nobel/National-Academy Biomedical Research

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$142,885	\$142,885	\$285,770			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$142,885</b>	<b>\$142,885</b>	<b>\$285,770</b>			

Strategy: 4-2-2 Institute for Innovations in Medical Technology

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,944	\$155,945	\$311,889			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,944</b>	<b>\$155,945</b>	<b>\$311,889</b>			

Strategy: 4-2-3 Metroplex Comprehensive Medical Imaging Center

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$129,960	\$129,960	\$259,920			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$129,960</b>	<b>\$129,960</b>	<b>\$259,920</b>			

Strategy: 4-2-4 Center for Obesity, Diabetes and Metabolism Research

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,952	\$155,952	\$311,904			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,952</b>	<b>\$155,952</b>	<b>\$311,904</b>			

Strategy: 4-2-6 Center for Research of Sickle Cell Disease

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$25,992	\$25,992	\$51,984			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$25,992</b>	<b>\$25,992</b>	<b>\$51,984</b>			

Strategy: 4-2-7 Texas Institute for Brain Injury and Repair

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$171,000	\$171,000	\$342,000			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$171,000</b>	<b>\$171,000</b>	<b>\$342,000</b>			

Strategy: 4-2-8 Center for Regenerative Science and Medicine

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018  
Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$182,400	\$182,400	\$364,800			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$182,400</b>	<b>\$182,400</b>	<b>\$364,800</b>			

Strategy: 4-2-9 Center for Advanced Radiation Therapy

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$22,800	\$22,800	\$45,600			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$22,800</b>	<b>\$22,800</b>	<b>\$45,600</b>			

Strategy: 4-3-1 Regional Burn Care Center

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$2,166	\$2,166	\$4,332			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$2,166</b>	<b>\$2,166</b>	<b>\$4,332</b>			

Strategy: 4-4-1 Program for Science Teacher Access to Resources (STARS)

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$12,996	\$12,996	\$25,992			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$12,996</b>	<b>\$12,996</b>	<b>\$25,992</b>			
Strategy: 4-5-1 Institutional Enhancement									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$18,240	\$18,240	\$36,480			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$18,240</b>	<b>\$18,240</b>	<b>\$36,480</b>			
<b>Item Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$1,317,340</b>	<b>\$1,317,341</b>	<b>\$2,634,681</b>			
<b>FTE Reductions (From FY 2020 and FY 2021 Base Request)</b>					<b>14.7</b>	<b>14.7</b>			

**2 Additional 2.5% (total 5.0%) of the Base Reduction Option**

**Category:** Programs - Service Reductions (FTEs-Layoffs)

**Item Comment:** An additional 2.5% incremental reduction (5.0% in total) planned by UTSW would cause the elimination of an additional 14.7 FTE's each year, resulting in a total reduction of 29.4 FTE's for each year. This reduction would be applied across-the-board to all our Special Item programs and would directly impact the services, activities and outcomes from these Special Item programs, disproportionately impacting research and education in the basic sciences.

Strategy: 1-5-1 Hold Harmless

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$272,716	\$272,716	\$545,432			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$272,716</b>	<b>\$272,716</b>	<b>\$545,432</b>			

Strategy: 4-1-1 Primary Care Residency Training Program

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$24,289	\$24,289	\$48,578			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$24,289</b>	<b>\$24,289</b>	<b>\$48,578</b>			

Strategy: 4-2-1 Institute for Nobel/National-Academy Biomedical Research

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$142,885	\$142,885	\$285,770			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$142,885</b>	<b>\$142,885</b>	<b>\$285,770</b>			

Strategy: 4-2-2 Institute for Innovations in Medical Technology



**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$155,944	\$155,945	\$311,889			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,944</b>	<b>\$155,945</b>	<b>\$311,889</b>			
Strategy: 4-2-3 Metroplex Comprehensive Medical Imaging Center									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$129,960	\$129,960	\$259,920			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$129,960</b>	<b>\$129,960</b>	<b>\$259,920</b>			
Strategy: 4-2-4 Center for Obesity, Diabetes and Metabolism Research									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$155,952	\$155,952	\$311,904			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,952</b>	<b>\$155,952</b>	<b>\$311,904</b>			
Strategy: 4-2-6 Center for Research of Sickle Cell Disease									

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$25,992	\$25,992	\$51,984			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$25,992</b>	<b>\$25,992</b>	<b>\$51,984</b>			

Strategy: 4-2-7 Texas Institute for Brain Injury and Repair

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$171,000	\$171,000	\$342,000			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$171,000</b>	<b>\$171,000</b>	<b>\$342,000</b>			

Strategy: 4-2-8 Center for Regenerative Science and Medicine

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$182,400	\$182,400	\$364,800			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$182,400</b>	<b>\$182,400</b>	<b>\$364,800</b>			

Strategy: 4-2-9 Center for Advanced Radiation Therapy

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$22,800	\$22,800	\$45,600			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$22,800</b>	<b>\$22,800</b>	<b>\$45,600</b>			

Strategy: 4-3-1 Regional Burn Care Center

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$2,166	\$2,166	\$4,332			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$2,166</b>	<b>\$2,166</b>	<b>\$4,332</b>			

Strategy: 4-4-1 Program for Science Teacher Access to Resources (STARS)

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$12,996	\$12,996	\$25,992			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$12,996</b>	<b>\$12,996</b>	<b>\$25,992</b>			

Strategy: 4-5-1 Institutional Enhancement

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$18,240	\$18,240	\$36,480			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$18,240</b>	<b>\$18,240</b>	<b>\$36,480</b>			
<b>Item Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$1,317,340</b>	<b>\$1,317,341</b>	<b>\$2,634,681</b>			
<b>FTE Reductions (From FY 2020 and FY 2021 Base Request)</b>					<b>14.7</b>	<b>14.7</b>			

**3 Additional 2.5% (total 7.5%) of the Base Reduction Option**

**Category:** Programs - Service Reductions (FTEs-Layoffs)

**Item Comment:** An additional 2.5% incremental reduction (7.5% in total) planned by UTSW would cause the elimination of an additional 14.7 FTE's each year, resulting in a total reduction of 44.1 FTE's for each year. This reduction would be applied across-the-board to all our Special Item programs and would directly impact the services, activities and outcomes from these Special Item programs, disproportionately impacting research and education in the basic sciences.

Strategy: 1-5-1 Hold Harmless

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$272,716	\$272,716	\$545,432			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$272,716</b>	<b>\$272,716</b>	<b>\$545,432</b>			

Strategy: 4-1-1 Primary Care Residency Training Program

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$24,289	\$24,289	\$48,578			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$24,289</b>	<b>\$24,289</b>	<b>\$48,578</b>			

Strategy: 4-2-1 Institute for Nobel/National-Academy Biomedical Research

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$142,885	\$142,885	\$285,770			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$142,885</b>	<b>\$142,885</b>	<b>\$285,770</b>			

Strategy: 4-2-2 Institute for Innovations in Medical Technology

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,944	\$155,945	\$311,889			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,944</b>	<b>\$155,945</b>	<b>\$311,889</b>			

Strategy: 4-2-3 Metroplex Comprehensive Medical Imaging Center

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$129,960	\$129,960	\$259,920			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$129,960</b>	<b>\$129,960</b>	<b>\$259,920</b>			

Strategy: 4-2-4 Center for Obesity, Diabetes and Metabolism Research

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,952	\$155,952	\$311,904			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,952</b>	<b>\$155,952</b>	<b>\$311,904</b>			

Strategy: 4-2-6 Center for Research of Sickle Cell Disease

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$25,992	\$25,992	\$51,984			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$25,992</b>	<b>\$25,992</b>	<b>\$51,984</b>			

Strategy: 4-2-7 Texas Institute for Brain Injury and Repair

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$171,000	\$171,000	\$342,000			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$171,000</b>	<b>\$171,000</b>	<b>\$342,000</b>			

Strategy: 4-2-8 Center for Regenerative Science and Medicine

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$182,400	\$182,400	\$364,800			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$182,400</b>	<b>\$182,400</b>	<b>\$364,800</b>			

Strategy: 4-2-9 Center for Advanced Radiation Therapy

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$22,800	\$22,800	\$45,600			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$22,800</b>	<b>\$22,800</b>	<b>\$45,600</b>			

Strategy: 4-3-1 Regional Burn Care Center

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$2,166	\$2,166	\$4,332			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$2,166</b>	<b>\$2,166</b>	<b>\$4,332</b>			
Strategy: 4-4-1 Program for Science Teacher Access to Resources (STARS)									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$12,996	\$12,996	\$25,992			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$12,996</b>	<b>\$12,996</b>	<b>\$25,992</b>			
Strategy: 4-5-1 Institutional Enhancement									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$18,240	\$18,240	\$36,480			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$18,240</b>	<b>\$18,240</b>	<b>\$36,480</b>			
<b>Item Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$1,317,340</b>	<b>\$1,317,341</b>	<b>\$2,634,681</b>			
<b>FTE Reductions (From FY 2020 and FY 2021 Base Request)</b>					<b>14.7</b>	<b>14.7</b>			



**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ <u>Method of Financing</u>	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

**4 Additional 2.5% (total 10.0%) of the Base Reduction Option**

**Category:** Programs - Service Reductions (FTEs-Layoffs)

**Item Comment:** An additional 2.5% incremental reduction (10.0% in total) planned by UTSW would cause the elimination of an additional 14.7 FTE's each year, resulting in a total reduction of 58.8 FTE's for each year. This reduction would be applied across-the-board to all our Special Item programs and would directly impact the services, activities and outcomes from these Special Item programs, disproportionately impacting research and education in the basic sciences.

Strategy: 1-5-1 Hold Harmless

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$272,716	\$272,716	\$545,432
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$272,716</b>	<b>\$272,716</b>	<b>\$545,432</b>

Strategy: 4-1-1 Primary Care Residency Training Program

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$24,289	\$24,289	\$48,578
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$24,289</b>	<b>\$24,289</b>	<b>\$48,578</b>

Strategy: 4-2-1 Institute for Nobel/National-Academy Biomedical Research

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$142,885	\$142,885	\$285,770			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$142,885</b>	<b>\$142,885</b>	<b>\$285,770</b>			

Strategy: 4-2-2 Institute for Innovations in Medical Technology

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,944	\$155,945	\$311,889			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,944</b>	<b>\$155,945</b>	<b>\$311,889</b>			

Strategy: 4-2-3 Metroplex Comprehensive Medical Imaging Center

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$129,960	\$129,960	\$259,920			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$129,960</b>	<b>\$129,960</b>	<b>\$259,920</b>			

Strategy: 4-2-4 Center for Obesity, Diabetes and Metabolism Research

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$155,952	\$155,952	\$311,904			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$155,952</b>	<b>\$155,952</b>	<b>\$311,904</b>			

Strategy: 4-2-6 Center for Research of Sickle Cell Disease

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$25,992	\$25,992	\$51,984			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$25,992</b>	<b>\$25,992</b>	<b>\$51,984</b>			

Strategy: 4-2-7 Texas Institute for Brain Injury and Repair

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$171,000	\$171,000	\$342,000			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$171,000</b>	<b>\$171,000</b>	<b>\$342,000</b>			

Strategy: 4-2-8 Center for Regenerative Science and Medicine

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$182,400	\$182,400	\$364,800			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$182,400</b>	<b>\$182,400</b>	<b>\$364,800</b>			

Strategy: 4-2-9 Center for Advanced Radiation Therapy

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$22,800	\$22,800	\$45,600			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$22,800</b>	<b>\$22,800</b>	<b>\$45,600</b>			

Strategy: 4-3-1 Regional Burn Care Center

General Revenue Funds

1 General Revenue Fund	\$0	\$0	\$0	\$2,166	\$2,166	\$4,332			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$2,166</b>	<b>\$2,166</b>	<b>\$4,332</b>			

Strategy: 4-4-1 Program for Science Teacher Access to Resources (STARS)

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: 729 Agency name: The University of Texas Southwestern Medical Center

Item Priority and Name/ Method of Financing	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$12,996	\$12,996	\$25,992			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$12,996</b>	<b>\$12,996</b>	<b>\$25,992</b>			
Strategy: 4-5-1 Institutional Enhancement									
<u>General Revenue Funds</u>									
1 General Revenue Fund	\$0	\$0	\$0	\$18,240	\$18,240	\$36,480			
<b>General Revenue Funds Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$18,240</b>	<b>\$18,240</b>	<b>\$36,480</b>			
<b>Item Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$1,317,340</b>	<b>\$1,317,341</b>	<b>\$2,634,681</b>			
<b>FTE Reductions (From FY 2020 and FY 2021 Base Request)</b>					<b>14.7</b>	<b>14.7</b>			
<b>AGENCY TOTALS</b>									
<b>General Revenue Total</b>				<b>\$5,269,360</b>	<b>\$5,269,364</b>	<b>\$10,538,724</b>			<b>\$10,538,724</b>
<b>Agency Grand Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$5,269,360</b>	<b>\$5,269,364</b>	<b>\$10,538,724</b>			<b>\$10,538,724</b>
<b>Difference, Options Total Less Target</b>									
<b>Agency FTE Reductions (From FY 2020 and FY 2021 Base Request)</b>				<b>58.8</b>	<b>58.8</b>				

**6.I. Percent Biennial Base Reduction Options**

**10 % REDUCTION**

86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018

Time: 3:29:11PM

Agency code: **729** Agency name: **The University of Texas Southwestern Medical Center**

Item Priority and Name/ <u>Method of Financing</u>	REVENUE LOSS			REDUCTION AMOUNT			PROGRAM AMOUNT		TARGET
	2020	2021	Biennial Total	2020	2021	Biennial Total	2020	2021	Biennial Total
<b>Article Total</b>				\$5,269,360	\$5,269,364	\$10,538,724			
<b>Statewide Total</b>				\$5,269,360	\$5,269,364	\$10,538,724			



86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

## 729 The University of Texas Southwestern Medical Center

	Act 2017	Act 2018	Bud 2019	Est 2020	Est 2021
<b>Gross Tuition</b>					
Gross Resident Tuition	6,282,895	6,368,132	6,396,400	6,396,400	6,396,400
Gross Non-Resident Tuition	8,421,603	8,414,332	8,451,700	8,451,700	8,451,700
<b>Gross Tuition</b>	<b>14,704,498</b>	<b>14,782,464</b>	<b>14,848,100</b>	<b>14,848,100</b>	<b>14,848,100</b>
Less: Resident Waivers and Exemptions (excludes Hazlewood)	(99,226)	(104,165)	(106,000)	(106,000)	(106,000)
Less: Non-Resident Waivers and Exemptions	(6,914,548)	(6,349,154)	(6,383,215)	(6,383,215)	(6,383,215)
Less: Hazlewood Exemptions	(316,104)	(280,579)	(285,000)	(285,000)	(285,000)
Less: Board Authorized Tuition Increases (TX. Educ. Code Ann. Sec. 54.008)	(554,230)	(606,350)	(610,000)	(610,000)	(610,000)
Less: Tuition increases charged to doctoral students with hours in excess of 100 (TX. Educ. Code Ann. Sec. 54.012)	0	0	0	0	0
Less: Tuition increases charged to undergraduate students with excessive hours above degree requirements. (TX. Educ. Code Ann. Sec. 61.0595)	0	0	0	0	0
Less: Tuition rebates for certain undergraduates (TX. Educ. Code Ann. Sec. 54.0065)	0	0	0	0	0
Plus: Tuition waived for Students 55 Years or Older (TX. Educ. Code Ann. Sec. 54.013)	0	0	0	0	0
Less: Tuition for repeated or excessive hours (TX. Educ. Code Ann. Sec. 54.014)	0	0	0	0	0
Plus: Tuition waived for Texas Grant Recipients (TX. Educ. Code Ann. Sec. 56.307)	0	0	0	0	0
<b>Subtotal</b>	<b>6,820,390</b>	<b>7,442,216</b>	<b>7,463,885</b>	<b>7,463,885</b>	<b>7,463,885</b>
Less: Transfer of funds for Texas Public Education Grants Program (Tex. Educ. Code Ann. Sec. 56c) and for Emergency Loans (Tex. Educ. Code Ann. Sec. 56d)	(1,045,658)	(1,284,448)	(1,217,636)	(1,217,636)	(1,217,636)
Less: Transfer of Funds (2%) for Physician/Dental Loans (Medical Schools)	0	0	0	0	0
Less: Statutory Tuition (Tx. Educ. Code Ann. Sec. 54.051) Set Aside for Doctoral Incentive Loan Repayment Program (Tx. Educ. Code Ann. Sec. 56.095)	0	0	0	0	0
Less: Other Authorized Deduction					
<b>Net Tuition</b>	<b>5,774,732</b>	<b>6,157,768</b>	<b>6,246,249</b>	<b>6,246,249</b>	<b>6,246,249</b>



86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

<b>729 The University of Texas Southwestern Medical Center</b>					
	<b>Act 2017</b>	<b>Act 2018</b>	<b>Bud 2019</b>	<b>Est 2020</b>	<b>Est 2021</b>
Student Teaching Fees	0	0	0	0	0
Special Course Fees	0	0	0	0	0
Laboratory Fees	49,128	49,858	40,000	40,000	40,000
<b>Subtotal, Tuition and Fees (Formula Amounts for Health-Related Institutions)</b>	<b>5,823,860</b>	<b>6,207,626</b>	<b>6,286,249</b>	<b>6,286,249</b>	<b>6,286,249</b>
<b>OTHER INCOME</b>					
<b>Interest on General Funds:</b>					
Local Funds in State Treasury	116,415	265,395	60,000	60,000	60,000
Funds in Local Depositories, e.g., local amounts	0	0	0	0	0
Other Income (Itemize)					
Miscellaneous Income	2,671	116,188	11,792	11,792	11,792
<b>Subtotal, Other Income</b>	<b>119,086</b>	<b>381,583</b>	<b>71,792</b>	<b>71,792</b>	<b>71,792</b>
<b>Subtotal, Other Educational and General Income</b>	<b>5,942,946</b>	<b>6,589,209</b>	<b>6,358,041</b>	<b>6,358,041</b>	<b>6,358,041</b>
Less: O.A.S.I. Applicable to Educational and General Local Funds Payrolls	(273,259)	(360,733)	(360,813)	(360,813)	(360,813)
Less: Teachers Retirement System and ORP Proportionality for Educational and General Funds	(277,928)	(367,504)	(376,289)	(376,289)	(376,289)
Less: Staff Group Insurance Premiums	(1,614,075)	(2,234,249)	(2,044,088)	(3,304,836)	(3,304,836)
<b>Total, Other Educational and General Income (Formula Amounts for General Academic Institutions)</b>	<b>3,777,684</b>	<b>3,626,723</b>	<b>3,576,851</b>	<b>2,316,103</b>	<b>2,316,103</b>
<b>Reconciliation to Summary of Request for FY 2017-2015</b>					
Plus: Transfer of Funds for Texas Public Education Grants Program and Physician Loans	1,045,658	1,284,448	1,217,636	1,217,636	1,217,636
Plus: Transfer of Funds 2% for Physician/Dental Loans (Medical Schools)	0	0	0	0	0
Plus: Transfer of Funds for Cancellation of Student Loans of Physicians	0	0	0	0	0
Plus: Organized Activities	0	0	0	0	0
Plus: Staff Group Insurance Premiums	1,614,075	2,234,249	2,044,088	3,304,836	3,304,836
Plus: Board-authorized Tuition Income	554,230	606,350	610,000	610,000	610,000
Plus: Tuition Increases Charged to Doctoral Students with Hours in Excess of 100	0	0	0	0	0

Schedule 1A: Other Educational and General Income

10/19/2018 3:29:12PM

86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

<b>729 The University of Texas Southwestern Medical Center</b>					
	<b>Act 2017</b>	<b>Act 2018</b>	<b>Bud 2019</b>	<b>Est 2020</b>	<b>Est 2021</b>
Plus: Tuition Increases Charged to Undergraduate Students with Excessive Hours above Degree Requirements (TX. Educ. Code Ann. Sec. 61.0595)	0	0	0	0	0
Plus: Tuition rebates for certain undergraduates (TX Educ.Code Ann. Sec. 54.0065)	0	0	0	0	0
Plus: Tuition for repeated or excessive hours (TX. Educ. Code Ann. Sec. 54.014)	0	0	0	0	0
Less: Tuition Waived for Students 55 Years or Older	0	0	0	0	0
Less: Tuition Waived for Texas Grant Recipients	0	0	0	0	0
<b>Total, Other Educational and General Income Reported on Summary of Request</b>	<b>6,991,647</b>	<b>7,751,770</b>	<b>7,448,575</b>	<b>7,448,575</b>	<b>7,448,575</b>

Schedule 2: Selected Educational, General and Other Funds

10/19/2018 3:29:13PM

86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

	Act 2017	Act 2018	Bud 2019	Est 2020	Est 2021
General Revenue Transfers					
Transfer from Coordinating Board for Texas College Work Study Program (2017, 2018, 2019)	10,973	10,973	10,973	0	0
Transfer from Coordinating Board for Professional Nursing Shortage Reduction Program	0	0	0	0	0
Transfer of GR Group Insurance Premium from Comptroller (UT and TAMU Components only)	17,977,409	17,657,544	17,515,876	0	0
Less: Transfer to Other Institutions	0	0	0	0	0
Less: Transfer to Department of Health, Disproportionate Share - State-Owned Hospitals (2017, 2018, 2019)	0	0	0	0	0
Other (Itemize)					
Other	13,982	13,982	19,492	0	0
Other: Fifth Year Accounting Scholarship	0	0	0	0	0
Texas Grants	0	0	0	0	0
B-on-Time Program	0	0	0	0	0
Texas Research Incentive Program	0	0	0	0	0
Less: Transfer to System Administration	0	0	0	0	0
GME Expansion	0	0	0	0	0
<b>Subtotal, General Revenue Transfers</b>	<b>18,002,364</b>	<b>17,682,499</b>	<b>17,546,341</b>	<b>0</b>	<b>0</b>
General Revenue HEF for Operating Expenses	0	0	0	0	0
Transfer from Available University Funds (UT, A&M and Prairie View A&M Only)	0	0	0	0	0
Other Additions (Itemize)					
Increase Capital Projects - Educational and General Funds	0	0	0	0	0
Transfer from Department of Health, Disproportionate Share - State-owned Hospitals (2017, 2018, 2019)	0	0	0	0	0
Transfers from Other Funds, e.g., Designated funds transferred for educational and general activities (Itemize)	0	0	0	0	0
Other (Itemize)					
<b>Gross Designated Tuition (Sec. 54.0513)</b>	<b>16,075,024</b>	<b>16,637,822</b>	<b>17,587,534</b>	<b>18,378,973</b>	<b>19,206,026</b>
<b>Indirect Cost Recovery (Sec. 145.001(d))</b>	<b>75,216,781</b>	<b>77,795,273</b>	<b>78,905,903</b>	<b>81,240,601</b>	<b>83,676,783</b>
<b>Correctional Managed Care Contracts</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

**Schedule 3B: Staff Group Insurance Data Elements (UT/A&M)**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

10/19/2018 3:29:13PM

**729 The University of Texas Southwestern Medical Center**

	<b>E&amp;G Enrollment</b>	<b>GR Enrollment</b>	<b>GR-D/OEGI Enrollment</b>	<b>Total E&amp;G (Check)</b>	<b>Local Non-E&amp;G</b>
<b>GR &amp; GR-D Percentages</b>					
GR %	96.00%				
GR-D/Other %	4.00%				
<b>Total Percentage</b>	<b>100.00%</b>				
<b>FULL TIME ACTIVES</b>					
1a Employee Only	780	749	31	780	7,295
2a Employee and Children	202	194	8	202	1,877
3a Employee and Spouse	186	179	7	186	1,275
4a Employee and Family	277	266	11	277	2,421
5a Eligible, Opt Out	0	0	0	0	59
6a Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>1,445</b>	<b>1,388</b>	<b>57</b>	<b>1,445</b>	<b>12,927</b>
<b>PART TIME ACTIVES</b>					
1b Employee Only	10	10	0	10	108
2b Employee and Children	2	2	0	2	19
3b Employee and Spouse	4	4	0	4	29
4b Employee and Family	0	0	0	0	44
5b Eligible, Opt Out	0	0	0	0	655
6b Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>16</b>	<b>16</b>	<b>0</b>	<b>16</b>	<b>855</b>
<b>Total Active Enrollment</b>	<b>1,461</b>	<b>1,404</b>	<b>57</b>	<b>1,461</b>	<b>13,782</b>

**Schedule 3B: Staff Group Insurance Data Elements (UT/A&M)**  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

10/19/2018 3:29:13PM

**729 The University of Texas Southwestern Medical Center**

	<b>E&amp;G Enrollment</b>	<b>GR Enrollment</b>	<b>GR-D/OEGI Enrollment</b>	<b>Total E&amp;G (Check)</b>	<b>Local Non-E&amp;G</b>
<b>FULL TIME RETIREES by ERS</b>					
1c Employee Only	434	417	17	434	889
2c Employee and Children	10	10	0	10	20
3c Employee and Spouse	208	200	8	208	426
4c Employee and Family	15	14	1	15	30
5c Eligible, Opt Out	0	0	0	0	0
6c Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>667</b>	<b>641</b>	<b>26</b>	<b>667</b>	<b>1,365</b>
<b>PART TIME RETIREES by ERS</b>					
1d Employee Only	0	0	0	0	0
2d Employee and Children	0	0	0	0	0
3d Employee and Spouse	0	0	0	0	0
4d Employee and Family	0	0	0	0	0
5d Eligible, Opt Out	0	0	0	0	0
6d Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total Retirees Enrollment</b>	<b>667</b>	<b>641</b>	<b>26</b>	<b>667</b>	<b>1,365</b>
<b>TOTAL FULL TIME ENROLLMENT</b>					
1e Employee Only	1,214	1,166	48	1,214	8,184
2e Employee and Children	212	204	8	212	1,897
3e Employee and Spouse	394	379	15	394	1,701
4e Employee and Family	292	280	12	292	2,451
5e Eligible, Opt Out	0	0	0	0	59
6e Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>2,112</b>	<b>2,029</b>	<b>83</b>	<b>2,112</b>	<b>14,292</b>

## 729 The University of Texas Southwestern Medical Center

	<b>E&amp;G Enrollment</b>	<b>GR Enrollment</b>	<b>GR-D/OEGI Enrollment</b>	<b>Total E&amp;G (Check)</b>	<b>Local Non-E&amp;G</b>
<b>TOTAL ENROLLMENT</b>					
1f Employee Only	1,224	1,176	48	1,224	8,292
2f Employee and Children	214	206	8	214	1,916
3f Employee and Spouse	398	383	15	398	1,730
4f Employee and Family	292	280	12	292	2,495
5f Eligible, Opt Out	0	0	0	0	714
6f Eligible, Not Enrolled	0	0	0	0	0
<b>Total for This Section</b>	<b>2,128</b>	<b>2,045</b>	<b>83</b>	<b>2,128</b>	<b>15,147</b>

**Schedule 4: Computation of OASI**  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

**Agency 729 The University of Texas Southwestern Medical Center**

Proportionality Percentage Based on Comptroller Accounting Policy Statement #011, Exhibit 2	2017		2018		2019		2020		2021	
	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>
General Revenue (% to Total)	96.7000	\$8,007,322	96.0000	\$8,657,598	96.0000	\$8,659,507	96.0000	\$8,659,507	96.0000	\$8,659,507
Other Educational and General Funds (% to Total)	3.3000	\$273,259	4.0000	\$360,733	4.0000	\$360,813	4.0000	\$360,813	4.0000	\$360,813
Health-Related Institutions Patient Income (% to Total)	0.0000	\$0	0.0000	\$0	0.0000	\$0	0.0000	\$0	0.0000	\$0
<b>Grand Total, OASI (100%)</b>	<b>100.0000</b>	<b>\$8,280,581</b>	<b>100.0000</b>	<b>\$9,018,331</b>	<b>100.0000</b>	<b>\$9,020,320</b>	<b>100.0000</b>	<b>\$9,020,320</b>	<b>100.0000</b>	<b>\$9,020,320</b>

**Schedule 5: Calculation of Retirement Proportionality and ORP Differential**

10/19/2018 3:29:13PM

86th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

**729 The University of Texas Southwestern Medical Center**

Description	Act 2017	Act 2018	Bud 2019	Est 2020	Est 2021
<b>Proportionality Amounts</b>					
Gross Educational and General Payroll - Subject To TRS Retirement	75,696,597	84,166,149	86,178,213	86,178,213	86,178,213
Employer Contribution to TRS Retirement Programs	5,147,369	5,723,298	5,860,118	5,860,118	5,860,118
Gross Educational and General Payroll - Subject To ORP Retirement	49,670,831	52,489,394	53,744,198	53,744,198	53,744,198
Employer Contribution to ORP Retirement Programs	3,278,275	3,464,300	3,547,117	3,547,117	3,547,117
<b>Proportionality Percentage</b>					
General Revenue	96.7014 %	96.0000 %	96.0000 %	96.0000 %	96.0000 %
Other Educational and General Income	3.2986 %	4.0000 %	4.0000 %	4.0000 %	4.0000 %
Health-related Institutions Patient Income	0.0000 %	0.0000 %	0.0000 %	0.0000 %	0.0000 %
<b>Proportional Contribution</b>					
Other Educational and General Proportional Contribution (Other E&G percentage x Total Employer Contribution to Retirement Programs)	277,928	367,504	376,289	376,289	376,289
HRI Patient Income Proportional Contribution (HRI Patient Income percentage x Total Employer Contribution To Retirement Programs)	0	0	0	0	0
<b>Differential</b>					
Differential Percentage	1.9000 %	1.9000 %	1.9000 %	1.9000 %	1.9000 %
Gross Payroll Subject to Differential - Optional Retirement Program	49,670,837	52,489,394	53,744,198	53,744,198	53,744,198
<b>Total Differential</b>	943,746	997,298	1,021,140	1,021,140	1,021,140



**Schedule 6: Constitutional Capital Funding**  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

10/19/2018 3:29:13PM

---

**729 The University of Texas Southwestern Medical Center**

---

<b>Activity</b>	<b>Act 2017</b>	<b>Act 2018</b>	<b>Bud 2019</b>	<b>Est 2020</b>	<b>Est 2021</b>
A. PUF Bond Proceeds Allocation	2,068,589	2,200,000	4,000,000	4,000,000	4,000,000
Project Allocation					
Library Acquisitions	0	0	0	0	0
Construction, Repairs and Renovations	2,068,589	2,200,000	4,000,000	4,000,000	4,000,000
Furnishings & Equipment	0	0	0	0	0
Computer Equipment & Infrastructure	0	0	0	0	0
Reserve for Future Consideration	0	0	0	0	0
Other (Itemize)					
B. HEF General Revenue Allocation	0	0	0	0	0
Project Allocation					
Library Acquisitions	0	0	0	0	0
Construction, Repairs and Renovations	0	0	0	0	0
Furnishings & Equipment	0	0	0	0	0
Computer Equipment & Infrastructure	0	0	0	0	0
Reserve for Future Consideration	0	0	0	0	0
HEF for Debt Service	0	0	0	0	0
Other (Itemize)					

**Schedule 7: Personnel**  
86th Regular Session, Agency Submission, Version 1  
Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018  
Time: 3:29:13PM

Agency code: **729**      Agency name: **UT SW Med Center**

	<b>Actual</b> 2017	<b>Actual</b> 2018	<b>Budgeted</b> 2019	<b>Estimated</b> 2020	<b>Estimated</b> 2021
<b>Part A.</b>					
<b>FTE Postions</b>					
<b>Directly Appropriated Funds (Bill Pattern)</b>					
Educational and General Funds Faculty Employees	316.9	346.9	346.9	346.9	346.9
Educational and General Funds Non-Faculty Employees	1,454.3	1,563.7	1,563.4	1,576.0	1,576.0
<b>Subtotal, Directly Appropriated Funds</b>	<b>1,771.2</b>	<b>1,910.6</b>	<b>1,910.3</b>	<b>1,922.9</b>	<b>1,922.9</b>
<b>Other Appropriated Funds</b>					
Other (Itemize)	28.8	46.2	46.5	33.9	33.9
<b>Subtotal, Other Appropriated Funds</b>	<b>28.8</b>	<b>46.2</b>	<b>46.5</b>	<b>33.9</b>	<b>33.9</b>
<b>Subtotal, All Appropriated</b>	<b>1,800.0</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>	<b>1,956.8</b>
Non Appropriated Funds Employees	13,425.4	14,150.2	14,150.2	14,150.2	14,150.2
<b>Subtotal, Other Funds &amp; Non-Appropriated</b>	<b>13,425.4</b>	<b>14,150.2</b>	<b>14,150.2</b>	<b>14,150.2</b>	<b>14,150.2</b>
<b>GRAND TOTAL</b>	<b>15,225.4</b>	<b>16,107.0</b>	<b>16,107.0</b>	<b>16,107.0</b>	<b>16,107.0</b>

**Schedule 7: Personnel**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018  
 Time: 3:29:13PM

Agency code: **729** Agency name: **UT SW Med Center**

	<b>Actual</b> 2017	<b>Actual</b> 2018	<b>Budgeted</b> 2019	<b>Estimated</b> 2020	<b>Estimated</b> 2021
<b>Part B.</b>					
<b>Personnel Headcount</b>					
<b>Directly Appropriated Funds (Bill Pattern)</b>					
Educational and General Funds Faculty Employees	327.0	357.0	357.0	357.0	357.0
Educational and General Funds Non-Faculty Employees	1,587.0	1,663.0	1,684.0	1,698.0	1,698.0
<b>Subtotal, Directly Appropriated Funds</b>	<b>1,914.0</b>	<b>2,020.0</b>	<b>2,041.0</b>	<b>2,055.0</b>	<b>2,055.0</b>
<b>Other Appropriated Funds</b>					
Other (Itemize)	31.0	49.0	50.0	36.0	36.0
<b>Subtotal, Other Appropriated Funds</b>	<b>31.0</b>	<b>49.0</b>	<b>50.0</b>	<b>36.0</b>	<b>36.0</b>
<b>Subtotal, All Appropriated</b>	<b>1,945.0</b>	<b>2,069.0</b>	<b>2,091.0</b>	<b>2,091.0</b>	<b>2,091.0</b>
Non Appropriated Funds Employees	14,553.0	15,319.0	15,319.0	15,319.0	15,319.0
<b>Subtotal, Non-Appropriated</b>	<b>14,553.0</b>	<b>15,319.0</b>	<b>15,319.0</b>	<b>15,319.0</b>	<b>15,319.0</b>
<b>GRAND TOTAL</b>	<b>16,498.0</b>	<b>17,388.0</b>	<b>17,410.0</b>	<b>17,410.0</b>	<b>17,410.0</b>

**Schedule 7: Personnel**  
 86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

Date: 10/19/2018  
 Time: 3:29:13PM

Agency code: **729**      Agency name: **UT SW Med Center**

	<b>Actual 2017</b>	<b>Actual 2018</b>	<b>Budgeted 2019</b>	<b>Estimated 2020</b>	<b>Estimated 2021</b>
<b>PART C.</b>					
<b>Salaries</b>					
<b>Directly Appropriated Funds (Bill Pattern)</b>					
Educational and General Funds Faculty Employees	\$58,465,557	\$64,204,079	\$63,985,645	\$63,985,645	\$63,985,645
Educational and General Funds Non-Faculty Employees	\$75,722,590	\$79,230,707	\$79,128,241	\$79,765,943	\$79,765,943
<b>Subtotal, Directly Appropriated Funds</b>	<b>\$134,188,147</b>	<b>\$143,434,786</b>	<b>\$143,113,886</b>	<b>\$143,751,588</b>	<b>\$143,751,588</b>
<b>Other Appropriated Funds</b>					
Other (Itemize)	\$3,407,454	\$5,517,852	\$5,560,379	\$4,037,045	\$4,037,045
<b>Subtotal, Other Appropriated Funds</b>	<b>\$3,407,454</b>	<b>\$5,517,852</b>	<b>\$5,560,379</b>	<b>\$4,037,045</b>	<b>\$4,037,045</b>
<b>Subtotal, All Appropriated</b>	<b>\$137,595,601</b>	<b>\$148,952,638</b>	<b>\$148,674,265</b>	<b>\$147,788,633</b>	<b>\$147,788,633</b>
Non Appropriated Funds Employees	\$1,257,921,870	\$1,324,160,130	\$1,324,160,130	\$1,324,160,130	\$1,324,160,130
<b>Subtotal, Non-Appropriated</b>	<b>\$1,257,921,870</b>	<b>\$1,324,160,130</b>	<b>\$1,324,160,130</b>	<b>\$1,324,160,130</b>	<b>\$1,324,160,130</b>
<b>GRAND TOTAL</b>	<b>\$1,395,517,471</b>	<b>\$1,473,112,768</b>	<b>\$1,472,834,395</b>	<b>\$1,471,948,763</b>	<b>\$1,471,948,763</b>

**Agency 729 The University of Texas Southwestern Medical Center**

<b>Project Priority:</b>	<b>Project Code:</b>	<b>Tuition Revenue Bond Request</b>	<b>Total Project Cost</b>	<b>Cost Per Total Gross Square Feet</b>
1	1	\$ 120,000,000	\$ 120,000,000	\$ 667
<b>Name of Proposed Facility:</b>		<b>Project Type:</b>		
UTD-UTSW Translational Biomedical Engineer		New Construction		
<b>Location of Facility:</b>		<b>Type of Facility:</b>		
UT Southwestern's Campus		Laboratory/Offices		
<b>Project Start Date:</b>		<b>Project Completion Date:</b>		
09/01/2020		12/31/2023		
<b>Gross Square Feet:</b>	<b>Net Assignable Square Feet in Project</b>			
180,000	110,000			

**Project Description**

Recent advances have begun to show the promise of application of previously unimaginable bioengineering approaches – such as tissue engineering, organ fabrication, and neuroprosthesis to restore function to damaged tissues and organs. Yet, there is a pressing need to translate biomedical technologies from the idea stage to improved treatment for millions of patients in Texas and beyond. UT Dallas and UT Southwestern – leveraging research strengths in basic and applied biomedical and engineering sciences – are poised to expand their collaborations into a center for biomedical innovation and translation. A critical missing ingredient is the proposed properly designed facility on UT Southwestern’s campus to optimally connect engineers and scientists with physicians and patients, accelerating the advancement of medical technologies, and training and education for students. The project will provide research and support space to dozens of faculty, graduate and undergraduate students.

Schedule 8B: Tuition Revenue Bond Issuance History

10/19/2018 3:29:14PM

86th Regular Session, Agency Submission, Version 1  
 Automated Budget and Evaluation System of Texas (ABEST)

729 The University of Texas Southwestern Medical Center

Authorization Date	Authorization Amount	Issuance Date	Issuance Amount	Authorized Amount Outstanding as of 08/31/2018	Proposed Issuance Date for Outstanding Authorization	Proposed Issuance Amount for Outstanding Authorization
1997	\$20,000,000	Sep 16 1998	\$20,000,000			
		<i>Subtotal</i>	\$20,000,000	\$0		
2001	\$40,000,000	Oct 2 2001	\$40,000,000			
		<i>Subtotal</i>	\$40,000,000	\$0		
2003	\$56,000,000	Nov 4 2004	\$56,000,000			
		<i>Subtotal</i>	\$56,000,000	\$0		
2006	\$42,000,000	Feb 15 2008	\$5,590,000			
		Jan 6 2009	\$33,025,000			
		Feb 18 2009	\$3,385,000			
		<i>Subtotal</i>	\$42,000,000	\$0		
2015	\$80,000,000	Jul 1 2016	\$40,000,000			
		Aug 22 2016	\$40,000,000			
		<i>Subtotal</i>	\$80,000,000	\$0		

**Schedule 8C: Tuition Revenue Bonds Request by Project**  
 86th Regular Session, Agency Submission, Version 1

Agency Code: **729**

Agency Name: **The University of Texas Southwestern Medical Center**

Project Name	Authorization Year	Estimated Final Payment Date	Requested Amount 2020	Requested Amount 2021
<b>SWM</b> North Campus Ph. III	1997	8/15/2018	\$ -	\$ -
<b>SWM</b> North Campus Ph. III Finish Out	1997	8/15/2018	\$ -	\$ -
<b>SWM</b> North Campus Ph. IV	2001/2003	8/15/2022	\$ 8,291,950.00	\$ 7,967,150.00
<b>SWM</b> North Campus Ph. V	2006	8/15/2021	\$ 4,033,750.00	\$ 3,344,250.00
<b>SWM</b> Vivarium and Aging Research Infrastructure	2015	8/15/2025	\$ 6,190,000.00	\$ 7,205,000.00
			<u>\$ 18,515,700.00</u>	<u>\$ 18,516,400.00</u>

---

**729 The University of Texas Southwestern Medical Center**

---

**Center for Advanced Radiation Therapy**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2016
Year Non-Formula Support Item Established:	2016
Original Appropriation:	\$1,000,000

**(2) Mission:**

Heavy Ion therapy is the most potent and effective form of radiation for cancer patients, but is not available in the U.S. In 2015, the Texas Center for Advanced Radiation Therapy (TCART) – with the research consortium led by UTSW and including MD Anderson, UT Austin, UTHSC San Antonio, Texas A&M, Prairie View A&M, Baylor Medical Center, NASA and others – secured one of two National Cancer Institute planning grants, which the 84th Legislature matched to help bring a center to Texas. A California team received the second grant, leaving Texas vying with California to secure sufficient support to establish the first U.S. Heavy Ion facility and an NCI Research Center of Excellence grant. UTSW requests \$9M more in State core research support to build on progress to date and bring the generation of cancer treatment to the Texas and the U.S.

**(3) (a) Major Accomplishments to Date:**

UTSW has made significant progress to date with State and matching planning funds invested, including completing the technical design of the extremely large-scale and highly specialized equipment needed, architectural design plans, securing FY18 federal omnibus budget intent to establish a center, and enabling competitive pilot projects by Texas research consortium members to advance the technology.

UTSW is perfectly positioned to capitalize on this opportunity for Texas, to establish the most comprehensive advanced radiation center in the world for cancer therapy, capable of carrying out basic, pre-clinical, clinical and physics-related research, as well as large scale clinical trials. Missing is full funding needed to complete the scientific and technical planning needed to equip and construct the facility.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

Efficacy of Heavy Ions has been established by foreign centers, but still critically needed to uncover its full potential are improved accelerator/beam delivery technology, an understanding of the underlying biology, and more clinical trials, including a rare international trial using foreign centers that UTSW has coordinated. UTSW researchers will continue to plan and conduct the scientific proof work needed, using foreign facilities, but the lack of a campus facility greatly hinders these efforts, which will be further maximized by the next generation technology that UTSW would install.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding



---

**729 The University of Texas Southwestern Medical Center**

---

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation reflected for this special item results in projected external funding of \$7,000,000.

**(9) Impact of Not Funding:**

The establishment of all centers worldwide has been made possible with government support given the prohibitive expense, ~\$230M at UTSW. UTSW is working to secure stakeholder commitment with vendor discussions and federal requests in work, as well as philanthropic donations, contingent on State and federal support. Now needed is additional State core research support to produce correlating data and advance the technology to the extent needed to competitively secure the inaugural NCI-designated U.S. center for Texas. Without additional core research support, Texas will lose competitive advantage to California and possibly other centers vying to establish the first Heavy Ion facility for cancer patients in the U.S.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Texas Center for Advanced Radiation Therapy (TCART) will be needed for two biennia to complete needed technical and research planning, and position Texas to secure the first national Heavy Ion center. After this, requests to continue the facility's research operations will be needed.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

---

**729 The University of Texas Southwestern Medical Center**

---

UTSW through the Texas Center for Advanced Radiation Therapy will work to secure the first Heavy Ion Research & Treatment Facility for cancer patients in the U.S. To accomplish this, UTSW and partner Texas research consortium institutions will continue necessary investigations to advance the technology, and UTSW will conduct limited clinical trials using foreign facilities to generate clinical data needed for approval for use in the U.S., as well as continue initiatives to secure federal and private stakeholder commitments to equip and construct a Texas facility. Performance can be assessed as follows:

- Peer-reviewed publications
  - Clinical trial planned and conducted
  - External research funding secured
  - Expert faculty retained
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Center for Gene Therapy & Curative Medicine**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2020
Year Non-Formula Support Item Established:	2020
Original Appropriation:	\$9,000,000

**(2) Mission:**

In recent years, biomedical researchers have made groundbreaking discoveries to help us understand the enormous potential of gene therapy in the treatment of disease, which holds the promise of a one-time "forever fix" or treatment for patients. UTSW's Center for Gene Therapy & Curative Medicine - with recent recruitment of a leader in gene replacement therapy and significant investment in a drug development facility - is poised to lead the U.S. in this next frontier of medicine, starting with the most rare conditions, ~7,000 that typically present in children, and eventually more complex diseases such as Alzheimer's. The Center's goal is to offer one-time curative treatment to children suffering from one of these 7,000 rare diseases caused by a single genetic mutation and eventually all patients suffering from diseases caused by more complex genetic mutations, forever changing the lives of impacted children, adults and their families. UTSW requests \$9M per year in State core research support to realize this goal.

**(3) (a) Major Accomplishments to Date:**

Several years ago, UTSW recognized the need to invest in this new frontier as a means of bringing hope to patients with rare or previously untreatable diseases. Early steps towards establishment of the Center included recruitment of a national leader in the successful development of an innocuous human virus as a vehicle for the delivery of gene therapy, and establishment of a rare Viral Vector Production Facility, on which the success of moving more gene therapy discovery into clinical testing is dependent. The planned facility and its scale is the only one of its kind at an HRI in Texas and the U.S., meeting FDA regulations to produce gene-based investigational drugs that may be injected into humans, and helping UTSW move researchers' discoveries into Phase I clinical trials.

UTSW also concurrently invested in offering a seamless bench-to-bedside pipeline with regulatory support to its researchers, emphasized a model of partnerships with nonprofits and disease stakeholders to help fund treatments, and begun building relationships with industry partners to ensure that early-phase trial drugs don't get stuck forever in research phase. The facility will be a driver for greater commercialization of gene therapies, with all of the benefits to patients and impact on the state economy that come with this.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

Rather than just managing the symptoms of chronic and untreatable diseases, gene therapy can fix a genetic problem at its source and stop the disease permanently. Many diseases have genetic causes, so the potential is boundless to move towards a care model of early diagnosis, followed by transformative treatment to prevent incurable conditions from ever developing.

Yet, in addition to the groundwork by UTSW in establishing the Center, much technical and proof-of-concept research remains to be conducted. UTSW requests State core research investment to capitalize on efforts to date to make Texas the leader in this new frontier of medicine - starting with genes responsible for devastating neurodevelopmental disorders in infants and children that are individually rare but collectively common - to achieve gene therapy as a standard, curative therapy for all patients suffering from one of these more than 7,000 rare diseases.

---

**729 The University of Texas Southwestern Medical Center**

---

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

N/A

**(9) Impact of Not Funding:**

Without core research support, the UTSW Center for Gene Therapy and Curative Medicine cannot realize the promise of gene therapy for children suffering from one of the 7,000 rare neurodevelopmental disorders caused by a single genetic mutation, nor eventually children and adults suffering from diseases such as autism and Alzheimer's caused by more complex mutations.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Center for Gene Therapy and Curative Medicine will be needed on a permanent basis.

UTSW's Center for Center for Gene Therapy and Curative Medicine will be at the forefront of the field, with a renowned leader in the field recently recruited and plans underway to establish the only viral vector engineering facility – necessary for developing and producing curative gene therapies – of its kind at an academic medical center. Additional faculty, including the Center director's lab of 10 from the University of North Carolina, will be recruited to Texas. Together, star faculty working in state-of-the-art facilities will help secure external funding brought to Texas to accelerate basic discovery and its bench to bedside translation for patients, expected at a 7:1 ROI on the State's investment. However, such leveraging for external research funds is only possible with core research support from the state.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

---

**729 The University of Texas Southwestern Medical Center**

---

**(13) Performance Reviews:**

The Center for Regenerative Gene Therapy and Curative Medicine will make seminal discoveries as a pioneer in a field that has the potential to change the lives of millions of children and eventually adults impacted by diseases caused by genetic mutation with a single “forever fix” or curative treatment. Progress towards this goal will be measured in basic discovery and translational efforts to develop findings into therapies. Performance can be assessed as follows:

- Peer-reviewed publications
  - Clinical trials planned and conducted
  - External research funding secured
  - Patents Issued and Licensing Agreements secured
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Center for Obesity, Diabetes, and Metabolism Research**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2008
Year Non-Formula Support Item Established:	2008
Original Appropriation:	\$18,000,000

**(2) Mission:**

Since it was founded in 2007, the interdisciplinary Center for Obesity, Diabetes and Metabolism Research has become widely recognized as the top obesity center in the world and uniquely positioned to tackle a medical crisis that costs Texas \$10 billion annually and continues to spiral out of control. The trends in obesity and related diseases are frightening, with the percent of overweight Texans increasing from 43% to 63% in just 15 years. What was once unheard of, Type II diabetes occurring in children, is now common and obesity dramatically increases not only the risk of diabetes but also heart disease, kidney failure, stroke, high blood pressure, respiratory problems and other chronic conditions. UT Southwestern's Obesity Center is committed to developing novel treatments for the prevention and treatment of obesity, to continued outreach to thousands of Dallas ISD elementary students to provide early intervention and an effective model for Texas, and to ensuring significant benefit to Texas from millions in external grant funding secured and eventual cost savings and revenue possible from breakthrough treatments.

**(3) (a) Major Accomplishments to Date:**

Since 2008, Center researchers have secured almost \$50M per year in external research funds and made over 90 seminal discoveries that have changed how we treat obesity:

- Controlling Type I Diabetes without insulin for weeks with treatment in human trials.
- Discovered how a hormone tells the brain to be hungry with drugs to block the mechanism now being pursued to effectively curb hunger. This hormone was also shown to be induced by exercise, which then stimulates hunger. This may explain why exercise alone does not result in long-term weight loss.
- Discovery of the brain pathways that led to Belviq, the first anti-obesity drug approved by the FDA in the last 15 years.
- Discovery of a new protein (PCSK9) that controls blood cholesterol levels, which resulted in development of recently approved therapy for the treatment of high cholesterol.
- A protein found on fat droplets was shown to reprogram muscle to burn more fat.
- A protein made in cancer cells and is secreted into the blood causes weight loss and cachexia by increasing the burning of fat – a potential new therapy for obesity.
- A hormone previously shown to promote weight loss and improve diabetes was also shown to reduce cravings for sugar and alcohol.
- Discovery of 2 proteins secreted from liver that function to ensure dietary fat is properly transported and stored in fat cells.
- Discovery of how a mutated gene interacts with the environment to promote fat accumulation in liver and eventual liver failure.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

---

**729 The University of Texas Southwestern Medical Center**

---

UT Southwestern's Center for Obesity, Diabetes, and Metabolism Research is uniquely positioned, compared to all other medical centers in the country, to tackle this national crisis that promises to cost Texas billions per year. With sufficient support, the preeminent team assembled at UTSW can continue its astounding pace of discovery and building on the great strides already made in understanding the fundamental causes and developing treatments. More groundbreaking advances and effective treatments can be expected from continuing research on other recent pivotal findings, including discovery of:

- Identification of fat metabolites that lead to liver cell injury, cirrhosis and liver failure.
- Determination of how changes in fat utilization by the heart leads to heart failure.
- Determine the regions of the brain that mediate improvements in diabetes in response to exercise.

The Center expects to remain highly successful at leveraging State funds, capitalizing on the ~\$50 million per year in outside grants secured since 2008. Continued State support will help seed more research, promising to reduce obesity and its costs, and bring more outside funding into the Texas economy.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

Previously partially funded with an NIH Planning Grant of \$3M over 3 years, which could be used for targeted projects. State funds support infrastructure necessary to secure additional competitive grants.

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation provided for this special item results in projected external funding of \$47,879,944.

**(9) Impact of Not Funding:**

---

**729 The University of Texas Southwestern Medical Center**

---

Since FY 10-11, funding support for the Center has decreased over 30%, leaving the opportunity cost of not funding or a further reduction enormous. Unless it is halted, the epidemic of obesity and its related diseases will cost Texas hundreds of billions of dollars in the future, and the preeminent team assembled at UT Southwestern is already making great strides in understanding the fundamental causes and developing highly-effective interventions. This funding has facilitated the recruitment and retention of some of the most prestigious obesity and metabolism experts in the world. Furthermore, the research labs supported by this funding will leverage the funding many-fold in the future. Continuing the stature of this Center as one of world's preeminent research centers in this field will take continued seed funding that this Exceptional Item provides. Not funding this Center would not only cost the state many millions of dollars in grant funding in the near term, but forfeit important advances in patient care and put at risk a valuable Texas resource. Most importantly, the opportunity cost of not realizing future discoveries may cost the State of dollars per year in the future that might otherwise be saved from treatments resulting from Center research.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Center for Obesity, Diabetes and Metabolism Research is needed on a permanent basis. Home to two Nobel Prize recipients, a Breakthrough Prize winner, and other esteemed scientists, State core research funding for this internationally respected Center for Obesity, Diabetes and Metabolism Research is needed on a permanent basis as it is critical to maintaining and growing the world-renowned research. State support allows UTSW to build upon seminal discoveries already made that are leading the effort in changing how we think and treat obesity, cholesterol and related diseases. Support for the Center allows retention of these top leaders in their field and is instrumental in recruitment of rising stars who train under them. Furthermore, the discoveries made in the Center have changed how we treat some of the nation's most common and costly diseases. Outside of this funding, there is limited support available to Texas' health related institutions for core research operations that are necessary to recruit and retain such top scientists, leverage external investment into the State and curb the trending high costs of obesity and high cholesterol across the United States.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Retention of top faculty, and continued recruitment of rising stars: core research support for the Center helps retain and recruit the world's top scientist in obesity, diabetes and related disease, who continue to make key discoveries that assist in tackling these epidemics and driving new dollars into the Texas economy.

Performance can be assessed as follows:

- Faculty retained and recruited
  - External funding secured
  - Discoveries, new therapies or treatments advanced
  - Peer-reviewed publications
-



---

**729 The University of Texas Southwestern Medical Center**

---

**Center for Regenerative Science and Medicine**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2016
Year Non-Formula Support Item Established:	2016
Original Appropriation:	\$8,000,000

**(2) Mission:**

Regenerative medicine is a new frontier of science that seeks to understand the mechanisms of tissue aging, injury, and repair. This is the most important and transformative mission in medicine today, extending from molecular biology to tissue engineering and organ fabrication to deliver novel solutions to damage affecting diverse organs including heart, liver, lung, and others, and improve human health.

UTSW has launched CRSM, a transformational large-scale initiative in this rapidly developing field, underrepresented in Texas. The goals are to: 1) discover fundamental mechanisms of tissue formation and repair; 2) develop transformative strategies and medicines for tissue regeneration; 3) train future generations of scientists and clinicians to translate this new scientific knowledge into novel human therapies; and 4) offer education and community outreach programs.

Degenerative diseases of the heart, brain and other tissues represent the largest causes of death/disability in the world, affecting virtually everyone over 40 and accounting for the lion's share of healthcare costs in Texas and the U.S. With State investment, CRSM can capitalize on competitive and private seed funding to strengthen our program, with profound implications for millions of Texans incapacitated by organ injury and disease. By bringing the vision, scientific excellence, and resources of UTSW to bear, we can make transformative contributions and novel regenerative therapies to improve care.

**(3) (a) Major Accomplishments to Date:**

Since the Center's establishment, the following have been accomplished:

- Using a new technique as a treatment for Duchenne Muscular Dystrophy (DMD) led to prevention of the disease in mice, then translated to humans by editing the mutant gene in cells from a young DMD patient, and corrected DMD in a dog model of the disease with the same mutation as the most common one in humans.
- Continued efforts to regenerate heart muscle lost during injury and aging including the discovery of a signaling pathway that when activated changes skin cells to functional heart cells. Learned that left ventricular assist devices can stimulate heart cells to proliferate, which may lead to new strategies to repair damaged hearts. In a similar study, a single gene and drug that can efficiently change skin cells into nerve cells was discovered, potential for treating many neurodegenerative diseases.
- Developed a way to convert scar-forming cells into motor neurons, potential in treatment of spinal cord injury and other neurological disorders. Similarly, established a method to create neurons of the central nervous system, as a means of addressing fundamental problems in brain disorders.
- Modeled brain disorders using induced pluripotent stem cells from patients with neurological disorders and using these cells to uncover new mechanisms of brain disease.
- Leveraged State funds to create new biotech company that will translate discoveries from the Center to treatment and numerous external grants.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

---

**729 The University of Texas Southwestern Medical Center**

---

UTSW is strategically positioned to lead the development of regenerative science and medicine with the goal of achieving new scientific breakthroughs that can improve human health. In the future, with the leadership of Center director Dr. Eric Olson, Chairman of Molecular Biology and a member of the National Academies of Sciences and Medicine, the goals are:

- Discover fundamental mechanisms of tissue formation and repair
- Develop transformative strategies and medicines to enhance tissue regeneration
- Continue to train future generations of scientists and clinicians who will translate this new scientific knowledge into novel human therapies
- Apply for Regenerative Medicine Training grant from NIH
- Continue to offer education and community outreach programs
- Develop program for postdoctoral fellows studying regenerative medicine

For the next two years, a major research goal is to optimize the CRISPR/Cas9 genome editing approach to cure DMD and refine it with the aim of securing approval and starting pre-clinical trials. In parallel, the Center will continue efforts to develop new regenerative therapies for cardiovascular and neurological disorders by reprogramming cells into cardiomyocytes and neurons, respectively. Work in these areas has progressed very rapidly in recent years so there is optimism about the opportunity for future contributions to these important areas.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation provided for this special item results in projected external funding of \$56,000,000.

**(9) Impact of Not Funding:**

---

**729 The University of Texas Southwestern Medical Center**

---

Scientific data and statistics show degenerative diseases of major organs and other tissues are the largest cause of disability and death in the world . As a result, billions of healthcare related costs and millions of Texans are directly affected by these diseases. With sufficient seed funding, UT Southwestern and its team of world class faculty, scientists and researchers have the unique opportunity to bring Texas to the forefront of regenerative science and medicine and to develop improved care for patients in Texas and beyond. In FY18-19 the Center sustained a nearly 10% reduction in state funding. Without sufficient support, advances in research and patient care will not be possible, associated healthcare savings will not be realized, and this unique opportunity for Texas to lead the country in this new regenerative medicine field in time will be ceded to other states.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Center for Regenerative Science and Medicine is needed on a permanent basis. UTSW's Center for Regenerative Science and Medicine is at the forefront of the field, already making discoveries that have the potential to correct the genetic mutation that causes Duchenne Muscular Dystrophy in humans. CRSM has also discovered that skin cells can be converted to healthy heart cells, aiding in repairing heart damage following injury, and similarly, to nerve cells to treat neurodegenerative diseases. To sustain the momentum and continue leveraging state investment for external dollars, this core research funding must continue indefinitely as it is the bedrock from which the Center retains these highly-sought researchers, recruits the brightest in the field, maintains the necessary lab infrastructure, seeks out further research opportunity built on their work and trains tomorrow's scientists . The resulting potential for investment into Texas by biotech companies looking to capitalize on the Center's discoveries is great, allowing our state to truly lead the field in the bench to bedside translation of regenerative science.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

The Center for Regenerative Science and Medicine is making seminal discoveries in a burgeoning field that has the potential to change the face of medicine through potential cures, understanding heart and nerve regeneration, recruiting and retaining top investigators from around the world, and importing more funds to Texas based on the Center's respected work. Performance can be assessed as follows:

- Discoveries (proven treatment of Duchenne Muscular Dystrophy in animal models, development as a therapy in humans; discovered that a cancer drug promotes damaged heart regeneration; discovered that skin cells can be converted to healthy heart or nerve cells)
  - Progress of companies started (example, Exonics Therapeutics)
  - External funding (Leveraged State funds to secure a multi-million dollar NIH grant to establish 1 of 6 national Wellstone Muscular Dystrophy Cooperative Research Centers at UTSW; to secure NIH grant on heart regeneration)
  - Faculty retention and recruitment
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Center for Research of Sickle Cell Disease**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2006
Year Non-Formula Support Item Established:	2006
Original Appropriation:	\$1,000,000

**(2) Mission:**

Sickle cell disease, the most serious disorder in the United States resulting from a single gene mutation, is most prevalent in persons of African descent. The condition causes excruciating pain, organ damage, and premature death in children and adults. There is a pressing need to better understand the biology of the disease and to translate scientific discovery into better treatments and eventually a cure. UT Southwestern's Comprehensive Sickle Cell Center has made dramatic progress in clinical research which has brought improved treatments and set the stage for future scientific discoveries. With continuing added support from this State Special Item, UT Southwestern's mission is to maintain and build upon its world class Comprehensive Sickle Cell Center focused on the following: research leading to curative treatments, development and refinement of new and improved therapies to control disease complications, and marked expansion of its outpatient clinics and inpatient services for children and adults with sickle cell disease in order to improve the length and quality of life. The Center has been and plans to continue to be recognized as one of the world's best.

**(3) (a) Major Accomplishments to Date:**

The Center has led efforts in basic and clinical research that continues to transform the care of children with sickle cell disease and understanding the fundamental processes, including the potential to repair the single genetic abnormality that causes the disease. UTSW researchers are internationally known for their seminal study, the Dallas Newborn Cohort, which represents one of the largest cohorts of children with sickle cell disease, many followed for thirty years, making this cohort among the world's most valuable resources to understanding the disease. Over 130 publications in major scientific journals have resulted from the Center's research.

The Center is also focused on developing new ways to deliver care and treatment options for patients, with UTSW pediatric hematologists focused on developing alternatives to Emergency Room care and eliminating early re-admissions for children. UTSW physicians are also utilizing allogeneic (blood forming) stem cell transplantation to achieve a cure for five to six children thought to have the most severe forms of the disease. Additionally, UTSW continues its efforts as one of 12 sites in the country tasked by the NIH in a follow-up analyses of the BABY HUG study of hydroxyurea as a treatment for infants with sickle cell disease. Finally, since 2016, six new clinical/translational research trials launched or completed, enrolling approximately 80 children.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

---

**729 The University of Texas Southwestern Medical Center**

---

The Center's primary aim remains the reduction or elimination of disease burdens, thus assuring an improved quality of life for patients with sickle cell disease in our community and elsewhere around the world. Goals for the next two years follow:

- Updating the Dallas Newborn Cohort database to leverage detailed information collected in the electronic medical records across campus
- Recruitment of faculty physicians with expertise in clinical and translational research in sickle cell
- Utilizing existing clinical programs, study how to improve the transition from pediatric to adult clinical care
- Augment the scope and scale of our clinical research programs which relies on aforementioned recruitment
- Continue to improve efforts to care for more North Texas children through the use of innovative therapeutics, new care delivery-models, and new molecular and clinical biomarkers to predict disease severity in a way that could guide therapy decisions, like the use of blood-forming stem cell transplant
- UTSW scientists are well-positioned to implement gene "editing" approaches that will ultimately allow genetic correction of the underlying cause of sickle cell disease.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation reflected for this special item results in projected external funding of \$7,979,944.

**(9) Impact of Not Funding:**

Sickle cell disease, one of the most common and devastating conditions affecting African Americans, is a genetic disorder resulting in the production of abnormally-shaped red blood cells that are extremely fragile and unable to carry oxygen normally. The condition causes severe pain, diminished IQ, severe organ damage (especially involving lungs, kidneys, and heart) and early death (often in young adulthood). Despite dramatic progress in recent years, it remains a disabling condition. All-out effort is needed to identify better treatments and find a cure. Already suffering over a 30% reduction in State support since FY 10-11, further cuts will seriously hinder the Center's continued efforts to serve as an international Center of Excellence to mount its broad attack on sickle cell disease, ranging from basic molecular genetics research to the development and refinement of new therapies. Moreover, State funding is essential for UT Southwestern to remain well positioned nationally and internationally to receive additional external support and continue its track record in groundbreaking discoveries and successful efforts to offer specialized care for these patients.

---

**729 The University of Texas Southwestern Medical Center**

---

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Center for Research of Sickle Cell Disease is needed on a permanent basis.

Core research support funding is needed for this nationally respected Center known for basic science research and discovery, leading efforts to develop worldwide guidelines for sickle cell disease clinical care and studying ways to improve healthcare delivery to patients. Home to one of the world's largest cohort studies of its kind, the Center's Dallas Newborn Cohort, State support allows this invaluable resource to continue which enhances the Center's ability to recruit and retain experts in this unique field. Continued State investment is necessary to further molecular understanding of the disease, identify possible causes and inform treatment and care across the globe.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Core research support for the Center helps retain and recruit the world's top scientist in Sickle Cell disease, and seeds basic and translational research, allowing for progress towards identifying causes that may lead to cures, and improved treatment and patient care. Performance can be assessed as follows:

- Faculty retained and recruited
  - Clinical trials
  - Peer reviewed publications
  - Patients served
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Institute for Innovations in Medical Technology**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2002
Year Non-Formula Support Item Established:	2002
Original Appropriation:	\$9,000,000

**(2) Mission:**

The mission of the Institute for Innovations in Medical Technology (IIMT) is to cultivate cutting-edge research with potential to develop into commercializable technologies, and to help transition them from discovery to patient care. This goal is being accomplished by developing and maintaining a unique group of specialized "Core" Laboratory facilities that support such research affordably and efficiently, retaining an extraordinary concentration of innovative biomedical scientists on our faculty and facilitating the recruitment of rising star faculty to Texas, bringing millions in federal and private grants to the state, and maintaining enhanced infrastructure and expert staff to facilitate commercialization, which in turn attracts vital biotechnology sector partners to North Texas.

**(3) (a) Major Accomplishments to Date:**

The Institute has provided essential infrastructure for early-stage research to identify drug targets and other treatments. To achieve its chief goal of transitioning technologies to patient care, IIMT has created 12 Core Labs to date that provide the latest equipment and expertise necessary to support faculty research. In 2018, four additional Cores were launched with IIMT support. They offer research services at marginal cost for use by all investigators, including those at other Texas academic institutions, and by commercial partners housed in our Bio Center. The cost to set up Cores in an individual lab or start-up company would be prohibitive, but by making their services widely available on a subsidized basis, many research projects can tap into state-of-the-art technologies to make scientific breakthroughs. Access to the Cores has aided scientific discovery and made hundreds of UTSW researchers more competitive for grants (>\$750 million brought to Texas since FY04). In addition, the UTSW Technology Development office has expanded. This is evidenced by UT Southwestern's recent ranking in Nature as No. 5 in the world for research that drives innovation. To date, 40 companies have been formed on the basis of faculty research, collectively raising >\$2B in financing; of these companies, 8 were formed this past year. These include companies that develop devices for long-term bed-ridden patients, anticancer drugs and therapies for Alzheimer's disease, respectively.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

With the Core Labs, North Texas is positioned to meet the needs of future biotech firms seeking state-of-the-art facilities. Since 1986, UTSW has received 669 U.S. patents, executed 924 licenses and options for patented and non-patented technologies, and raised over \$199 million in license revenue. Products are currently in clinical trials or pre-clinical toxicology studies. This trend anticipates the Institute will launch additional biotechnology companies in Dallas over the next two years.

It is also expected that the IIMT will continue to support research with its unique Core facilities, and to support technology transfer. For example, in fall 2018, the Institution will establish a new state-of-the-art Advanced Optics Imaging Core facility in which custom-made microscopes are made available to investigators. Continued research support will make hundreds of UT Southwestern investigators more competitive for grant funding, resulting in millions more dollars in external funding coming to Texas. Such external funding not only enhances economic development in the short-term by funding salaries and supplies for researchers, it also enhances economic development in the long term through scientific discoveries that form the basis for high-tech industries. Together, research and technology transfer support will lead to groundbreaking findings, patent filing, and ultimately, commercializable technologies that will improve treatments for patients in Texas and the world.

---

**729 The University of Texas Southwestern Medical Center**

---

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation reflected for this special item results in projected external funding of \$47,877,956.

**(9) Impact of Not Funding:**

When the Institute was assessed in 2008 by external scientific reviewers on behalf of THECB, it received the highest possible ratings with such comments as “the Institute is making a significant impact on the Texas economy and that funding should be continued for this exceptionally productive and innovative project.”

While IIMT capitalized on momentum built since 2002, the continued reductions in funding for research special items implemented since FY10-11, now an over 30% decrease as of FY18-19, have hindered research that might otherwise have led to the development of new biotechnologies and limited the crucial development of Core Labs to facilitate the transition from discovery to commercialization.

Having access to the Core Labs has not only aided scientific discovery, it has made UTSW researchers more competitive for grants, resulting in >\$43 million in funds brought to Texas annually.

UTSW has the opportunity to build off its recent ranking of No. 5 in the world for biotech according to Nature and create a significant commercialization center in Dallas. The BioCenter, an incubator to house industry partners and foster collaborations with UTSW faculty holds promise for creating a critical mass of biotech in North Texas. Without continued funding, not only will research that is already identifying drug candidates and other treatments be further impaired, but the promise of a biotech industry in North Texas becomes unfeasible.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuation:**



---

**729 The University of Texas Southwestern Medical Center**

---

Core research support for the Institute for Innovations in Medical Technology is needed on a permanent basis .

Funding the Institute for Innovations in Medical Technology is needed on a permanent basis as it is critical to maintain and continue to build “Core labs” that lead to medical innovation. Dependent on ever-advancing technology, these Cores also serve as a recruitment tool to attract and retain the world’s top scientists who show promise in translating discovery to patient therapies. As a result, the biotech sector is increasingly attracted to investing in North Texas given the bedrock of basic research greatly enabled by these cutting-edge labs. Such investments have resulted in commercialization and advancing patient care – both a positive influence on the Texas economy. Outside of this funding, there is limited support available to Texas’ health related institutions for core research tools that are necessary to support 21st century labs and ensure the most cutting-edge capabilities. Absent these resources, the State cannot compete in a global economy that offers far more competitive opportunities.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Performance can be assessed as follows:

-Retaining and establishing Core Labs that enable discoveries that produce patents and licenses, and attract further external investment into the State through grants and startups.

-UTSW currently ranks in the Top 10 among all Academic Institutions nationally in the number of Annual Invention disclosures, Patent Applications Filed, Patents Issued, Licenses Executed, and Start-Up companies formed per \$100 million in biomedical research expenditures, compared to other Academic Institutions – UTSW will maintain or improve these national rankings.

-Since 2018, four new IIMT-supported Cores launched including the Microbiome Core/Bacterial DNA Sequencing Core, the Viral Vector Core, the Proteomics Core, and the Cryo-Electron Microscopy Core – with adequate funding, UTSW will establish new Core technologies as they are developed and needed.

-40 companies have been formed, including 8 in 2017-18 – UTSW will continue start-up company formation.

-More than \$750M in external grants to Texas since 2004 - UTSW will continue its traditional 7:1 ROI on State investment.

---

---

**729 The University of Texas Southwestern Medical Center**

---

**Institute for Nobel/National-Academy Biomedical Research**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2004
Year Non-Formula Support Item Established:	2004
Original Appropriation:	\$7,000,000

**(2) Mission:**

The Institute for Nobel/National-Academy Biomedical Research began in 2004, predicated on the fact that Texas' long-term success in biomedical science and biotechnology sector depends on having research leaders at our health institutions who rank among the best in the world. This Institute is extremely effective in facilitating this for Texas' future. The National Academy of Sciences is the scientific hall of fame and election as a member is the highest honor in the U.S. for a scientist. With almost 75% of all National Academy members at Texas health institutions at UTSW, and with three of its six Nobel laureates as active faculty members, UTSW is exclusively positioned in Texas for the Institute for Nobel/National-Academy Biomedical Research.

Investigators of Nobel Prize-and National Academy-caliber conduct cutting-edge research, bring to Texas millions of dollars in grant funds, and attract the best and brightest co-workers. UTSW is working to further leverage the success of our globally-recognized research leaders in order to expand research opportunities, recruit more world-class scientists and secure more funds from sources outside Texas. Exceptional Item funding has been appropriated specifically to:

- Provide incentives for highly sought-after scientists to remain in Texas
- Bring millions in outside grants to Texas
- Cultivate state-of-the-art research and technologies
- Recruit rising-star scientists mentored by our accomplished faculty members

**(3) (a) Major Accomplishments to Date:**

Before funding the Institute, UTSW was home to 4 Nobel Laureates and 13 of 16 National Academy of Sciences members in Texas. In only eight years, a star faculty member recruited back from California in 2011 with Institute support won the 2011 Nobel Prize for seminal discoveries made at UTSW in the 1990s. At present, 22 UTSW faculty members have been elected to the National Academy of Sciences, 16 have been elected to the National Academy of Medicine, and 15 named Investigators of the Howard Hughes Medical Institute (HHMI). This represents a majority of elected members and HHMI Investigators at all Texas HRIs. This support has paid tremendous dividends for Texas in other ways. The Institute has had remarkable success in leveraging State investment, with more than 100 highly sought after, rising-star scientists having been successfully recruited to Texas from Harvard, Yale, and elsewhere in order to collaborate with UTSW National Academy members and Nobel laureates. Also, with Institute support all but a few of UTSW's elite scientists have been retained despite external recruitment. Beyond maintaining vigorous research programs, these individuals are crucial to recruiting the best junior faculty from other leading institutions. Finally, UTSW has leveraged Institute seed research funding into a major economic engine for Texas that brings in about \$7 for every State research \$1 invested, and accordingly, Institute scientists have secured ~\$40M/year in external grants.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

---

**729 The University of Texas Southwestern Medical Center**

---

When the Institute was assessed in 2006 by external scientific reviewers on behalf of THECB, it received the highest possible ratings and accolades. Reviewers pointed out that every measurable record of academic productivity, performance and quality had been achieved. This high praise is indicative of the wisdom of targeting funding based on programmatic quality and underscores how doing so is an outstanding investment for the state .

Reduced over 30% since FY10-11, current funding levels will leave UTSW unable to continue to fully leverage the remarkable success of our globally-recognized research leaders in biomedicine in order to:

- recruit more world-class collaborators who in turn attract the best and brightest co-workers (to date, more than 120 highly sought after young scientists have been recruited to Texas, and one lead faculty member won a 2011 Nobel Prize and another a 2016 Breakthrough Prize)
- yield new discoveries and cultivate patentable technologies for our most common, chronic and devastating diseases, and
- bring even more tens of millions of dollars per year in external funds into the Texas economy (>\$35M/year since 2004).

Ultimately, Nobel Prize- and National Academy-caliber faculty leaders enable remarkable research productivity at UTSW. In FY17 our faculty members were responsible for \$455M in total research expenditures. These research dollars are spent in Texas and generate enormous job growth and have a great economic impact.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation reflected for this special item results in projected external funding of \$43,868,069.

**(9) Impact of Not Funding:**

---

**729 The University of Texas Southwestern Medical Center**

---

Without funding these elite scientists, Texas is highly vulnerable to outside recruitment interested in developing their commercial medical business base. The loss of even one National Academy member would have a correspondingly large impact on reducing technical talent and result in the loss of millions of outside funding to Texas. Moreover, with increasing competition for NIH funding, attracting the best investigators becomes more important for growing the research base in Texas. As the competition becomes fiercer, institutions without independent funding sources will struggle to recruit and retain star researchers.

Funding to the Institute positions Texas to offer research support to attract and retain either current National Academy members or rising-star investigators who collaborate with them. No other state program can specifically target such a large number of faculty members of this caliber, ensure they remain in Texas, further propel their research with the resources to build teams of collaborators and allow them to mentor the next generation of medical-science leaders. In just the past year, UTSW has been named by Nature as the No. 1 academic medical center for published research in the world and No. 5 for research that drives innovation. Such State investment in these scientists allows us to have a medical school that ranks among the top in the nation, a ranking that ensures the best students in Texas need not leave the state to obtain a stellar education.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Funding for the Institute is needed on a permanent basis as it provides core research support to continue seeding infrastructure and early stage work for which there is no other source of funds, and is essential to recruitment of the best and brightest. Consistent access to the most modern technologies and ability to focus on early-stage research is important to all investigators' success, but is vital for the rising star faculty that this item greatly supports as it is this basis that makes them exponentially more well-positioned to secure competitive grants.

Ongoing funding is also critical to the recruitment and especially retention of top senior scientists. This funding allows Texas' top ranked public research institution to continue to recruit the brightest minds in their fields who have made discoveries that change the practice of medicine, and leverage the State's investment 7:1 in external research dollars brought to Texas. There is limited funding available to Texas' HRIs for core research support that is necessary to recruit and retain highly sought investigators and their teams, and to support essential core labs, thus such investment is pivotal. Absent these resources, the State cannot compete in a global economy that offers far more competitive opportunities and the economic ROI and impact on advances for patients will not be possible.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

---

**729 The University of Texas Southwestern Medical Center**

---

Recruitment and retention of top scientists to Texas to ensure research excellence that results in teaching and training tomorrow's scientists, leveraging outside investment into the Texas economy, and delivering unmatched patient care to safeguard human potential. Performance in recruitment and retention can be assessed from the following basis:

- 22 UTSW faculty have been elected to the National Academy of Sciences
  - 16 UTSW faculty have been elected to the National Academy of Medicine
  - 15 UTSW faculty have been named Investigators of the Howard Hughes Medical Institute
  - Over 120 highly sought after scientist have been recruited to Texas from Harvard, Yale and other reputable research powerhouses
  - Since inception, all but a few of UTSW's top scientist have been retained despite aggressive outside recruitment
  - Institute scientists have secured ~\$40M/year in external grants to Texas
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Institutional Enhancement (Academic and Student Support)**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2000
Year Non-Formula Support Item Established:	2000
Original Appropriation:	\$1,000,000

**(2) Mission:**

Institutional Enhancement funding plays a significant role in financing the core missions of all Health Related Institutions by providing a base level of funding for services and programs. Institutional Enhancement funding helps support leading-edge and innovative programs in graduate research education not otherwise supported by formula funding. The purpose of Institutional Enhancement at UT Southwestern is to help provide the highest quality education and training in the prevention, diagnosis, and treatment of disease to our medical students.

**(3) (a) Major Accomplishments to Date:**

Institutional Enhancement support has contributed to maintaining the highest standard of excellence in the missions for which the state has tasked UT Southwestern. According to the 2018 U.S. News & World Report, UT Southwestern Medical Center is ranked among 160 medical schools nationally No. 19 for primary care, No. 26 for research, and the No. 1 hospital in Dallas-Fort Worth, No. 2 in Texas. In 2018, the institution was named by Nature as the world's No 1 academic medical center in published research and No. 5 in impact on biotech development. All of this has been built and made possible by the bedrock of State support that provides for education, training and research operations at UTSW.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

UTSW will continue to expand and revamp existing clinical programs and develop new clinical programs to sustain the quality of our medical education. Major objectives for the school are the integration and expansion of programs in the basic and clinical neurosciences, including the O'Donnell Brain Institute's move to a third tower expansion at Clements University Hospital that is research and patient focused on the ever-increasing cognitive diseases of the aging brain. UT Southwestern will also continue growing its programs in clinical investigation, including epidemiology, medical informatics, bioinformatics, and clinical trials along with the continued development of new programs in population and health outcomes research. While the total extent and costs of these programs continues to be defined, student participation will require additional State support.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Institutional Enhancement

---

**729 The University of Texas Southwestern Medical Center**

---

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

2018	\$725,000	Federal Funds
2019	\$725,000	Federal Funds
2020	\$725,000	Federal Funds
2021	\$725,000	Federal Funds

**(9) Impact of Not Funding:**

The highest quality medical education at UTSW is supported through Institutional Enhancement. An important component of its medical education is accomplished for ~675 students in the second, third and fourth years of medical school when they rotate through the many clinical clerkships offered. Medical students participate first-hand in patient management, learning how to apply the information they learned in the first 1.5 years of medical school, and acquiring new knowledge. The excellence of these clinical programs is one of the reasons UTSW is highly regarded as a medical school, and is sought after by the most qualified medical school applicants from across Texas and beyond.

In the past, programs such as oncology and clinical epidemiology have been targets for development to support excellence in medical education. UTSW must remain constantly vigilant to identify new clinical programs that must be developed or expanded to maintain our cutting-edge medical education. However, as all funding sources contract, established primary care programs that are equally essential to medical education, such as Family Practice and Internal Medicine, are now also supported with these funds.

Any reduction to a nearly 30% decrease since FY10-11 would thus result in severe deterioration of myriad programs, lowering the standard of excellence and quality of our medical teaching programs, and result in declines in the level of services that we have been able to deliver to students.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Institutional Enhancement support is needed on a permanent basis to supplement and enhance core educational operations for our medical student rotations. Institutional enhancement funding is bedrock to UTSW's ability to educate and train tomorrow's physicians. State support for educating medical students has declined since the formulas were conceived, and faces further reductions as new medical schools continue to be established. Absent this funding, medical school class size slots will be at risk of reduction at UTSW to ensure program quality in increasingly costly medical school operations.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

---

**729 The University of Texas Southwestern Medical Center**

---

**(13) Performance Reviews:**

Institutional enhancement allows UTSW to maintain medical school class size and program quality. Performance can be assessed as follows:

- Number of medical school enrollees maintained.
-



---

**729 The University of Texas Southwestern Medical Center**

---

**Metroplex Comprehensive Medical Imaging Center**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2006
Year Non-Formula Support Item Established:	2006
Original Appropriation:	\$7,500,000

**(2) Mission:**

Modern imaging techniques permit exquisite views of both structure and function from views of every atom in a protein molecule to functional magnetic resonance images of the neural activities that underlie complex behaviors in humans. With such amazing opportunities, the Imaging Center's scientists and doctors are engaged in both the development of imaging technologies and their exploitation to understand and treat disease. The goals of the Center are to:

- Provide the only imaging center of its kind in the Southwest, allowing UT Southwestern researchers and collaborators at local universities to investigate molecular and cellular mechanisms of disease.
- Advance the diagnosis, treatment, and prevention of numerous debilitating diseases through the development and use of advanced medical imaging.
- Retain highly sought-after basic and clinical researchers and recruit rising star faculty to Texas.
- Bring millions in federal and private grants to Texas.

To achieve these goals, the Center at UTSW encompasses a broad spectrum of imaging activities. The Advanced Imaging Research Center established in collaboration with UT Dallas and UT Arlington houses necessary state-of-the-art instruments and a variety of other imaging capabilities contained in Core Labs. Ultimately, the unprecedented images and measurements of healthy and diseased tissue that modern imaging provides are crucial to developing effective treatments for the sick and, eventually, preventive care.

**(3) (a) Major Accomplishments to Date:**

Funding has accelerated existing research, enabled recruitment of more world-class faculty in imaging-related fields, and made state-of-the-art imaging facilities accessible to all collaborators from the UTSW, UTD and UT Arlington campuses. There is no other center in Texas that can match the combination of basic science strengths and advanced equipment available to clinicians seeking new insights into metabolic, neurologic, psychiatric and other diseases. The Center includes research-dedicated 3T and 7T human and animal MRIs, a recently-installed cyclotron, analytical NMR and small animal PET systems, optical imaging, and in-house radiochemistry and imaging agent development.

The Center's equipment and corresponding imaging expertise have stimulated funding on all three campuses and catalyzed many collaborative research and educational programs. In 2018, three new CPRIT awards were made to faculty in the Center and funding from the NIH has included support for major new equipment in multiple awards as well as the "National Center for In Vivo Metabolism's" recent renewal. The Green Fellows program, which brings 20 of UTD's brightest undergraduate science and engineering students to UTSW for a concentrated research effort continues to thrive. The Center continues to successfully recruit outstanding new faculty from leading institutions across the world and new funding in the imaging sciences has steadily increased since establishment, totaling more than \$35M annually.

---

**729 The University of Texas Southwestern Medical Center**

---

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

No other Imaging Center in Texas can match the proximity of the research labs in the Center to clinical facilities at UTSW, a catalyst for progress. Advanced imaging is critical to the future of Texas and to the development of personalized medicine. Absent top imaging facilities, expertise will lag and hinder top-tier medical research status. In the next two years, the Center will use a recently installed cyclotron to produce PET imaging isotopes that will catalyze development of novel metabolic tracers for improved imaging of cancer, metabolic diseases, and diseases of the aging brain. Additionally, the Center has just installed a new hyperpolarization imaging instrument that allows the use of stabilized isotopes to probe metabolism in patients suffering from fatty liver disease, cancer, congestive heart failure, and diabetes. A major advantage is the absence of ionizing radiation, so the technology is particularly relevant to younger patients and useful for repeated exams to assess the response of human patients to experimental therapies. This effort will be expanded substantially and integrated with conventional imaging, advanced metabolomics and mathematical analysis, a combination of methods that will provide new insights into high-impact diseases. These efforts will enable UTSW to improve diagnosis and treatment, leverage State investment to bring in more funding, recruit new faculty and students, and to advance in its quest for Top 10 status.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation provided for this special item results in projected external funding of \$39,899,944.

**(9) Impact of Not Funding:**

---

**729 The University of Texas Southwestern Medical Center**

---

When the Center was assessed in 2008 by external scientific reviewers on behalf of THECB, it received the highest possible ratings, with such comments as “special item funding should be continued and should be a state priority. And “it is especially important to continue supporting this effort.”

Visitors often remark on the uniqueness and breadth of Center capabilities. The operation of this facility housing costly state-of-the-art equipment requires support for the engineers, staff, and physicists that operate it. Retention and recruitment of world-class faculty to continue to position Texas as a leader in imaging science demands such infrastructure. Without support, the facility could not be maintained, top faculty could not be retained and rising stars could not be recruited. Funding is vital for economic development, production of a highly-trained workforce to develop imaging technologies in Texas, and research collaboration among the three North Texas UT institutions.

The over 30% reduction to research Special Items since FY10-11 has already hindered vital support. The opportunity cost of not funding or further reductions for this facility and expertise would be in the loss of scientific discovery and hundreds of millions in future external grants. Funding enables UTSW to improve diagnosis and treatment for Texas patients, to leverage State investment to bring in millions in grants, and to advance in its quest to soon claim Texas’ first Top 10 university ranking.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support for the Metroplex Comprehensive Medical Imaging Center is needed on a permanent basis as it is critical to maintain and continue providing unmatched imaging technology to Texas scientists.

UTSW and higher education institutions from across the state benefit from this unique Center that houses the latest imaging necessary for scientific breakthroughs. Whether individually or collaboratively, Texas’ institutions of higher education depend on this resource to build their research and investigate medical questions at the molecular level. The Center also serves as a recruitment tool to attract and retain the world’s top scientist and leverage external funding because of its unparalleled technology. Outside of non-formula support, there is limited funding available to Texas’ health related institutions for core research tools that are necessary to support 21st century labs and ensure the most cutting-edge capabilities.

There is no other source of funding for these core research costs and absent these resources, the State cannot compete in a global economy that offers far more competitive opportunities.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Maintaining and expanding on the most state-of-the-art imaging available in state allows scientists across Texas academia to utilize this unique convergence of research tools to recruit and retain top talent and leverage outside funding into the State, allowing Texans to answer some of science’s most pressing questions.

Performance can be assessed as follows:

- Faculty retained and recruited
- External funding secured
- Collaborators, participants and students from partner Texas institutions

---

**729 The University of Texas Southwestern Medical Center**

---

---

**729 The University of Texas Southwestern Medical Center**

---

**Primary Care Residency Training Program**

<b>(1) Year Non-Formula Support Item First Funded:</b>	1996
Year Non-Formula Support Item Established:	1996
Original Appropriation:	\$1,557,500

**(2) Mission:**

Medical education is only partially complete when the M.D. degree is awarded. Further education in accredited residency programs is essential for the development of the full range of knowledge and skills to perform medical diagnosis, treatment and certification required for a doctor to practice. This residency education is a major part of the primary mission of Texas' medical schools. UTSW shoulders the burden of training the vast majority of residents, in primary and specialty care, in all of North Texas. Consequently, it has more residents than every other State institution, and thus bears the greatest share of the State's resident costs. Serving the mission of training residents has significant costs, and the primary cost borne by medical schools is that of providing education by faculty. A portion of the costs associated with faculty supervising the care residents provide is paid with Medicare GME funds. Other than the State GME formula, which pays less than 30% of the ~\$20,000 annual per resident faculty supervision cost, there are no dedicated funds for residents' education.

This strategy helps fund the disproportionate cost UTSW bears in educating one of the State's largest number of primary care residents, including direct resident support through payment of 15 stipends. It is essential to continue the number and quality of primary care residency programs at UTSW since such programs are the most important source of primary care doctors in N Texas and statewide.

**(3) (a) Major Accomplishments to Date:**

This item critically supports the statewide goal of decreasing the shortage of primary care doctors and providing quality primary care to the citizens of Texas. UT Southwestern continues to train more primary care doctors than any other State institution in Texas, with 392 residents in primary care programs, compared to 346 for the next highest State institution. An additional combined training program in Internal Medicine/Pediatrics was initiated in 2016. The Family Medicine Residency program was expanded in 2017 to include the Texas Health Dallas training site. These new programs have added an additional 25 primary care training residency positions.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

Approximately 30% of UT Southwestern's 1,370 residents are in primary care programs. At maturity, the Family Medicine and Internal Medicine/Pediatrics training programs will add an additional 34 primary care training residency positions. UT Southwestern intends to continue maintaining the largest and most competitive primary care residency training programs in Texas, in order to continue graduating ~120 primary care doctors every year to address the shortage of primary care doctors and provide quality primary care to the citizens of Texas.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

Previously funded by MSRD Funds

---

**729 The University of Texas Southwestern Medical Center**

---

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Healthcare Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

2018	\$ 207,436	Federal Funds
	\$ 525,921	Private Funds
2019	\$ 207,436	Federal Funds
	\$ 525,921	Private Funds
2020	\$ 207,436	Federal Funds
	\$ 525,921	Private Funds
2021	\$ 207,436	Federal Funds
	\$ 525,921	Private Funds

**(9) Impact of Not Funding:**

The program has experienced a 38% funding reduction since FY10-11 and thus resulted in fewer critically-needed primary care residents supported. A further reduction would have similar impact. With increasing pressure on other sources of funding and with no other funding dedicated to this purpose, a reduction in primary care residency program funding would not be replaced and would impact the quality of the education received by the largest number of primary care residents among Texas health institutions. It would also directly result in a reduction in the number of primary care residents trained. With an existing shortage of primary care doctors practicing in the state, Texas can ill afford to lose any primary care residency positions at any institution across the state.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Funding for the Primary Residency Training Program is needed on a permanent basis as it is critical to addressing the physician shortage in Texas. Moreover, as medical graduates increase statewide with the advent of new schools, the number of residency positions must keep pace as they are necessary to ensure graduates do not leave the State for other residency opportunities. This funding pays a small portion of the costly endeavor of training tomorrow's doctors, but there is no other source and is essential to producing practicing physicians to provide needed care to an ever-growing population.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

---

**729 The University of Texas Southwestern Medical Center**

---

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Retention and expansion of residency training programs. Performance can be assessed as follows:

- Retention of 15 stipends for direct resident support
  - Added a combined training program in Internal Medicine/Pediatrics
  - Expanded the Family Residency Program to include the Texas Health Dallas training site
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Program for Science Teacher Access to Resources (STARS)**

<b>(1) Year Non-Formula Support Item First Funded:</b>	1994
Year Non-Formula Support Item Established:	1994
Original Appropriation:	\$750,000

**(2) Mission:**

The Science Teacher Access to Resources (STARS) program is dedicated to maintaining a robust educational partnership between UTSW and secondary teachers, and providing programs for bright secondary school students. STARS has two goals: to improve science education in the North Texas area and beyond, and to increase the interest and enthusiasm among bright secondary school students to pursue careers in STEM fields, especially as they impact the future of biomedicine.

**(3) (a) Major Accomplishments to Date:**

STARS continues to offer professional development services and resources for science teachers, as well as programs for secondary school students, all virtually free of charge and many with paid stipends and other incentives. Since its inception in 1991, STARS has offered services to over 14,000 teachers from 3,500 schools. An estimated 65,000 students have been impacted by teacher and direct student participation. In each succeeding year, there has been significant growth in the program, with demand for participation from both teachers and students increasing.

Several programs continue to be offered that have been staples in the STARS core offerings for many years. These include a monthly Basic Science Symposium and In-services program for teachers, Summer Research Programs for students (close to 900 applications received for 51 positions) and teachers (8 weeks of full-time research), customized Medical Center Tours for school classes (3-4 per week), a monthly Exploring Post for secondary school students to explore careers in biomedicine, annual Women in Science and Medicine symposia, and hands-on summer Biology, Chemistry, Physics, and inaugural Biotechnology Workshops/Camps at which inexperienced teachers are coached by master teachers as they give lessons and direct lab exercises to students. STARS has also been able to promote these science summer camps beyond those held at UT Southwestern with Wylie ISD now offering the Biology camp based on the STARS model.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**



---

**729 The University of Texas Southwestern Medical Center**

---

Interest and participation in STARS will continue to grow in the next two years. The following are planned programs and expected numbers of participants during this time:

- STARS Basic Science Symposia attracts over 100 students and teachers monthly. The 2018-2019 program will include a full-day symposium on “Women in Science and Medicine,” “Autism Spectrum Disorders,” and a new collaboration with the Inter-professional Leadership Committee to host the “Careers in Biomedical Sciences Symposium” with an expected registration of 400 per event.
- New hands-on In-Service for teachers on “Visualizing the Molecules that Drive Biology,” as well as a “Biotechnology 101” workshop will be offered.
- Multiple, weekly tours of medical school for nearly 4,000 high school students will continue.
- Expect STARS’ award-winning monthly Exploring Post to expand.
- Develop additional middle school programs with school representatives.
- Continue hosting the Uplift District science and engineering fair, work with Irving ISD to host its Biomedical Sciences Academy Science Fair, and provide judges for other science fairs.
- Continue STARS biology, chemistry, physics, and biotechnology camps
- With the approval of a recently submitted external grant, STARS will expand its summer science camp model to Fort Worth ISD, targeting Career and Technical Education teachers and students and focusing on rapidly developing science topics impacting biomedical and health science practice today.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

N/A

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Public Service

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

2018	\$ 51,341	Federal Funds
	\$ 89,822	Private Funds
2019	\$ 55,000	Federal Funds
	\$ 55,000	Private Funds
2020	\$ 55,000	Federal Funds
	\$ 55,000	Private Funds
2021	\$ 55,000	Federal Funds
	\$ 55,000	Private Funds

---

**729 The University of Texas Southwestern Medical Center**

---

**(9) Impact of Not Funding:**

State funding is essential to sustain STARS core programs and new initiatives which already face pressures of high demand and limited monies to provide access . Without funding, valuable professional development for teachers will be curtailed, and the 8-10 point improvement students have shown on End of Course science related exams will suffer, students will be unable to tour medical facilities which inspire a career in STEM, and students seeking early research opportunities through the program will have to search for alternative options where currently only 6% of applicants can be accommodated. Unfortunately, external funds have been far more challenging to obtain in the last few years as science and outreach budgets tighten so state support is critical. For example, the Howard Hughes Medical Institute stopped its pre-college programs in 2012, and the NIH has transferred much of its outreach budget to fund its core research mission. Similarly, state funding has been reduced by over 30% since FY11-12 which makes support all the more essential to maintain STARS activities.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core support for the Program for Science Teacher Access to Resources (STARS) is needed on a permanent basis to maintain and continue the remarkably oversubscribed Program for Science Teacher Access to Resources (STARS). The program ensures that North Texas students and teachers have access to invaluable STEM related hands-on professional development, summer camps, science programs, research opportunities and tours of medical facilities that foster curiosity and innovation among our youngest Texans, who will ultimately steer the future of science and medicine in the 21st century and concurrently help to drive our State's economy.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Program for Science Teacher Access to Resources (STARS) provides high-quality STEM related professional development, student focused programs throughout the school year and summers that include research opportunities, tours and camps to the North Texas region. Performance can be assessed as follows:

- number of teacher participants
  - number of student participants
  - numbers of schools impacted
  - number of summer program applicants and slots available
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Regional Burn Care Center**

<b>(1) Year Non-Formula Support Item First Funded:</b>	1978
Year Non-Formula Support Item Established:	1978
Original Appropriation:	\$125,000

**(2) Mission:**

To provide state-of-the-art comprehensive acute burn care, burn rehabilitation, education, supplies, and banked skin allograft tissues for clinical transplant for adult and pediatric patients and healthcare professionals. The Center is also the only American Burn Association and American College of Surgeons-verified burn center in North Texas, providing a regional resource for disaster management for those with burns.

**(3) (a) Major Accomplishments to Date:**

The Burn Center continues to support faculty, fellow, resident, student, and advanced clinical personnel training in burn treatment as well as providing state-of-the-art care for Texans. In 2017, the Center admitted 932 patients (20% children) and during this time clinical outcomes such as mortality were very low, less than 4% of patients admitted, while hospital length of stay remains below national norms.

Educating the next generation of providers remains a focus, with ~80 residents rotating through the center annually from 5 residency programs. The Center also recently developed a Burn Surgery Fellowship that includes Critical Care Certification; and six surgeons who have completed the program are actively providing burn care; comprising ~25% of all burn surgeons trained in 2016-17.

Improvements in clinical outcomes and education are due to many factors, significantly supported by State funds. Advancements in resuscitation including patented technology, improved quality of surgical intervention, and improved metabolic support are only a few of the advances produced. Equally important, the Center continues to serve as a state and national resource for teaching and referral for the latest techniques in burn care and prevention, and leveraging of State funds has resulted in continued high national and international recognition and successful competition for federal grants.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

The Center combines emergency care and in-hospital treatment of acute pediatric and adult burns, as well as reconstructive surgery and rehabilitation to meet the UT-Southwestern mission to provide the best comprehensive burn care. While providing world-class burn care, the Center will remain active in clinical research to further improve understanding and efficacy of treatments to improve outcomes in burns.

In the next biennium, the Center expects to complete 5 clinical trials as well as institute another 3 trials in muscle and skin regeneration and mitigation of blood loss in the treatment of burns. The Faculty serving in the Center have well-established burn research programs, with the expectation to publish between 20-25 peer-reviewed papers per year describing improvements in burn care.

Through these efforts, the Center also serves to advance the goals of medical care, improved patient survival and morbidity. In addition, excellence in research and patient care allows the Center to continue to actively improve and provide excellence in education for fellows, residents, medical students and professional health students in clinical and rehabilitative burn treatment.

---

**729 The University of Texas Southwestern Medical Center**

---

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

Limited funding from extramural granting agencies.

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Healthcare Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

2018	\$ 431,105 Federal Funds
	\$ 140,000 Private Funds
2019	\$ 431,105 Federal Funds
	\$ 140,000 Private Funds
2020	\$ 431,105 Federal Funds
	\$ 140,000 Private Funds
2021	\$ 431,105 Federal Funds
	\$ 140,000 Private Funds

**(9) Impact of Not Funding:**

Facing an over 30% reduction in funding since FY 10-11, further curtailment of the only American Burn Association and American College of Surgeons-verified burn center in North Texas would seriously hamper the continuation of current services to adult and pediatric patients and health care professionals in the region, and delay the development of critical improvements such as permanent skin coverage for critically-injured burn patients and improvement in critical care outcomes and rehabilitation/reconstruction strategies. Loss or further reduction of funding would also delay development and implementation of regional disaster management preparedness, and significantly hinder education and training for students, resident and other providers of burn care.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuation**

Funding for the Regional Burn Care Center is needed on a permanent basis to enable continuous provision of state-of-the-art burn care and education in this critical field.

The only American Burn Association and American College of Surgeons-verified burn center in North Texas, the Regional Burn Care Center is critical to serving the region for these acute, life-threatening and intensely painful injuries. The Center's expert staff is also responsible for training tomorrow's specialists in burn care and prevention. Finally, the state's support is leveraged to bring in more outside dollars to support the education, research and patient care the Center provides.

---

**729 The University of Texas Southwestern Medical Center**

---

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Funding for the Center is critical to training tomorrow's burn specialists in prevention and treatment, providing infrastructure to support clinical trials, publishing peer-reviewed research findings that inform burn care, and attracting more dollars to the state. Performance can be assessed as follows:

- Faculty retained and recruited
  - Fellows and residents trained
  - Patients treated by Center faculty
  - Clinical trials maintained and started, predicated on available Center infrastructure
  - Peer-reviewed publications
-

---

**729 The University of Texas Southwestern Medical Center**

---

**Texas Institute for Brain Injury and Repair**

<b>(1) Year Non-Formula Support Item First Funded:</b>	2014
Year Non-Formula Support Item Established:	2014
Original Appropriation:	\$7,500,000

**(2) Mission:**

Translational research by UTSW faculty who apply their basic discoveries to specific diseases have led to a successful history in the bench-to-bedside development of new treatments. UTSW is at a pivotal point for advancing our faculty's discoveries in brain care, with their efforts uniquely supported by necessary expansion at Clements University Hospital that will be home to the research intensive Peter O'Donnell Brain Institute (OBI) and neurological teams focused on care for patients suffering from related illnesses. As part of the OBI, the Texas Institute for Brain Injury and Repair will continue its translational research success at UTSW which has included:

- Research support from autopsy-confirmed cases that there is a relationship between concussion and dementia
- Discovered a genetic trigger that may improve the brain's ability to heal from conditions ranging from concussion and stroke to spinal cord injury
- A novel protein target for the development of drugs to treat and prevent Alzheimer's.

Despite these successes, development of basic discoveries into transformative therapies at UTSW suffers from lack of core research funding for the early steps in translational research. State funding supports the extension of basic discoveries from the lab for which there are no other sources of funding, yet are essential for producing novel patient therapies to treat brain injury, with great promise for better patient care, lower costs, and ROI to the State.

**(3) (a) Major Accomplishments to Date:**

One of the largest returns for the State on its investments comes from its top research schools, with each State dollar leveraged as much as 7:1 with external grants brought to Texas. Investing in these programs is as important as investing in STEM and emerging research universities, to drive the development of a skilled workforce and because these programs can have an immediate impact on Texas' economy. Furthermore, discoveries made at Texas' top medical research schools and investment in UTSW's Brain Institute hold enormous promise to improve patient care and lower the state's healthcare costs.

UTSW established TIBIR to catalyze comprehensive transformative approaches to how brain injuries can be prevented and treated. Drawing on deep bench strengths, a four-pronged approach is being taken, involving innovative neuroscience research, clinical translation, education, and prevention. To these ends, a Core Lab providing subsidized services for imaging the normal and injured brain was started; pilot research projects that seek new knowledge in therapeutic approaches to the diagnosis, prevention, or treatment of brain injury were funded; as part of the North Texas Concussion Study (ConTex), an outreach program that educates high school football coaches & players in the signs and symptoms of brain injury was organized; a large study to examine brain function in former NFL players was started; & a novel imaging system to map nerve cell connections in the brain was installed.

**(3) (b) Major Accomplishments Expected During the Next 2 Years:**

---

**729 The University of Texas Southwestern Medical Center**

---

Research in traumatic brain injury will expand to understand seizures that occur more frequently after injury, the role of stem cells in brain repair, and neuropsychological studies in individuals with brain trauma, including former professional football and hockey players, military personnel, and high school athletes.

Recruitment for ConTex is ahead of schedule and has successfully established the initial phase of the large database that is necessary to conduct analyses related to concussion risk and outcomes. Preliminary work has been presented at national meetings and several manuscripts have been submitted for publication. An important outgrowth of ConTex, the statewide concussion registry (ConTex2), is underway to examine the frequency, severity, and causes of concussion in UIL-participating school districts across the state, representing one of the nation's first and largest efforts to record and track concussion injuries in youth athletes.

Recruitment efforts continue to bring additional high-caliber researchers who are experts in neurodegenerative conditions and rehabilitation from brain injuries. Finally, preliminary findings from related studies have suggested a link between brain injury and the later development of the protein tau in some individuals. Additional findings revealing the mechanism by which amyloid fibrils composed of the protein tau are formed in Alzheimer's disease provide a potential link and application in brain injury.

**(4) Funding Source Prior to Receiving Non-Formula Support Funding:**

Such core research support has not been available prior to the State appropriation. Limited federal grants for specific research projects have been greatly leveraged using State funds as described above.

**(5) Formula Funding:**

No formula funding

**(6) Category:**

Research Support

**(7) Transitional Funding:**

N

**(8) Non-General Revenue Sources of Funding:**

UT Southwestern has maintained a successful pattern of leveraging state research support over the years. Federal grants, private grants and gifts for research have resulted in a 7:1 realized return on state investments for research. The application of this multiplier to the annual appropriation reflected for this special item results in projected external funding of \$52,500,000.

**(9) Impact of Not Funding:**

---

**729 The University of Texas Southwestern Medical Center**

---

UT Southwestern's historical core strength in uncovering the genetic and molecular causes of disease has already led to UTSW being recognized as a highly accomplished basic research institution. UT Southwestern faculty members are poised to have an analogous substantial impact on the bench-to-bedside development of medical breakthroughs in traumatic brain injury, yet without continued funding of this initiative, UTSW cannot capitalize or expand on our faculty's expertise in accelerating the translation of scientific discoveries into novel patient therapies.

Already sustaining an almost 10% reduction in state support since FY14-15, the cost of not funding or further reduction to the Texas Brain Injury and Repair Institute at UT Southwestern will result in missed opportunities to bring in millions of dollars more in grant funding to Texas, to accelerate the translational research of its renowned faculty, to recruit rising stars in translational research, to track and understand the long-term impact of brain injury from the earliest stages, and to yield breakthrough treatments for our most devastating neurological diseases.

**(10) Non-Formula Support Needed on Permanent Basis/Discontinuu**

Core research support funding for the Texas Institute for Brain Injury and Repair is needed on a permanent basis.

A pillar of UTSW's Peter O'Donnell Brain Institute, TIBIR depends on state funding to support its core research operations on a permanent basis as it continues to make unparalleled strides in understanding and treating traumatic brain injury from the youth athlete to the United States soldier.

Underscoring the immense talent and promise of research endeavors at TIBIR, the NFL tapped one of the top leaders in this field to co-chair their Head, Neck and Spine Committee and Texas tasked the Institute to develop a concussion registry in collaboration with the UIL to begin tracking incidents among Texas children. In order to retain momentum, continued funding is essential to: ensure the reach and scope of the ConTex initiative, retain and recruit top scientists, and build off early findings which suggest links between brain injury and a protein implicated in Alzheimer's disease. As a result, the ConTex database will inform protocol and patient care nationwide; scientists will continue uncovering dysfunction of the brain following injury, including from damage following stroke and spinal cord injury; and Texas will be seen as a leader in this area of neurodegeneration that affects too many patients and families in our state and beyond.

**(11) Non-Formula Support Associated with Time Frame:**

N/A as non-formula support is needed on a permanent basis.

**(12) Benchmarks:**

Suggested performance metrics associated with permanent funding are reflected in Section 13.

**(13) Performance Reviews:**

Core research operations support helps TIBIR retain and recruit the world's top scientist in traumatic brain and related injuries which allows for progress towards identifying causes with great promise to lead to cures, improved treatment and patient care. Performance can be assessed as follows:

- Faculty retained and recruited
  - ConTex: number of participating school districts and youth athletes
  - Discoveries published in peer-reviewed publications
-